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Summary 
 
Angiogenesis inhibitors (AIs) diminish or block the de novo formation of capillaries 
from pre-existing blood vessels and have been considered a breakthrough concept in cancer 
therapy for many years. To date, however, pre-clinical data on AIs did not translate very 
productively into the clinic. AI monotherapy can apparently raise the tumor´s aggressiveness 
and has been associated with an increasing likelihood for metastases to occur. Perhaps, this 
AI-mediated increase in tumor virulence stems from the drugs propensity to escalate both 
extent and severity of tissue hypoxia. In contrast, treatments that normalize the usually 
chaotic tumor vasculature with its erratic blood flow back to a functional network are indeed 
able to elevate in vivo oxygen tensions within the malignant mass in correlation with a 
reduced occurrence of cancer spread.  
Despite the frequent use of AIs to combat cancer growth and malignant progression, the 
impact of manipulations on fundamental physiological parameters such as vascular 
normalization, blood flow and local tissue oxygenation within the tumor are insufficiently 
understood. This is mostly due to the lack of good pre-clinical models to evaluate tumor 
angiogenesis and its responses to different anti-angiogenic compounds. Prof. T. Cerny, 
president of the Swiss Cancer League, therefore stressed in an interview with the Neue 
Zürcher Zeitung the urgent need for additional research to identify most effective anti-
angiogenic treatment strategies at minimal negative impact for the patient (NZZ, No. 58, 
March 11, 2009).   
An effective anti-cancer therapy needs to target not only the oxygenated/aerobe 
compartment of the tumor adjacent to its vascular structures through blood-borne cytotoxins 
but also the vessel-remote areas enriched with severely hypoxic/glycolytic cells. Owing to 
the selection in favor of surviving hypoxic cells, a selective kill of oxygenated cells only 
furthers malignant progression since the tumor might develop widespread resistance to 
treatment and adopt a much more virulent phenotype. Therefore this project tests the 
established AI Avastin® (vascular endothelial growth factor (VEGF) antibody) alone and in 
combination with the Monocarboxylate Transporter 1 (MCT1) Inhibitor -
Cyanohydroxycinnamate (CHC).  
6 
 
 
The combined AI/anti-MCT1 strategies can target simultaneously both oxygenated and 
hypoxic tumor compartments. MCT1 inhibitors lead in hypoxic cells to glucose starvation 
by rerouting glucose from hypoxic to oxygenated cells and thus might indirectly eradicate 
hypoxic/glycolytic tumor cells and render hard-to-treat malignancies more susceptible to 
therapy. The combination of MCT1 inhibition (to target hypoxic cells) with AI agents (to 
starve oxygenated regions from nutrients) is conceptually a very promising and novel 
approach. The efficacy of these combination therapy protocols was examined by the animal 
saving ex ovo Chorio-allantoic membrane (CAM)/tumor explant assay. Using the CAM 
assay, so far we were able to induce solid tumors with human hepatoma (Hep3B), mammary 
carcinoma (MCF7), and glioblastoma (U87), cell lines on chicken embryos. For U87 tumors, 
explants showed clear decreased blood perfusion (FLUX arbitrary unit) with combinotorial 
treatment of AI (Avastin®) and MCT1 inhibitors as compared to Avastin® alone and 
controls. Tumor sizes were determined by analysis of tumor images, using computer-aided 
image analysis, which reproduced comparable results showing additive effect of Avastin® 
& MCT1 inhibitors. Tumor oxygenation was inferred by pimonidazole staining which 
echoed the similar findings. To study tumor cell spreading on CAM under said treatments a 
more virulent cell line MDA-MB 231 was used which showed an overall increase in spread 
(motility) of MDA-MB231 cells with AVA treatment as compared to controls while 
reduction in motility was observed with combinatorial treatment. To check the efficacy of 
CAM/migration assay, as a side project tumor cell spreading was also studied in Ewing 
sarcoma tumor with IL-6 treatment which showed dose dependent increase in cell migration. 
   In conclusion, we demonstrate the applicability of CAM/explant methodology as a 
cheap, easy-to-implement pre-clinical drug screen allowing 1) high-throughput screening of 
drugs and 2) an animal saving alternative to rodent models. By combining angiogenic 
inhibitors with agents able to selectively target hypoxic microenvironments in the tumor, the 
intervention protocol might be able to shrink primary masses and minimize the risk of 
malignant progression and tumor spread at the same time. Of course, these strategies need 
further analyses of suitable cell models and drug combinations in CAM and murine models 
followed by clinical studies.  
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Zusammenfassung 
 
Angiogenesehemmer (AHs) unterdrücken oder blockieren die de novo Bildung von 
Kapillaren aus schon vorhandenen Blutgefässen und wurden deswegen für viele Jahre als 
Durchbruch in der Krebstherapie angesehen. Heute zeigt sich jedoch, dass die viel 
versprechenden Daten aus vorklinischen Studien sich nicht sehr produktiv in der Klinik 
umsetzen liessen. AH Monotherapie kann offenbar die Aggressivität eines Tumors steigern 
und wurde mit einer erhöhten Wahrscheinlichkeit für Metastasenbildung assoziiert. 
Möglicherweise rührt die AH-induzierte Steigerung der Tumorvirulenz von der dem 
Wirkmechanismus immanenten Neigung der AHs sowohl die Ausdehnung als auch die 
Intensität des Sauerstoffmangels zu verstärken. Im Gegensatz dazu erreichen Therapien, die 
die üblicherweise chaotische Gefässversorgung mit fehlerhafter Durchblutung 
normalisieren, eine Verbesserung der Sauerstoffversorgung in der Tumormasse, was mit 
einer geringeren Metastasierungstendenz einhergeht. 
Trotz des verbreiteten Einsatzes von AHs zur Bekämpfung des Wachstums solider 
Tumore und des Fortschreitens einer Krebserkrankung sind die Effekte der Manipulation 
fundamentaler physiologischer Parameter wie Gefässnormalisierung, Durchblutung und 
lokaler Sauerstoffversorgung in Tumoren nur unzureichend verstanden. Das liegt 
grösstenteils an einem Mangel an guten vorklinischen Modellen, mit denen 
Tumorangiogenese und deren Antwort auf verschiedene anti-angiogenetisch wirksame 
Substanzen untersucht werden könnten. Deshalb forderte Prof. T. Cerny, Präsident der 
Schweizer Krebsliga vor einiger Zeit in einem Zeitungsinterview mit der Neuen Züricher 
Zeitung zusätzliche Forschungsanstrengungen, um neue, effektivere anti-angiogenetische 
Therapiestrategien mit minimalem negativen Effekten auf den Patitenten zu finden (NZZ, 
No. 58, March 11, 2009). 
Eine effektive Krebstherapie muss nicht nur die sauerstoffreichen, aeroben Bereiche des 
Tumors, die neben den Blutgefässen liegen, mittels über das Blut herantransportierten 
Zytostatika treffen, sondern auch die gefässfernen, stark hypoxischen Tumorzellen. Wegen 
der positiven Selektion von hypoxischen Tumorzellen, verstärkt eine ausschliessliche 
Vernichtung oxigenierter Tumorzellen nur die maligne Progression der Krebserkrankung 
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und könnte zur Entstehung einer Therapieresistenz und der Entwicklung eines bösartigeren 
Phänotyps der Krebszellen führen. Daher wurde in dem vorliegenden Projekt ein etablierter 
AH, Avastin® (vascular endothelial growth factor (VEGF) Antikörper), allein und in 
Kombination mit dem Monocarboxylate-Transporter 1 (MCT1) Inhibitor -
Cyanohydroxycinnamate (CHC) getestet. 
Die kombinierte AH/ant-MCT1 Strategie kann gleichzeitig die oxigenierten und 
hypoischen Tumorareale treffen. MCT1-Inhibitoren schneiden die hypoxischen 
Tumorzellen von der Glukose- und damit Energieversorgung ab, indem sie die Glukose den 
oxygenierten Tumorzellen zuführen. So können indirekt die hypoxischen Tumorzellen 
ausgemerzt und schwer therapierbare Krebsleiden besser behandelbar werden. Diese 
Kombination von MCT1-Inhibitoren (um hypoxische Tumorzellen zu treffen) mit AHs (um 
sauerstoffreiceh Tumorareale von der Nährstoffversorgung abzuschneiden) ist ein 
konzeptionell neuer, viel versprechender Ansatz. Die Effektivität dieser 
Kombinationstherapie wurde mit dem versuchstiersparenden ex ovo Chorio-allantoic-
membrane (CAM) Assay nach Explantation von Tumorzellen durchgeführt. Mit dieser 
Methode konnten wir bis jetzt humane Hepatom- (Hep3B), Mammakarzinom- (MCF7) und 
Glioblastom- (U87) Zellen zu solidenn Tumoren auf dem CAM des Hühnerembryos 
anzüchten. U87-Tumorexplantate zeigten eine klare Durchblutungsverminderung nach 
Kombinationstherapie mit AH, Avastin® und MCT1-Inhibitor im Vergleich zu Avastin® 
Monotherapie und unbehandelten Kontrolltumoren. Das Tumorwachstum wurde mit Hilfe 
computergestützter Bildanalyse gemessen und zeigte einen vergleichbaren additiven Effekt 
der Avastin® und MCT1-Inhibitor Behandlung. Die lokale Tumorhypoxie wurde mit Hilfe 
einer Pmonidazolfärbung untersucht und bestätigte diese Befunde. Um die spontane 
Zellausbreitung der Tumore unter den genannten Therapien zu untersuchen wurde eine 
virulentere Zelllinie, MDA-MB 231, benutzt, mit der sich zeigte, dass eine Avastin® 
Monotherapie die Zellausbreitung (Zellbeweglichkeit) in das normale CAM-Gewebe im 
Vergleich zu unbehandelten Kontrollen erhöhte, während die Avastin® / MCT1-Inhibitor 
Konbinationsbehandlung die Zellausbreitung unterdrückte. 
Schlussfolgernd konnten wir mit dieser Studie demonstrieren, dass die 
CAM/Tumorzellexplantationsmethode als einfache, kostengünstige vorklinische 
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Medikamentenscreeningmethode geeignet ist und 1) einen hohen Durchsatz für 
Medikamententeste erlaubt und 2) eine versuchstiersparende Alternative zu den sonst 
üblichen Nagermodellen ist. Durch die Kombination von Angiogenesehemmern mit 
Substanzen, die spezifisch hypoxische Tumorareale treffen, wird es möglich sein, den 
Primärtumor zu schrumpfen und dabei gleichzeitig das Risiko einer malignen Progression 
und Metastasierung zu minimieren. Natürlich bedarf diese Strategie noch weiterer 
Untersuchungen an geeigneten Zellmodellen und anderen Medikamentenkombinationen in 
CAM- und Mausmodellen, gefolgt von klinischen Studien. 
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Abbreviations: 
 
AIs: Angiogenesis inhibitors  
Ang: Angiopoietin 
ARNT: Aryl hydrocarbon receptor nuclear translocator 
ATP: Adenosintriphosphat 
AVA: Avastin® 
B16-F10: Murine Melanoma 
bFGF: Basic fibroblast growth factor  
BMDCs: Bone marrow derived cells  
CAFs: Carcinoma-associated fibroblasts 
CAM: Chorioallantoic membrane  
CHC: -cyanohydroxycinnamate  
CML: Chronic myeloid leukemia  
CXCR4: C-X-C chemokine receptor type 4 
ECM: Extracellular matrix  
EDF1: Endothelial differentiation-related factor 1  
EGF: Epidermal growth factor  
eNOS: endothelial nitric oxide synthases  
EphB4: Ephrin type-B receptor 4 
FDA: Food and Drug Administration 
FGFR: Fibroblast growth factors receptor 
FGFs: Fibroblast growth factors  
Hep3B: Human hepatoma  
HIF1: Hypoxia inducible factor 1 
HIF2: Hypoxia inducible factor 2 
HIFa: Hypoxia inducible factor alpha  
IL-6: Interleukin 6 
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IL-10: Interleukin 10  
iNOS: inducible Nitric oxide synthases  
LDG: Lactate dehydrogenase  
MCT1: Monocarboxylate transporter 1  
MCT4: Monocarboxylate transporter 4  
MMP: Matrix metalloproteases  
MSCs: Mesenchymal stem cells  
NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells 
nNOS: neuronal Nitric oxide synthases  
NO: Nitric oxide 
NOS: Nitric oxide synthases 
PDGF: Platelet-derived growth factor 
PDGFR: Platelet-derived growth factor receptor 
PIGF: Placenta-derived growth factor  
RCC4: Renal clear cell carcinoma 
ROS: Reactive oxygen species  
SDF1: Stromal cell–derived factor 1  
TAMs: Tumor Associated macrophages  
TGF-β: Transforming growth factor beta 
Tie1: Tyrosine kinase with immunoglobulin-like and EGF-like domains 1 
TMs: Transmembrane helices 
TSP1: Thrombospondin1  
U-87: Glioblastoma 
VEGF: Vascular endothelial growth factors  
VEGFR: Vascular endothelial growth factors receptor 
WHO: World Health Organization 
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Project A 
 
(Chick embryo chorioallantoic membrane assay for pre-clinical evaluation of efficacy and 
safety of anti-angiogenic and hypoxic cell-starving tumor interventions) 
 
1. Introduction: 
 
1.1 Overview to cancer biology 
 
Although cancer a heterogeneous disease, originates from a single cell (first proposed by 
Theodor Boveri in 1902 [1]) harboring a mutant DNA sequence that manipulates the crucial 
regulatory pathways involved in cell survival, proliferation and apoptosis. 
 
Based on statistics from World Health Organization (WHO): Cancer is one of the major 
cause of death worldwide, accounting for 8.2 million deaths in 2012 [2] and is projected to 
rise continuously, to an estimated 13 million deaths within the next two decades. In 2012 
itself cancer burden was increased to 14 million new cases, a figure expected to rise to 22 
million in next two decades [2]. Looking at this statistics, clearly a better understanding of 
the molecular mechanisms underlying the various forms of cancer remains of utmost 
importance to improve therapies and eventually develop cancer cure. 
 
In 1873 Theodore Billroth was the first to successfully perform a surgical procedure to treat 
cancer of the larynx [3]. The next century saw rapid progress and is often referred to as "the 
century of the surgeon". To date surgery is one of the most effective methods in the treatment 
of localized primary tumor and associated regional lymphatic nodes. Use of Radiation 
therapy was first reported in 1896 by Emil Grubbé to treat breast cancer [4], [5] and has been 
widely used since 1920s. The 1940s saw the advent of chemotherapy with Nitrogen mustard 
(mechlorethamine) introduced in 1949 to become the first chemical agent approved by the 
Food and Drug Administration (FDA) for the treatment of leukemias and lymphomas [6]. 
This development was followed by rapid progress made in immune therapy (e.g. Herceptin) 
and hormone therapy (e.g. Tamoxifen). Until the late 1980’s the majority of the medications 
used in cancer treatments were DNA-damaging agents designed to kill or inhibit rapidly 
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dividing cells (e.g. Cisplatin), which, however, also had substantial adverse effects on 
proliferating normal cells.  
 
During the last decades, numerous advances in the field of cancer therapy (anti-angiogenic 
protocols, chemotherapy, gene therapy etc.) have helped physicians, while researchers 
increasingly focused on the outcome of combining surgery with medications and/or 
radiation. But despite the latest advantages, the known genetic instability and cellular 
heterogeneity particularly solid neoplasms still carry high risk of a therapy-driven selection 
of cell clones resistant to chemo- and/or radiation treatment. As an alternative:  combination 
therapies should be designed to simultaneously target multiple cancer cell-specific pathways 
in order to prevent the emergence and spread of resistant clones. 
 
Tumorigenesis is a multistep process, initiated by so-called driver mutations, allelic 
deletions or chromosomal translocations. The occurrence of secondary events (e.g. 
passenger mutations) will eventually drive the advanced transformation of normal human 
cells into highly malignant derivatives with growth/survival advantage over wild type 
progenitors. Most tumor transformative processes are not inherited but triggered by somatic 
mutations invoked by etiological agents like carcinogenic chemicals, smoking, infections 
(e.g. Papilloma virus, Hepatitis B/C), excessive sun exposure, radiations, stress, tobacco, 
diet and obesity etc (WHO statistics suggest about 30% of cancer deaths are due to 
behavioral and dietary risks [2]). These DNA defects cause regulatory circuits that govern 
normal cell proliferation and homeostasis to derail, thereby producing malignant 
phenotypes. There are more than 100 distinct types of cancer, and subtypes of tumors that 
can be found within almost all organs. Since neoplasms carry numerous mutations, this 
genetic heterogeneity also confers a growth advantage to the malignant mass itself and is 
responsible for development of drug resistance during treatment. In 2000 Hanahan and 
Weinberg [7] suggested that this complexity illustrated by a huge catalog of cancer cell 
genotypes, basically indicates six essential alterations in cell physiology that are essential 
for malignant growth and progression of tumors, commonly referred as hallmarks of cancer 
(figure 1a, 1b). Throughout the past decade, further evidence suggested two additional 
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(newly emerging) hallmarks and two enabling characteristics of cancer (figure 1b) to 
influence the pathogenesis of some or perhaps all cancers. 
 
 
 
 
 
Figure 1. The hallmarks of cancer. (a) Six hallmarks of cancer first suggested in 2000 by 
Hanahan and Weinberg [7]. (b) With the past decade of extensive research, added evidence 
suggested the role of two emerging core hallmarks and two enabling characteristics in the 
pathogenesis of some or perhaps all cancers (figure acquired from Hanahan and Weinberg 
[8]). 
 
 
a) 
b) 
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As an outcome of genetic alterations, microenvironmental heterogeneity etc. many solid 
cancers are characterized by phenotypic and functional diversity among the population of 
malignantly transformed cell progeny, some of which able to endorse a growth and survival 
benefit to the entire mass [9], [10].  A landmark publication by Fidler and Hart demonstrated 
for the first time in 1982 the existence of biological diversity in metastatic neoplasms [11].  
 
Tumor cell proliferation is often fueled by stimulated glycolysis, even under aerobic 
conditions (Warburg effect), and an ever-increasing demand of glucose and oxygen. As the 
size of the neoplasm increases more and more cells come to lie outside the region that can 
be supplied with substrates from the capillary network of the tumor. Since the tumor 
vasculature is categorically a poor provider of a continuous supply of substrates to the tumor 
cells (for details, see section: 1.3.2: Tumor metabolism), the neoplastic mass of cells is often 
characterized by an enormous microenvironmental heterogeneity and steep inward diffusion 
gradients for O2 and glucose (i.e. maximal concentrations at vessel proximity to minimal 
concentrations at vessel-remote areas of malignancy) plus outward-operating gradients of 
lactate and other metabolic end products.  
 
This tumor heterogeneity leads to the expression of diverse factors [e.g. endothelial 
differentiation-related factor 1 (EDF1), vascular endothelial growth factors (VEGF), 
interleukin 10 (IL-10) and TGF-β], which may induce a complex immunosuppressive 
response, both locally and regionally [12], [13], but which also may vary depending on the 
type of lesion [14].  
 
A number of recent studies utilizing next generation sequencing has confirmed tumor 
heterogeneity [15] and its role in acquired drug resistance [16]. This hypothesis is well 
supported by the clinical observations. E.g. chronic myeloid leukemia (CML) characterized 
by genetic abnormality (translocation) shows better response to therapy as compared to 
extremely heterogeneous tumor types (e.g. ovarian cancer, breast cancer) [17]–[19].  
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1.2 Angiogenesis in physiology 
 
Angiogenesis, i.e. the process of growing new blood vessels from pre-existing ones requires 
the coordination of multiple signaling pathways, cell–cell and cell–matrix interactions [20]. 
While angiogenesis is typically dormant in adults, except for its temporary activation during 
menstrual cycle-specific processes (e.g. ovulation, endometrial growth, implantation, 
placentation, etc.) or wound healing, it is often stimulated in numerous pathologies (diabetic 
retinopathy, rheumatoid arthritis, cardiac ischemia, psoriasis, tumor growth). Angiogenesis 
can broadly be classified into intussusceptive angiogenesis and sprouting angiogenesis, 
which both occur during embryogenesis as well as in adults [21], [22]. Intussusceptive 
angiogenesis, which occurs by internal splitting of the preexisting capillaries, plays a 
particularly critical role in embryogenesis with its rapid growth [23], [24]. This particular 
mode of vascular expansion is driven through the rearrangement, but not the proliferation, 
of endothelial cells. Intussusceptive angiogenesis occurs via four subsequent steps, including 
(i) protrusion of opposing endothelial cells into the capillary lumen, (ii) formation of a tube-
shaped tissue bridge extending across the lumen enveloped by endothelial cells, (iii) 
formation of a core structure at the contact points between pericytes and myofibroblasts (i.e. 
these cells are responsible to synthesize collagen fibers for the growth of wider vessels), (iv) 
serial transformation of the point of contact to enlarge  in the pillar diameter [24], [25]. While 
intussusceptive angiogenesis was first discovered by Caduff et.al. in postnatal lungs of rats 
[26], [27], it is now known to occur in the choroid of the eye, vascular baskets around glands, 
intestinal mucosa, kidney, ovary, and uterus [28], [29]. Rate limiting steps in intussusceptive 
angiogenesis are far less understood then in sprouting angiogenesis.  
 
Sprouting angiogenesis, the predominant form of angiogenesis in embryonic development, 
wound healing, reproduction [30], [31], and tumors [8], [32] is primarily initiated in regions 
insufficiently supplied with oxygen in the attempt to maintain or stabilize the delivery of O2 
and blood-born substrates. That way parenchymal cells (myocytes, hepatocytes, neurons, 
astrocytes, etc.) aim to stay aerobic by secreting pro-angiogenic growth factors to foster 
sprouting angiogenesis [33], [34]. The entire process starts through the nitric oxide (NO•) 
dependent vasodilation in conjunction with a local breakdown of the endothelial integrity of 
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the parental vessel. It then proceeds via the (i) degradation of the basement membrane by 
proteolytic enzymes, (ii) proliferation and migration of endothelial cells, starting with a tip 
cell that moves along a gradient of pro-angiogenic factors, (iii) formation of tube like 
structures through increase in numbers of endothelial cells, (iv) synthesis of new basement 
membrane and (v) recruitment plus stabilization of vascular smooth muscle cell [33]. 
 
Although vascular endothelial growth factors (VEGF) are considered the most critical 
drivers of angiogenesis [35] (table 1), the process of neovascularization requires a plethora 
of growth and other modulating factors, including fibroblast growth factors (FGFs) [36], 
transforming growth factor-β (TGF-β), angiopoietins [35], platelet-derived growth factor 
(PDGF) [37], and the ephrin family of cytokines [38]. VEGFs and FGFs are two classes of 
heparin-binding glycoproteins that promote both physiological (productive) and 
pathological (non-productive) angiogenesis in response to hypoxia. VEGFs include 
placenta-derived growth factor (PlGF), viral VEGF homologs and a family of the 
structurally related dimeric glycoproteins VEGF-A, VEGF-B, VEGF-C and VEGF-D. All 
VEGF family members share a highly preserved VEGF homology domain, encoded by 
exons 1 to 5. These growth factors act via endothelial-specific receptor tyrosine kinases, 
VEGFR1 (vascular endothelial growth factors receptor 1) (Flt1), VEGFR2 (KDR/Flk1), and 
VEGFR3 (Flt4) [39], [40] to govern both proliferation and differentiation of the endothelial 
lineage from the earliest stages of development. 
 
VEGF Family Functions VEGF Receptors 
VEGF-A Angiogenesis vascular maintenance VEGFR1, VEGFR2, neuropilin-1 
VEGF-B Not known VEGFR1 
VEGF-C Lymphagiogenesis VEGFR2, VEGFR3 
VEGF-D Lymphagiogenesis VEGFR2, VEGFR3 
VEGF-E (viral factor) Angiogenesis VEGFR2 
PIGF Angiogenesis Inflammation VEGFR1, neuropilin-1 
Table 1: List of VEGF family members 
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FGFs also prompt neovascularization and have been implicated in the growth of new blood 
vessels during wound healing and embryogenesis. In Drosophila, the homologous signaling 
between FGF ligand (BRANCHLESS, BNL), emanating from hypoxic target tissues, and 
FGF receptor (BREATHLESS, BTL) located on the surface of sprouting tracheal branches, 
is coordinated with exquisite sensitivity by the hypoxia inducible factor alpha subunit (HIF, 
Sima) cascade [41], [42]. In this model it is clear that HIF/Sima is instrumental for 
sensitizing (i.e. driving BTL induction), progressively ramifying and guiding the gas-
exchanging surfaces of tracheal sprouts towards incoming BNL cues from O2-deprived 
tissues, much like productive sprouting angiogenesis operates during wound healing or 
embryogenesis of mammals (figure 2). In vertebrates 22 members (molecular mass ranging 
from 17 to 34 kDa) of the FGF family are differentially expressed in many tissues. Essential 
angiogenic isoforms include the acidic FGF1 and the basic FGF2. FGF1 and FGF2 promote 
the proliferation of endothelial cells and the physical organization of endothelial cells into 
tube-like structures. The FGF-Receptor family is comprised of four members, FGFR1-
FGFR4 [43]–[45].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Sprouting tracheal branches in Drosophila, is coordinated with exquisite sensitivity 
by the hypoxia inducible factor alpha subunit (HIF, Sima) cascade, (figure acquired from 
Centanin et al. [41] ) 
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Angiopoietins, important partners of VEGF signaling, are involved in the formation of 
mature blood vessels. Four angiopoietins Ang1, Ang2 and Ang3 (mouse)/Ang-4 (human) 
act by binding to Tie1 (Tyrosine kinase with immunoglobulin-like and EGF-like domains 1) 
and Tie2 tyrosine kinases receptor [46]. It has been observed that angiopoietins primarily 
bind to Tie2 receptor tyrosine kinases, while the role of Tie1 is still controversial. These 
receptors are selectively expressed within the vascular endothelium (despite expression in 
some other cells, such as in the haemopoietic lineage) [47]. Especially Ang1 and ephrin-B2 
are subsequently required for further remodeling and maturation of the initially immature 
vasculature during development as well as adulthood [47], [48]. 
 
Although Ephrins were first/initially characterized in the nervous system [49], [50], later 
knockout studies suggested their key role in vascular development. Ephrins are membrane 
bound proteins that serve as ligand for Ephrin receptors (largest known subfamily of receptor 
protein-tyrosine kinases). Mainly Ephrin-B2 and EphB4 (Ephrin type-B receptor 4) 
receptors are involved in establishing arterial versus venous identity, perhaps in fusing 
arterial and venous vessels at their junctions [49], [51]. 
 
 
1.2.1 Pathological angiogenesis with particular focus on tumors 
 
Typically angiogenesis is quiescent during adulthood, with only 0.01% of endothelial cells 
undergoing division [52]. However endothelial cells can retain their ability of rapid cell 
division (during angiogenesis) in response to an external stimulus. Such stimuli mainly 
include metabolic stress (e.g. low pO2, low pH or hypoglycemia), immune/inflammatory 
response, genetic mutations and mechanical stress [34]. However, any shift in the delicate 
balance between stimulators and inhibitors can lead to a number of angiogenesis-related 
disorders where new blood vessels either grow excessively or insufficiently [52], [53]. Such 
an imbalanced production of pro- versus anti-angiogenic factors is, presumably, why the 
process of pathological angiogenesis, in contrast to the physiological situation during 
embryogenesis or menstruation, often yields aberrant and poorly functional vascular 
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networks. Pathological angiogenesis is suspected to underlie more than 70 disorders to date. 
As point in case, excessive neovascularization is known to occur in conditions like diabetic 
retinopathy, age-related macular degeneration, rheumatoid arthritis and psoriasis. 
Conversely, in disorders such as coronary artery disease, preeclampsia, chronic wounds etc. 
angiogenesis is generally insufficient, causing EC dysfunction/vessel malformation delayed 
wound healing, regeneration and revascularization [34], [52], [53].  
 
The presence of a capillary network in tumors and its generation from the host vascular bed 
was first demonstrated by Virchow and Thiersch as early as 1863. In 1908 Goldmann 
established the requirement of a vascular system for a solid tumor to grow [54]–[56]. To date 
it is clear that occurrence of angiogenesis and malignant progression of tumors is intimately 
coupled by one of the most prevalent and cell-behavior/metabolism-altering characteristics 
of the tumor microenvironment: severe tissue hypoxia. 
 
Tissue hypoxia can be defined as the condition where the progressing imbalance between 
O2 consumption (=high, due to wildly proliferating cancer cells) and supply (=low/unsteady, 
due to poorly functional tumor vascular networks) has finally reached a point where O2 
partial pressure (pO2) is equal to, or falls below, a tissue (cell)-specific critical value [57]. 
For a healthy subcutaneous tissue, the median pO2 usually lies between 40 and 60 mmHg 
where a regulated (more or less constant) O2 consumption rate is matched by high oxidative 
(mitochondrial) adenosine triphosphate (ATP) production rates, which allow aerobic 
metabolism. In growing tumors [58], the widening supply/demand imbalance yields median 
pO2 of, approximately, 10 mmHg [59], thus indicating severe local hypoxic 
microenvironment across the neoplasm, accompanied by switch to anaerobe metabolism 
[57].  
 
Tumor hypoxia triggers transactivation of numerous genes (below) and generally associates 
with the malignant progression of the disease along with heightened resistance to 
chemo/radiation therapy. Hypoxia-assisted genomic instability and mutations are known to 
exert a strong selection pressure on malignant cells [60], [61], which drives these cells 
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towards a more virulent phenotype and an increased tendency to develop distant metastases. 
Different subcategories of tumor hypoxia are diffusion-, perfusion-, or anemia-related [60]–
[62]. Diffusion-related hypoxia is caused by inadequate O2 /nutrient supply to distant cells 
(>70 μm) from nearest blood vessel mainly due to increase in diffusion distance as an 
aftermath of tumor expansion. Perfusion-related hypoxia is mainly caused by inadequate 
blood flow to tissue, while anemia-related hypoxia describes a reduced O2 carrying capacity 
of the blood, mainly because of tumor- and/or therapy-induced anemia [60]–[62]. 
 
Regardless of subtype, pathological angiogenesis sparked by growing malignancies is 
notorious for yielding tortuous and leaky vessels along with a highly erratic blood flow. 
Most solid malignancies, particularly highly aggressive ones such as glioblastomas, colon 
carcinomas and renal cell carcinomas, are actively engaged in de novo vascularization. In 
this regard, tumor angiogenesis has opened a critical therapeutic opportunity as many entities 
strictly depend upon growing new vessels to achieve a size beyond 1-2 mm3 and to 
disseminate to distant organs [63] (see section: 1.3: Tumor Microenvironment and 
Angiogenesis). As outlined above, tumor hypoxia is critical and responsible to initiate 
angiogenesis in the attempt to counter increasing diffusion insufficiencies of nutrients and 
oxygen [64], [65], which, for solid malignancies, is considered to be rate limiting for further 
development and spreading [63]. The main angiogenic cytokine, VEGF [66], [67], and its 
endothelial-specific receptors VEGFR1 (Flt1) and VEGFR2 (KDR/Flk1) [68], [69], are 
known to be co-induced by cancer cells during low oxygen partial pressures (pO2) in part 
via the hypoxia inducible factors 1 and 2 (HIF-1/-2) to generate new capillary sprouts which 
are believed to aid, as the tracheal ramification in Drosophila does, in maintaining the 
oxygen carrying capacity of the vasculature during hypoxia. Particularly neoplasias with 
high local vascular permeability often show VEGF/ PlGF overexpression [70]. Other factors 
frequently seen to be involved in tumor angiogenesis include PDGF, FGFs, Ang2, epidermal 
growth factor (EGF), transforming growth factor beta-1 (TGF-β1), interleukin 1-beta, tumor 
necrosis factor alpha, and matrix metalloproteinases [71]–[73]. Because many tumors are 
able to induce production of VEGF in their surrounding stromal tissue [73], and since the 
basal lamina, exposed during this vascular leak, is prone to recruit and trigger platelets to 
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release permeability and angiogenic factors in the local environment, both types of paracrine 
signaling will further intensify the local angiogenic response (figure 3) [74]. 
 
It, thus, emerges that both growth and spread of solid malignancies critically depend on 
angiogenic signaling pathways, whose balance, however, has frequently been tipped in favor 
of neovascularization (figure 3). Importantly, and counter to common perception, tissue 
(tumor) oxygenation generally shows little, if any, signs of improvement despite ongoing 
angiogenesis. Tumor angiogenesis does little to prevent or mitigate the development of 
tissue hypoxia during growth. As point in case, recent spectral imaging studies by Hardee et 
al. on microvessel hemoglobin saturation clearly demonstrated that, even in areas of very 
active angiogenesis in tumors, a significant portion of the neoplastic tissue contained 
deoxygenated blood from trapped and hemorrhaged red blood cells [75], [76]. Collectively, 
erratic perfusion, endothelial leakiness, edema and continually impaired tissue oxygenation 
all contribute to the non-productive form of angiogenesis typically seen in tumors [76], [77]. 
 
                          
Figure 3: Angiogenic signaling pathways are induced and exploited by the malignant tumors 
with angiogenic switch tipped in favor of neovascularization. Major driver in this process is 
the oxygen tension within the tumors microenvironments (figure acquired from [78]) 
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1.3 Tumor Microenvironment and Angiogenesis 
 
Cancer cells are generally influenced by their surrounding microenvironment and are in 
constant adaptation to spatial and temporal changes of this milieu. The stromal component 
of this microenvironment is mainly composed of fibroblasts, myoepithelial cells, endothelial 
cells, macrophages, leucocytes and extracellular matrix (ECM). Early evidence about the 
effects of the environment on the tumor were reported in the 70s by Solt and Farber [79]. It 
has also been shown that pre-existing genetic mutation in the stromal tissue itself can 
mediate tumor formation in target epithelial cells [80], [81]. Monifer et al. showed that there 
are concurrent and independent genetic alterations in the stromal and epithelial cells of 
mammary carcinoma [80]. Upon transformation into a malignant cell, a number of signaling 
pathways are derailing.  
  
Yet, the tumor microenvironment also has a crucial role in regulating the angiogenetic 
capacity of the mass via signaling between epithelial tumor cells and stromal fibroblasts 
[82]. Nearby tumor associated stroma is known to provide nutrients and oxygen to growing 
tumors through its vasculature [63]. To gain direct excess to blood vessels tumors have to 
first invade the surrounding stroma and transmit paracrine signals to induce angiogenesis. 
Solid evidence suggests the role of stromal cells in tumor progression, invasion and 
metastasis [83]–[85]. Regarding the cellular component, tumor microenvironments can be 
broadly classified into two categories, i.e. i) Cells already present in the tissue (e.g. 
fibroblasts, endothelial cells etc.) and ii) recruited cells (e.g. inflammatory cells, immune 
cells). In this section I discuss different tumor microenvironment associated cells and their 
critical role in tumor angiogenesis. 
 
Fibroblasts regulate epithelial cell differentiation, inflammatory response to tissue insults 
and are also involved in synthesis and deposition of extracellular matrix (ECM) [86], [87]. 
Carcinoma-associated fibroblasts (CAFs) [88] present in the tumor microenvironment are 
thought to be involved in tumor progression [89]. As majority of ECM proteins (e.g. 
collagens, fibronectin) are produced by CAFs. CAFs play a foremost role to profoundly alter 
the ECM structure [90]. ECM accumulation around tumors leads to increased interstitial 
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fluid pressure thus obstructing the diffusion of nutrient and oxygen supply to tumors [91], 
[92].  Hence, CAF activity can induce tissue hypoxia/ischemia, which might lead to the 
stabilization of HIF-1α and, eventually, stimulated angiogenesis through VEGF induction. 
CAFs are also involved in tumor progression, as suggested in a recent mouse xenograft study 
by Orimo et al. [93]. According to this work, mixing human breast carcinoma cells with 
CAFs promoted tumor growth and angiogenesis through secretion of stromal cell–derived 
factor 1 (SDF1) from CAFs and the binding of the factor to the CXCR4 (C-X-C chemokine 
receptor type 4) receptor on tumor cells [93]. Furthermore, CAFs have been implicated in 
invasion [94] and metastases [95], [96]. In short CAFs have a significant role in promoting 
tumor growth and angiogenesis. 
 
Basic fibroblast growth factor (bFGF) is a heparin binding growth factor (see FGF family 
description in section “Angiogenesis in Physiology”) that motivates tumor cell proliferation 
through FGFR signaling by both paracrine and autocrine modes [97]–[99]. 
 
Thrombospondin 1 (TSP1), a glycoprotein that facilitates cell-cell and cell-matrix 
interactions, acts as a strong angiogenic inhibitor [100]. TSP1 binding to CD36 on the 
endothelial cell surface renders these cells insensitive to VEGF [101], [102]. Moreover, 
TSP1 expressed in stroma shows an initial strong inhibitory effect on tumors [103]. 
However, several publications also show the down-regulation of TSP1 expression in 
numerous breast cancer cell lines [103], [104].  
 
The cytokine TGF-β controls important cell functions like cell proliferation or cellular 
differentiation in most cells [105]. An interesting paradox exists with regard to the 
angiogenic effect of TGF-β [82]. While under in-vivo conditions a potent pro angiogenic 
effect was demonstrated [106] in-vitro data illustrated growth inhibition of endothelial cells 
by TGF- [107], [108]. In addition, TGF-β1 is known to either stimulate expression of Tsp1 
[109], [110] or of VEGF [111], [112]. In short, depending on the microenvironment, TGF-
β can lead to pro-angiogenic changes via VEGF or anti-angiogenic changes via TSP1. 
 
25 
 
 
Platelet-Derived Growth Factors (PDGFs) are regulatory proteins that control cell growth 
and cell division. PDGF is a potent stimulator for FGFs expression [113] and eventually 
VEGF in tumor associated stroma [114]. Further, Brogi et al. showed inhibition of PDGF 
activity by administering PDGFR, which in turn inhibited tumor angiogenesis [111]. These 
data evidence PDGF to act as strong inducer of stromal VEGF expression. However the 
activity of PDGF still needs to be studied in details as it has also been shown to stimulate 
TSP1 (angiogenic inhibitor) expression [115].  
 
The expression of hormones like estrogen and androgen also affects the tumor 
microenvironment. Both these steroids are thought to inhibit the expression of TSP1 [116], 
[117] but through different mechanisms. In a recent publication, Gupta et al. demonstrated 
estrogen to have a proangiogenic effect on estrogen receptor-negative breast cancers [118].  
Lipid synthesis in stromal fibroblast is known to activate neovascularization of tumors. One 
component in this signaling is the production of sphingosine 1 phosphate, which is able to 
suppress Tsp1 expression and, that way, support tumor angiogenesis [119]. 
 
For tumor cells to show invasion and metastasis they have to be able to degrade the extra 
cellular matrix (ECM). Matrix metalloproteases (MMP) play a crucial role in matrix 
degradation and remodeling [120] and, eventually, in supporting tumor angiogenesis. By 
using MMP inhibitors (batimastat), Noel and colleagues succeeded in eliminating the tumor-
promoting effect of fibroblasts in mice bearing MCF7 induced tumors [121]. In addition to 
this, MMPs are also involved in converting latent TGF-β to active forms, thus stimulating 
mammary tumors growth [122]. 
 
Bone marrow derived cells (BMDCs) are specialized cells that migrate to tumors often due 
to the secretion of chemokines by tumor cells or as consequence of a tumor-associated 
inflammatory response. BMDCs, nestled within the tumors microenvironment, are known 
to contribute to the malignant progression of various entities [123]–[125]. The most common 
cell types among BMDCs include mesenchymal stem cells, neutrophils, macrophages, mast 
cells, and T cells [126].  
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Mesenchymal stem cells (MSCs) have a unique differentiation plasticity along osteogenic, 
chondrogenic and adipogenic lineages [127]–[129]. The cells are abundantly recruited to 
inflammatory or wounded sites as well as locations of growing neoplasms. Within the tumor 
microenvironment, malignant cells secret a large variety of cytokines (CCL2, CCL7, and 
CXCL12 (SDF-1)) and growth factors (VEGF, bFGF, IL-8, EGF, HGF, and PDGF), all of 
which are potent cues for the recruitment of MSCs [130]–[134]. The precise mechanism of 
the role of MSCs involvement in tumor growth and progression is yet to be determined, but 
it is thought that MSCs promote tumor growth through secretion of pro angiogenic growth 
factors [135], [136]. 
 
Hypoxia and high lactate levels are responsible to recruit Tumor Associated Macrophages 
(TAMs) to both tumors and wounds [137]. TAMs, in turn, fuel the expression of pro-
angiogenic growth factors (e.g. bFGF, VEGF, TNFα etc.) in the majority of solid 
malignancies [137]. Mast cells also confer proangiogenic effects in tumors as recently 
demonstrated by Soucek et al. In this work, Myc-induced pancreatic islet tumors were 
superior over control islets in recruiting mast cells for tumor expansion. In contrast, mast 
cell inhibitors rapidly elicited hypoxia and death of tumor cells [138]. 
 
1.3.1 HIF and Tumor Angiogenesis 
 
Changes of gene activity at transcriptomic level are critical for cells to successfully adapt 
and survive periods of O2- and nutrient-deprivation. The transcription factors HIF-1 
(Hypoxia-inducible factor-1) and HIF-2, i.e. master regulators of the hypoxic cell response, 
are highly conserved heterodimeric protein containing O2-regulated HIF-1 or HIF-2 
subunits and a constitutively expressed HIF-1β subunit, also known as ARNT (aryl 
hydrocarbon receptor nuclear translocator). The  and  subunits of HIF are members of the 
basic-helix-loop-helix PER-ARNT-SIM domain (bHLH-PAS) family of transcription 
factors. Under normoxic conditions, HIF-1/-2 are rapidly inactivated and degraded in an 
O2-dependent manner whereas hypoxia results in stabilization, accumulation and finally 
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transcriptional competence of active alpha subunits. Stabilized HIF-1/-2 subunits 
translocate into the nucleus of hypoxic cells where they form 1:1 or 2:1 heterodimers 
and, in this form, possibly control several hundreds of hypoxia-responsive genes [139], 
many of which are involved in angiogenesis (e.g., VEGF), anaerobic metabolism (e.g., 
glucose transporters and glycolytic enzymes; see next section for details), O2 transport (e.g., 
erythropoietin), and other activities crucial for cell survival and metastasis [44], [45]. 
 
Contribution of HIF-1 in tumor growth is well documented. Studies in mouse models 
demonstrated a significant role for HIF-1 in tumor angiogenesis and growth [140], [141], 
despite the fact that signaling cascades other than HIF-1 also impinge on VEGF mRNA 
steady state levels in hypoxic cells. As outlined above, hypoxic conditions and activated 
HIF-1 will directly activate VEGF and VEGFR1 transcription [140], [142]. Higher 
expression of HIF-1 and VEGF correlates in human patients with more aggressive and 
malignant lesions [143], [144]. Carmeliet et al. demonstrated that loss of function of HIF-
1 in mouse embryonic stem (ES) cells reduces hypoxia-induced expression of VEGF and 
prevents formation of large vessels in ES-derived tumors resulting in hypoxic 
microenvironments within the tumor mass [145]. A recent study on HIF-1 demonstrated 
autocrine signaling between VEGF and its receptors to regulate endothelial cell and tumor 
cell metabolism [146]. Deletion of HIF-1 in endothelial cells interrupts this loop necessary 
for hypoxic induction of VEGFR-2 by VEGF signaling through VEGFR-1 [145], [146]. 
These examples illustrate the predominant role of the hypoxic stimulus in the regulation of 
tumor angiogenesis. 
 
Nitric oxide (NO), a free radical and important signaling molecule in the regulation of 
vascular tone is produced by nitric oxide synthases (NOS) via l-arginine-nitric oxide 
pathway [147]. Three distinct isoforms of NOS, neuronal NOS (nNOS; NOS1) [148], 
inducible NOS (iNOS; NOS2) [149], and endothelial NOS (eNOS; NOS3) [150] exhibit 
unique tissue/cell type distributions and regulatory mechanisms [151]. nNOS and eNOS are 
constitutively expressed with functions largely limited to neurons and endothelial cells 
[152]. NO and eNOS functions merge with the oxygen sensing machinery to define vascular 
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function and angiogenesis [153]. The third member iNOS is profoundly induced by hypoxia, 
particularly when co-occurring with inflammatory cytokines. Notably, endothelial iNOS is 
required for hypoxia mediated VEGF expression but does not affect expression of other HIF-
1α responsive genes [154]. As a consequence, HIF-1α stimulated NO production would 
result in cooperation with VEGF to promote vascular permeability [155]–[158]. 
 
In addition to HIF, the induction of neovascularization in response to hypoxia can also be 
mediated by NF-B (nuclear factor kappa-light-chain-enhancer of activated B cells) [159]. 
Schmidt et al. showed that junB, a hypoxia-responsive transcription factor activated by NF-
B, induces VEGF expression independent of HIF activity [160]. Given the multiplicity of 
mechanisms and target genes involved in angiogenesis, hypoxic microenvironments in 
tumors evidently promote angiogenesis, and hence tumor growth, via HIF-dependent and 
independent mechanisms. 
 
 
1.3.2 Tumor metabolism (glycolysis) 
 
In normal and transformed cells, presence of oxygen stimulates the complete oxidization of 
acquired glucose to pyruvate, and inside mitochondria further to CO2 and H2O, thus keeping 
the glycolytic conversion of glucose to the lactate end product at minimum. As long as O2 is 
not limiting, oxidative phosphorylation of carbohydrate substrates yields up to 38 molecules 
of adenosintriphosphat (ATP) per glucose molecule whereas anaerobic glycolysis produces 
only 2 ATPs per glucose. Yet, once supply of oxygen starts to dwindle, glucose flux through 
glycolysis is markedly elevated to somewhat compensate for the far lesser energetic efficacy 
by higher substrate throughput (i.e. Pasteur effect [161]). In addition, cancer cells [162]–
[164], but not only those (see below), are able to sustain their high mitotic activities on the 
basis of aerobic glycolysis. This so-called Warburg effect is characterized by a significantly 
increased rate of glycolytic sugar consumption and lactate build-up under aerobic oxygen 
tensions. When Otto Warburg first described prominent aerobic fermentation as unique 
dedifferentiation-feature of tumor cells some 80 years ago, he saw in it the tumor’s 
compensatory reprogramming effort to the initial and cancer-causing insult: an irreversible 
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injury of respiration (“Die aerobe Glykolyse der Tumorzelle rührt in jedem Falle von einer 
Störung der Atmung her”; translation: “Aerobe glycolysis in tumor cells is in every case due 
to an impaired respiration”; O. Warburg, 1929) [165], [166]. Warburg had, in essence, 
associated the mutually antagonistic relationship between respiration (= impaired) and 
glycolysis (= activated), as formulated by the Pasteur effect, to the genesis of cancer. His 
discovery has had a very strong impact on the oncological community and, to this day, 
aerobic up-regulation of glycolysis [163] or a predominantly glycolytic metabolism in 
general [167] are regarded as near-universal property of primary and metastatic cancers, i.e. 
remain associated with tumorigenesis. However, during the post-Warburg era it became 
evident that a strong basal glycolytic capacity is neither the cause nor a universal 
characteristic of malignancies ([162], [168] for critical review on Warburg effect and its 
interpretation). Instead, cancer cells are able to carry out the oxidative phosphorylation of 
glucose by mitochondria in the presence of oxygen just as effectively as normal cells do. 
Aerobe cancer cells utilize, in absolutely comparable fashion to non-transformed cells, only 
minor (20-25%) contributions of their ATP production from the anaerobic glucose-to-
lactate conversion (e.g. McA-RH7777 Hepatoma [169], MCF7 breast carcinoma [170], ) 
while fueling a 75-80% fraction of their energy budget by the complete oxidation glucose-
to-CO2 oxidation [171], [172].  Moreover, a tight coupling between proliferative and 
glycolytic rates exists even in non-cancer cells (i.e. primary thymocytes), as was revealed 
by Brand and Hermfisse [173], [174]. According to these authors, resting thymocytes meet 
88% of their ATP demands via oxidative glucose breakdown, whereas proliferating 
thymocytes switch almost entirely to glycolysis and gain 86% of their ATP from glucose-
to-lactate catabolism. As hypothesized by Brand and Hermfisse, this switch to glycolysis in 
fast growing cells and tissues could, through the production of potent scavengers for reactive 
oxygen species (ROS) (i.e. pyruvate), be part of an antioxidant strategy to minimize 
oxidative stress during sensitive phases of the cell cycle (i.e. S phase, above) [173], [174]. 
Thus, a Warburg effect-type glycolysis is neither restricted to cancerous backgrounds nor 
does it derive from dysfunctional oxidative processes or is, in any way, causally linked with 
the development of tumorigenesis. 
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1.3.3 Production and uptake of lactate in cancer cells 
 
Through anaerobic glycolysis a significant proportion of pyruvate is reduced into lactate by 
lactate dehydrogenase (LDH). Physiological concentrations of lactate in normal tissues 
fluctuate around 1.8 - 2.0 mM. In contrast, 4 - 40 mM lactate may occur in human tumors 
such as cervical cancer [175], [176]. Deoxygenated tumor cells export lactate together with 
protons through the monocarboxylate transporter 4 (MCT4), a member of the lactate-proton 
symporter family, and that way avoid intracellular acidification [177]. Yet, in stark contrast 
to cultured cancer cells, in tumors the exported lactate is not lost as extracellular waste but 
“recycled” by oxygenated cells via monocarboxylate transporter 1 (MCT1) where it fuels 
the oxidative metabolism (TCA cycle). It becomes clear that glycolytic and oxidative tumor 
cells mutually regulate their access to energy metabolites and that monocarboxylate 
transporter (MCT) proteins are at the heart of this interdependence. 
  
The MCT family in humans consists of 14 members (MCT1-MCT14), encoded by the 
SLC16 gene family [178]. The stereotypical MCT protein has intracellular N- and C-termini, 
12 transmembrane helices (TMs), and a large cytosolic loop between TMs 6 and 7 [179]. 
While MCT1-4 are all known to facilitate the proton-linked transport of metabolic 
monocarboxylic acids such as lactic acid, MCT1 functions primarily in the uptake/import of 
monocarboxylates through the plasma membrane. Besides being a high affinity importer for 
L-lactate, MCT1 can also shuttle acetate, pyruvate, D-β-hydroxybutyrate, acetoacetate and 
propionate across the membrane [178]. Compared to other family members, MCT1 evidently 
transports a rather wide range of carboxylates. MCT2 has, relative to MCT1, a higher affinity 
for L-lactate, pyruvate, acetoacetate and D-β-hydroxybutyrate. Since MCT1 and MCT2 are 
situated on different cells when expressed in same tissue they may occupy different roles as 
metabolic shuttles [180], [181]. MCT3 was first identified in chicken and is only expressed 
in specific tissue (choroid plexus and retinal pigment epithelium) [182], [183]. MCT4 is 
mainly associated with the export of lactate from cells with high glycolytic fluxes (i.e. 
Pasteur effect) during hypoxia [177]. Hence, MCTs make important contributions to the 
carcinogenesis, malignant progression and spreading of cancer cells by playing a dual role: 
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by exporting lactate from hypoxic and importing it into aerobic regions, they are vital to the 
interactive symbiosis between differently oxygenated tumor areas. By exerting pH control 
functions (lactate/H+-symporter), they are key to the emergence of the acid-resistant 
phenotype.  
 
 
1.4 Anti-angiogenic cancer therapy: Yin and Yang 
 
Angiogenesis inhibitors (AIs), i.e. compounds that specifically block the sprouting of 
capillaries from pre-existing blood vessels (= angiogenesis), have been considered a 
breakthrough in cancer therapy for many years. Currently (2013) numerous different anti 
angiogenic drugs (bevacizumab, aflibercept, sunitinib, sorafenib, pazopanib, everolimus and 
axitinib) have been approved by the FDA for the treatment of 10 different types of cancer 
[184][185]. However, clinical experience with AIs showed that while these compounds work 
well in slowing the growth of primary tumors they can trigger cancer recurrence and 
increasing incidence of metastasis. Also the effect of anti-angiogenic therapy is short-lived, 
as withdrawal from such treatment induces rapid re-growth of tumor vessels and relapse 
[186], [187]. In addition, two major papers by Pàez-Ribes et al. and Ebos et al. in Cell 
demonstrated the role of antiangiogenic therapy as a driving force in tumor progression to 
stages of greater malignancy, echoed by increased invasion into surrounding tissue and in 
some cases boosted lymphatic and distant metastasis [188], [189]. AI therapy presumably 
raises the tumor´s aggressiveness by increasing both extent and severity of tissue hypoxia 
within the targeted mass (figure 4). In contrast, treatments that normalize the usually chaotic 
tumor vasculature with its erratic blood flow were indeed able to elevate in vivo oxygen 
tensions within the malignant mass in correlation with a reduced occurrence of cancer 
spread. Thus, normalized tumor blood supply is associated with a therapeutic gain.  
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In addition to the sobering clinical outcome of AI therapy, the impact of AI compounds 
on fundamental physiological parameters such as vascular normalization, blood flow and 
local tissue oxygenation within the tumor are insufficiently understood, despite the frequent 
use of these drugs to combat cancer growth and malignant progression. This enormous gap 
between goal and reality is mostly due to the lack of good pre-clinical models to evaluate 
tumor angiogenesis and its responses to different anti-angiogenic compounds. 
 
To target tumor angiogenesis and, that way, tumor size and virulence, a panoply of drugs 
has been tested and several advanced into clinical use (cf. above). Along with the heightened 
risk of cancer recurrence, the clinical application of AI drugs showed a number of severe 
side effects such as hypertension, kidney damage or arterial thromboembolic events. Given 
that tumor angiogenesis can result from several parallel hypoxia signals, any single-agent 
approach seems insufficient to induce adequate tumor responses and subsequent 
Figure 4: Mechanistic model how antiangiogenic therapy induces increased tumor 
invasiveness and metastasis reducing overall patient survival. a) Growing tumor inducing 
angiogenesis, b) Anti-VEGF therapy leads to slowing the growth of primary tumors, c) Anti-
VEGF therapy presumably raises the tumor´s aggressiveness by increasing both extent and 
severity of tissue hypoxia within the targeted mass, d) thus triggering cancer recurrence and 
increasing incidence of metastasis (figure acquired from [192]).  
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improvement of the disease-free and overall survival [76], [190]. Not surprisingly then, 
mono-therapeutic angiogenesis inhibition protocols have yet to deliver convincing evidence 
for tumor remission [190]. Even excessive vascular regression in the tumor with high doses 
of anti-VEGF/anti-VEGFR protocols may be counterproductive because it basically leaves 
(much of) the tumor inaccessible for blood-born cytotoxins. Thus, there is growing 
awareness that tumor angiogenesis mechanisms are rather heterogeneous and that they may 
or may not depend on VEGF-signaling. In addition, very recently published work suggests 
that the principle heterogeneity of the tumor regarding its energy metabolism favors the 
selection of the most aggressive and hypoxia tolerant tumor cell clones as an unwanted side 
effect of any anti-angiogenic therapy (figure 4).  
 
A major consequence of the insufficient, yet over-stimulated, tumor vasculature is the fact 
that most solid tumors, regardless of type and despite continuing angiogenesis, nonetheless 
develop severe regional hypoxia as they grow, due to a progressive mismatch between the 
high O2 demands of proliferating cells and the erratic or inadequate O2 supply by the tumor’s 
vasculature (see sections: 1.2.1: Pathological angiogenesis with particular focus on tumors 
for background). As hypoxic tumor cells are forced to primarily use glucose for glycolytic 
energy production and will release lactic acid as end product, this footprint of anaerobe 
glycolysis activity by the hypoxic patches is known to create a lactate gradient in inverse 
orientation to the oxygen gradient across the malignancy. However, in vivo this lactate is not 
lost but re-used by well oxygenated cancer cells [191]. Not only are tumors a metabolic 
patchwork of aerobic and hypoxic cells, but the ratio of both populations might change upon 
medical treatment. Anti-angiogenic monotherapy, for example, was unexpectedly found to 
select for more hypoxia tolerant tumor cells that can withstand hypo-perfusion better but are 
also more prone to produce metastases [76], [77], [192]. Therefore it is mandatory to address 
hypoxia resistant tumor cells specifically and in parallel with an anti-angiogenic cancer 
therapy. For all these reasons, a “back-to-the-board” reevaluation of anti-angiogenic 
therapies by proper pre-clinical models is urgently needed [77], [192], [193]. 
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1.5 New therapeutic anti-cancer strategy  
 
In answer to this need my thesis project intended to analyze and target certain metabolic 
pathways and angiogenesis of glioblastoma, breast carcinoma and melanoma cells, 
explanted on the surface of the chorioallantoic membrane (CAM) of the chick embryo. As 
noted above O2 profiles across solid tumors are quite heterogeneous. Effective anti-cancer 
therapies, therefore, need to target not only the oxygenated/aerobe compartment of the tumor 
but also the severely hypoxic/glycolytic cells. This overarching goal should be considered 
because a selective kill of oxygenated cells might leave too many surviving hypoxia tolerant 
cell clones. Ensuing selection among these clones might only further malignant progression 
in the residual mass, and, that way, greatly assist in the emergence of a phenotype prone to 
develop therapeutic resistance and a highly metastatic behavior (figure 4, 5). 
 
Thus, to reduce the incidence of tumor recurrence and spread a strategy needs to be worked 
out, which aims to kill cells in vessel-remote, deeply hypoxic areas of the tumor in parallel 
with anti-angiogenic therapies to prevent or minimize this selection toward more aggressive 
tumor cell clones. Such an aerobe-/hypoxic-area hitting strategy could combine AIs such as 
Avastin® (VEGF antibody), with the Monocarboxylate Transporter 1 (MCT1) CHC that 
blocks lactate uptake. The groups of Mark Dewhirst (Duke Univ. Med. Center) and Pierre 
Sonveaux (Univ. Louvain Med. School) were previously able to show that the CHC blockade 
of the MCT1-mediated uptake of lactate is able to drive oxygenated tumor cells to commit 
to aerobic glycolysis through the acquisition and use of glucose instead of lactate as prime 
energy providing substrate. Through CHC treatment, oxygenated cells start to increasingly 
compete with hypoxic areas for glucose, which can eventually result in a highly efficient kill 
particularly of hypoxic cells. According to this concept, inhibition of MCT1 should trigger 
a re-routing of glucose from hypoxic to oxygenated cells, thereby dooming the hypoxic cells 
due to glucose starvation (figure 5). A more efficient treatment of hypoxia tolerant cells 
residing in deoxygenated tumor regions and, in consequence, a more efficient means in 
opposing an emerging therapeutic resistance of the cancer, can fruitfully exploit the reliance 
of these cells on glucose-fueled anaerobic glycolysis together with the above mentioned 
concept of the tumor as a metabolic symbiont [191]. 
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Figure 5: Lactate released from hypoxic cells is recycled by well-oxygenated cells of the 
tumor where it fuels high rates of oxidative substrate turnover and respiration. This oxidative 
signature spares glucose from consumption by oxygenated cells and allows the sugar to 
diffuse into the hypoxic areas of the neoplasm where it sustains anaerobic metabolism. 
Blocking lactate uptake by inhibition of MCT1 triggers a re-routing of glucose from hypoxic 
to oxygenated cells, thereby dooming the hypoxic cells due to glucose starvation (figure 
acquired from [191]). 
 
Coinciding with the lactate-import function by aerobe cells, MCT1 protein in xenografted 
tumors was mainly expressed within well-vascularized (positive CD31 staining) and 
oxygenated (negative HIF-1and pimonidazole staining’s) tumor margins. In contrast, 
hypoxic (positive HIF-1 and pimonidazole staining) and poorly vascularized regions of the 
tumor were completely devoid of MCT1 signal [177], [191]. Importantly, upon selective 
inhibition of MCT1, either by CHC treatment or as shRNA-driven knockdown, oxidative 
tumor cells switched from lactate oxidation to aerobic glycolysis (i.e. acquisition of Warburg 
phenotype). This prevented adequate glucose delivery to glycolytic hypoxic cells, which 
consequentially, died from glucose starvation even at a high distance to the drug-supplying 
blood vessels [191]. This glycolytic switch was associated with a decrease in oxygen 
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consumption of surviving tumor cells and, consequentially, an increasing tumor pO2 [191]. 
Thus, MCT1 inhibition is a potent anti-cancer strategy that indirectly eradicates 
hypoxic/glycolytic tumor cells and thus might render hard-to-treat malignancies more 
susceptible to therapy. The combination of MCT1 inhibition (to target hypoxic cells) with 
vessel normalizing agents (to render oxygenated cells more accessible for blood born drugs) 
is conceptually a very promising and completely novel approach. 
 
 
1.6 Chorioallantoic membrane (CAM) assay 
 
One century ago a US biologist J.B. Murphy showed that inoculation of Jensen rat sarcoma 
in developing chick embryos gives a fast growing tumor and could be maintained by 
continuous passage from egg to egg [194]. Fertilized chicken eggs (embryos) during their 
early stage of development are considered a border line model that bridges in vitro and in 
vivo systems and provides a highly vascularized membrane scaffold to study angiogenic 
processes in the context of tumorigenesis. Moreover, the CAM assay during the early stages 
of chick development is not considered an animal experiment (see below for rationale). Thus, 
CAM-based screens of AI protocols will help to reduce the number of animals needed in 
pre-clinical tests of anti-tumor compounds. 
 
CAM assays involve the xeno-grafting of tumor cell explants on top of the developing CAM. 
The developing chick embryo possesses four extra-embryonic membranes, including the a) 
yolk sac, b) allantois, c) amnion, d) serosa (chorion) membrane. On day 3.5 (d3.5) of embryo 
development the allantois appears from the ventral wall of endodermal hindgut. The allantoic 
vesicle expands very rapidly from d4 to d10. During this period the fusion of the mesodermal 
layer of allantois with the mesodermal layer of the chorion generates the CAM. The CAM 
develops an extremely rich vascular network that is connected via allantoic arteries and veins 
to the embryonic circulation. By d8 immature blood vessels and smooth muscle cells 
dispersed into the mesoderm, grow quickly to give rise to the capillary plexus. Rapid 
capillary proliferation is seen until d11 after which it starts to decline. By d14, the capillary 
plexus is well located at the surface of the ectoderm and by d18 the vascular system has 
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reached its final topography [195]. Eventually, by day 14, the mean surface area of the CAM 
measures approximately 65cm2 [196], while the thickness of the fully expanded CAM ranges 
between 20-100 µm [197], [198]. In addition to the respiratory exchange of oxygen and 
carbon dioxide as “embryonic lung”, the CAM also serves as reservoir for waste products 
(urea in early development; uric acid in later development). It is also involved in calcium 
mobilization from the shell, during bone growth [199]. 
 
The CAM assay represents a valuable methodological alternative to the most commonly 
used model of experimental tumors: xenografted cancer cells in immunodeficient mice. This 
inoculation of tumor cell lines into mice has several disadvantages. First, such models are 
limited with respect to the number of tumors that can be observed within one animal. Second, 
the accessibility of the tumors is generally hampered by at least the skin of the animals. In 
the ex-ovo mode of a CAM assay (figure 6) the membrane can be inoculated with several 
different tumors in parallel and is not covered at all by host tissue [200]–[202].  
 
Hence, tumor grafts are directly accessible, a huge gain for controlled manipulations (e.g. 
drug application) or optical readout methods. Third, the use of tumor models in animals is 
always an ethical problem due to potential suffering of the animals. In contrast, the CAM 
contains no nerves during early embryo development; thus tumor growth cannot induce pain 
Figure 6: Ex-ovo assay enhances the accessibility of the CAM and chick embryo, allowing easy in 
vivo documentation of effects and facilitating experimental manipulation of the embryo.   
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in the embryo. Consequently, by Swiss law the CAM assay is not considered an animal 
experiment up to embryonic day 14.5 of development [203], [204]. Fourth, owing to the lack 
of a mature lymphoid system, early stage chick embryos are naturally immunodeficient and, 
thus, cannot reject xenogenic tumor cells [200]–[202]. Fifth, the CAM assay greatly 
facilitates a high throughput of tumors treated with different therapeutic strategies. It also 
serves as repository for cells that escaped from the primary site and intravasated into the host 
vasculature or organs, thus, making the CAM an excellent tool to study kinetics and single 
step processes of tumor cell metastasis under quasi in vivo conditions [200]–[202]. There are 
number of modifications for the original chick embryo assay. Commonly used are in-ovo 
and ex-ovo assays. In in-ovo assays a small window is made into the eggshell and 
experiments are carried out on top of the CAM within the egg. This approach has significant 
limitations, in assessing CAM and photo documentation of experiments. Yet, ex-ovo assays 
(figure 6) enhance the accessibility of the CAM and chick embryo, allow easy in vivo 
documentation of effects and facilitate experimental manipulation or observation of the 
embryo. For example, with laser perfusion-imaging technique [205] applied on ex-ovo assay 
real-time monitoring of tumor blood flow can be done. 
 
 
 
  
39 
 
 
2. Specific Aims 
 
i) To establish a pre-clinical angiogenesis model of different tumor types in form 
of the ex ovo chicken chorio-allantoic membrane (CAM)/tumor cell explant assay 
as a fast, cheap, easy-to-implement and animal-saving methodology for pre-
clinical drug screenings. By using this bioassay we will assess the following 
parameters for explanted tumor cells:  a) tumor growth, b) vascular functional 
performance (real-time blood flow using Laser-Doppler imaging; permeability 
of Evans blue), c) tissue oxygenation (pimonidazole staining), d) in vivo cell 
migration (ddPCR), e) Metastasis detection (MRI).  
ii) anti-angiogenic Avastin® (VEGF antibody), monotherapeutic treatment; 
iii) The same pro-/anti-angiogenic protocols as under (ii) but now in combination 
with an anti- monocarboxylate transporter 1 (MCT-1 inhibitor: CHC) strategy. 
 
Regarding aim iii, angiogenesis inhibition is commonly regarded not only to starve the 
tumor by reducing the rate of vessel growth per time unit but also to spark normalization of 
both structure and function of the tumor vasculature in the attempt to raise the efficacy in 
the specific targeting of the tumors’ oxygenated compartments close to blood vessels. In 
contrast, the anti-MCT1 protocol has recently been put forward as novel and effective means 
to selectively kill profoundly hypoxic tumor cells that are for example less radiosensitive. 
Thus, under (iii), both oxygenated and hypoxic compartments should be targeted, which is 
expected to shift the ratio between hypoxia tolerant and hypoxia sensitive cells in the tumor 
towards the ladder, which in turn, should sensitize the malignancy. 
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3. Materials & Methods 
 
 
3.1 Reagents: 
 
All cell culture media and media supplements were purchased from GIBCO Switzerland. 
The anti-VEGF antibody Bevacizumab (trade name: Avastin®, hereafter abbreviated AVA) 
was purchased from Roche (Genentech) Switzerland. -Cyano-4-hydroxycinnamic acid (C-
2020) (abbreviated as CHC) and Razoxane (ICRF 159; (±)1,2-di(3,5-dioxopiperazin-1-yl) 
propane) were bought from Sigma-Aldrich (R8657) (Switzerland) and Sunitinib (N-[2-
(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-
dimethyl-1H-pyrrole-3-carboxamide) (SUTENT) from Pfizer (Switzerland).  
 
 
3.2 Cell Lines  
 
Glioblastoma: U-87 MG (HTB-14TM) and murine melanoma: B16-F10 (CRL-6475TM) 
cell lines used in this study were purchased at ATCC® (American Type Culture Collection). 
Several lines were generously handed to us, i.e. MDA-MB231 cells from Prof. E. Dahl,  
(University Hospital of the Rheinisch-Westfälische Technische Hochschule Aachen, 
Aachen, Germany), Ewing Sarcoma cells (A4573 line) from Prof. Kontny (University 
Medical Center Freiburg, Freiburg, Germany) and renal clear cell carcinoma cells with (i.e. 
RCC4) and without (i.e. VHL reverted cell line: RCC4/VHL) loss-of-function (LoF) 
mutation in the VHL tumor suppressor gene from Prof. M. Wiesener (University of 
Erlangen-Nuremberg, Erlangen, Germany). Human hepatoma (Hep3B) and melanoma (501) 
cells [206] and breast carcinoma (MCF7, MDA-MB468) cells [207] were used in earlier 
publications of the laboratory and were available in the lab as stocks. 
 
 
3.3 Cell Culture 
 
Cell lines Hep3B, U87, RCC4 with VHL LoF (=RCC4) plus RCC4 with reconstituted 
wildtype VHL allele (=RCC4/VHL), MCF7, MDA-MB468 were all cultured in Dulbecco's 
Modified Eagle's Medium (DMEM). Eagle's minimum essential medium (EMEM) was used 
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for B16F10 cells, while 501 melanoma and Ewing Sarcoma cells were cultured in RPMI 
medium (RPMI Media 1640). Each medium contained high glucose levels (4.5g/l) was 
supplemented with 10% Fetal Bovine Serum (GIBCO 10270-106) and 1% 
penicillin/streptomycin. To maintain the selection pressure in RCC4 and RCC4/VHL cell 
lines the G418 (0.5mg/ml) aminoglycoside antibiotic was added to the medium at all times. 
All cell lines were maintained at 37°C in water–saturated room air with 5% CO2 and an 
oxygen-partial pressure (pO2) of 141.6 mmHg ([O2] = 18.6% O2).  
 
 
3.4 Fertilized chicken eggs 
 
Fresh fertilized eggs were purchased from a local hatchery (Animalco AG; Staufen, 
Switzerland; http://www.animalco.ch). In the laboratory eggs were stored at 10°C for up to 
one week before commencing incubation and embryo development. For egg incubation, a 
HEKA cabinet incubator with fully automatic egg-turning capacity (HEKA-Format) was 
used. The eggs were continually rotated throughout the incubation period at 37.5°C and a 
humidity of 60-62% for 72 hours before starting the CAM assay. To maintain aseptic 
conditions when preparing the embryos ex ovo, all used tools where wiped with 70% ethanol 
(ETOH) while other reagents maintained under sterile conditions. Prior to incubation all 
eggs were thoroughly wiped with paper towels soaked with 70% ETOH to remove any 
feathers, dirt and excrement [208]. 
 
 
3.4.1 Ex ovo CAM assay 
 
After 72 hours of incubation the eggs were wiped again with 70% ETOH and marked on the 
topside to indicate the side of the embryo and keep it in an upright position. On days 3 of 
chick development eggs were cracked horizontally with the marking facing up, through 
gentle blows on a metal edge lying perpendicular to the long axis of the egg. Sufficient 
cracking led to leaking of egg white, which indicated the beginning perforation of the egg 
membrane. Trough gentle pressure along the egg`s equator the egg finally opened and it’s 
in contents were gently poured into small, sterile plastic bowls with intact yolk sack 
containing embryo and yolk vessels on top. These ex-ovo chicken cultures were then covered 
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with petri dish leads and placed into incubators (Forma Scientific, Model-3336), were they 
were kept at 37°C and 60% humidity for the entire duration of the experiment. As all 
experiments were terminated before embryonic day 14.5 the CAM assays of this study were 
not considered an animal experiment according to Swiss legislation.  
 
 
3.5 Cell Preparation and Tumor Explants 
 
Prior to explanting cancer cells onto the CAM, or i.v. injecting them into the circulation of 
the membrane, cells were processed by trypsin/EDTA detachment and re-collected by 
centrifugation at 1000 rpm for 4 min, supernatant removal and a repeat spinning step for 2 
mins to remove all remaining supernatant. Cell pellets were then re-suspended in medium at 
a final concentration of 4 million cells per 15 l. On day 9 (d9) of chicken embryo 
development, 4 million cells (15l) were explanted onto the CAM to trigger tumor 
formation. CAM survival was recorded for chicken embryos having single tumor explants, 
multiple (two) tumor explants and no explants at all. Similarly i.v. injections of tumor cells 
were also accessed to check chicken embryo survival.  
 
 
3.6 CAM-cell line assessment 
 
The suitability of the CAM models for development and malignant progression of tumor 
explants was assessed using nine different cell lines, including human Hep3B hepatoma, 501 
melanoma, U87 glioblastoma, RCC4 and RCC4/VHL renal cancer, MDA-MB-468 
andMCF7 breast carcinoma, A4573 Ewing sarcoma lines, as well as the murine B16F10 
melanoma line. Initially, 2x106 cells were loaded at off-center locations of the CAM that did 
not directly superimpose with the embryo (see figure 6) on d9 of chick embryo development. 
The media volumes of cells to be explanted ranged from 10-50 l. Direct pipetting of the 
cell suspensions onto the CAM surface was found to yield superior rates of growing tumors 
compared to various cell retaining scaffolds (e.g. Teflon rings, 1% methylcellulose solution, 
miniature cotton balls, filter paper disks etc.).  
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Successful tumor establishment of the above cell lines was analyzed by scoring growth, solid 
mass formation (3D structure) and angiogenesis on d14 of embryo development. Positive 
scores were given, if growth (i.e. increase in surface area of tumors) was observed and 
negative scores for dried cell mass (dead cells) with no growth. Similarly, explants were 
observed for solid mass formation. Positive scores indicated tumor explants forming 
spherical structures on the CAM, whereas negative scores indicated cells diffusing away 
from the application site. Regarding angiogenesis, positive scores resulted when major 
vessels turned towards cues from the tumor explant and/or smaller vessels (capillaries) were 
being formed in the periphery of the neoplastic mass. Negative scoring was applied when no 
such vascular changes were visible. Scoring was carried out for each parameter to select a 
suitable cell line. Based on these three criteria, U87 cell line was finally selected as the line 
of interest for further experiments. 
 
 
3.7 In vitro and chicken embryo-toxicity assay 
 
Use of drugs at non-toxic concentrations was ascertained by applying a) increasing 
concentrations of the reagents mentioned above to cultured cells (in vitro toxicity), and b) 
doses of the respective compound, corresponding to validated safe-usage applications with 
human patients (see below), onto the CAM on d10 of embryo development (i.e. in vivo 
toxicity).  
 
Regarding (a), cytotoxic effects of different anti-angiogenic drugs to U87 cells were assessed 
for concentration ranges shown in Table 2 with cultures kept at an average confluency of 
80%. Stocks were prepared as follows: Sunitinib 40mg/ml in DMSO, Razoxane 40mg/ml in 
DMSO, CHC 1mol/l in DMSO and AVA 25mg/ml. 24 hours after drug application, cell 
viability was assessed via Trypan blue dye exclusion assays by staining a 1:1 dilution of the 
cell suspension with a 0.4% Trypan Blue solution. Cell counts were then determined using 
a Neubauer Counting chamber. (BLAUBRAND® counting chambers, Cat. No. 718605). 
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Table 2: Drug treatment on U87 cells. 
Avastin® 0 mg/ml 
(PBS) 
0.01 mg/ml 0.05 mg/ml 0.1 mg/ml 0.5 mg/ml 1 mg/ml 5 mg/ml 
Sunitnib 0μM 
(DMSO) 
0.01 μM 0.1 μM 1 μM 10 μM 100 μM  
Raxozan
e 
0 μM 
(DMSO) 
5 μM 10 μM 50 μM 100 μM 200 μM  
CHC 0 mM 
(DMSO) 
5 mM 10 mM 15 mM 25 mM   
 
Regarding (b), calculated mg/kg embryo concentrations of the respective drugs used embryo 
weights taken from published chick embryo development charts [201], [209] along with non-
toxic, yet effective, doses from human applications. Normally on d10 of development, the 
chick embryo weighs on average 2.26 gm. Thus, 0.0226mg of AVA (derived from 10mg/kg 
for human application of AVA IgG; [210]), 0.00226mg of Sunitnib ≅ 1mg/kg (derived from 
50 mg orally once daily [211]), and CHC (60mg/kg) were applied onto the CAM. The 
60mg/kg dose of CHC was used based on in vitro cell toxicity data and the fact that 
100mg/kg CHC and 80mg/kg showed complete inhibition of tumors [212]. Thus to study 
the effect of AVA in combination as well, CHC concentration was reduced to 60mg/kg. 
 
In addition, the outcome after i.v. injection of the same amount of AVA into CAM vesssels 
was examined. As control, an equal volume of PBS was loaded onto another CAM. Embryos 
were observed until day 14.5 for any occurring fatalities.  
 
 
3.8 Drug treatments 
 
On d10 of embryonic development, one day after tumor cell explants the chicken embryos 
were treated with anti-angiogenic drug treatment AVA (10mg/kg), with MCT1 inhibitor 
CHC (60mg/kg) alone and with the combination of both compounds. Body weight of living 
embryo on day 10 was taken into consideration while loading drugs [201], [202].  
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3.9 Impact of drug treatment on tumor growth 
 
Growth kinetics of U87 tumors was monitored by taking digital images of tumors on 
developmental days 10, 12 and 14. These images where analyzed with MCIDTM software by 
marking the tumor borders and assuming a spherical volume of the explanted mass (i.e. 
volume v=4/3πr3, with r=1/2√ (D1xD2)). The treated tumors were compared to controls, 
whose volume was set to 100% [213]. Starting with an initial volume set to 100% on day 2 
(embryo development d10) post-explantation, the relative volume increase on day 4 (embryo 
d12) and 6 (embryo d14) of AVA, CHC and AVA+CHC treated tumors was compared to 
PBS-treated control explants. 
 
 
3.10 Assessment of perfusion   
 
Blood flow around the tumor periphery was measured by employing real-time Laser Doppler 
perfusion imaging (moorFLPI, Moor Instruments) [205] that measures blood flow in 
microcirculation without physical contact with the tissue or the use of dyes or tracer 
elements. The techniques works, in principle, by irradiating low power monochromatic light 
onto the tissue and collecting returning photons, whose frequency spectra show considerable 
broadening due to their multiple scatterings by moving blood cells. This Doppler shift-based 
change of the laser frequency is then analyzed. The result is a computer-generated color-
coded image of the spatial distribution of micro vascular blood flow. Red colors indicate 
maximal, and blue tones least, amount of motion (figures 12b, e). Next, relative fluxes can 
be calculated in the region of interest using the software provided with the laser Doppler 
imaging system. Routine applications grafted 4 million tumor cells onto the CAM and 
allowed tumors to grow for 6 days. Laser Doppler measurements on d14 of embryo 
development (6 days after tumor explantation) were performed by focusing the imager 
specifically on the tumor (as major area) and the surrounding CAM tissue. To block 
background interference due to the yolk sack perfusion, different contrast solutions such as 
Evans blue, Trypan blue in glycerol/PBS in varying concentrations, were injected beneath 
the CAM. While these dyes reduced the motion artifacts to some extent, results were still 
inconclusive, presumably due to the protocols poor compatibility with the chicken embryo. 
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Injecting the contrast agents directly underneath the chorioallantoic membrane into the egg 
white often resulted in the premature death or stunted growth of the embryo. Eventually, 
however, a small cut into a poorly vascularized region of the CAM allowing the insertion 
and placement of a spoon-shaped strip of polystyrene plastic directly underneath the tumor 
explant  prior to readout, was found to be superior in blocking background noise from tumor-
associated perfusion signals (figure 12). 
 
Next, relative fluxes were calculated in the region of interest using software provided with 
the laser Doppler imaging system (MOOR Instruments, UK). For every explant-carrying 
CAM 12 different regions (each with 4200 pixel area) were measured around the tumors 
treated with anti-angiogenic protocols versus PBS-treated control tumors at high 
resolution/low speed settings (10sec/frame). To gather information on the CAM-internal 
variance of flow, 4 out of 12 regions measured blood flow on remote CAM sites, while 8 
regions documented blood perfusion around the periphery of the tumors.  
 
 
3.11 Pimonidazole Staining 
 
To visualize extent and severity of tissue hypoxia in U87 grafts tumor-bearing embryos were 
injected i.v. on d14 with the hypoxia specific probe pimonidazole (aka Hypoxyprobe™-1, 
NPI, Inc.; dose used: 60mg/kg) 20 mins prior to tumor harvest. Dissected tumors were fixed 
in 4%PFA for 48 hours and then cryo-protected by 30% sucrose solution (48 h). Tissue was 
then snap frozen in ice-cold isopentane (kept at -20°C) and tissue sections of 12m thickness 
prepared with cryotome. Sections were washed in PBS 3-times for 5-mins and blocked for 
one hour with 1% goat serum in PBS (to avoid non-specific antibody reaction). Next, 
sections were incubated overnight at 4°C with pAb2627 anti-pimonidazole rabbit antiserum 
(NPI, Inc; diluted 1/800 in PBS), followed by Cy-3 conjugated secondary goat antirabbit 
antiserum (Jackson ImmunoResearch 111.165.003) diluted 1/700 in PBS. The slides were 
then cover-slipped with an anti-bleaching reagent and images were acquired using identical 
settings of the camera/light intensity. Pimonidazole signals were quantified using MCID 
software according to a) intensity, and b) area. To calculate normalized pimonidazole 
staining intensities as proxy for the severity of tissue hypoxia the average signal measured 
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in the stained region was divided by the average background signal of the tissue. Percent 
pimonidazole positive area as proxy for the extent of tumor hypoxia was calculated as ratio 
of the stained (“pimo-positive”) area divided by the total tumor area in a given section. These 
ratios after treatment are expressed relative to control sections, set to 100%.  
 
 
3.12 Vessel Staining with Evans blue 
 
Evans blue staining was done, to visualize the effect of drug treatment on U87 tumor vessels. 
Tumor-bearing embryos were injected i.v (150µl). On d14, 20 mins prior to tumor harvest, 
with 4% Evans blue dye dissolved in PBS. Dissected tumors were snap frozen and tissue 
sections prepared with cryotome. The slides were then cover-slipped with an anti-bleaching 
reagent and images were acquired.  
 
 
3.13 Generating fluorescing stable tumor cell clones. 
 
U87 glioblastoma and MCF7 breast carcinoma cells were transfected with a GFP expression 
plasmid (gift from Prof. Kontny as University Medical Center Freiburg, Freiburg, Germany; 
basis of from BD biosciences Clontech Inc: 6084-1) or an IRFP expression plasmid (gift 
from Prof. Ian Frew Univ. of Zurich, Switzerland, basis of Addgene Inc: 31856) was used 
for another MCF7 transfection. For transfection respective plasmids (0.8ug) and 2 μl 
Lipofectamine™ 2000 (Invitrogen Inc.) were diluted separately in Opti-MEM® I Reduced 
Serum Medium (Invitrogen Inc. 31985-062) and incubated for 5 minutes. The diluted 
plasmid and Lipofectamine™ 2000 were mixed and incubated at room temperature for 20 
min to generate the transfection mixture. Cells were washed with serum-free opti-MEM 
medium, the transfection mixture was added to the twenty-four-well plates and incubated 
for 6 hr. Transfected cells were maintained at 37°C in an environment of 5% CO2. After 24 
hrs the cells were split into 12 well plates containing increasing concentrations of G418 (0 
mg/ml, 0.05 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 0.4 mg/ml, 0.8 mg/ml, and 1 mg/ml). Cells were 
fed with selection medium every 2nd day to maintain the selection pressure and inspected 
daily for toxicity. Depending upon the microscopic examination an optimal concentration of 
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G418 (0.1mg/ml) was selected. Using standard medium and optimal G418 concentration, 
cells were plated in a 96-well plate with 10 cells per well in a final volume of 100 μl. Cells 
were kept under selection pressure for 3 weeks and routinely analyzed for positive clones 
with fluorescence microscopy and only those wells were selected for further propagation 
that had more than 90% GFP positive cells. During the whole G418 selection process 
samples of un-transfected cells were used as negative control.  
 
 
3.14 In Vivo cell migration Assay 
 
To study cellular invasiveness and metastasis, ex-ovo Cam assay was arranged as described 
above. Highly tumorigenic MDA-MB231 breast carcinoma cells, with ascertained in vivo 
metastatic behavior [214], [215] were used for this assay since U87/GFP clones did not yield 
any spread of cells away from the initial explant (e.g. in liver) during the short time window 
of inoculation (6 days). The more aggressive MDA-MB231 cells were incubated in cell 
culture with 20µM fluorescent CellTracker™ Green CMFDA (5-chloromethyl fluorescein 
diacetate) dye (Invitrogen, Cat No: C2925) in serum free medium for 30mins followed by 
removing the culture medium from plates and rinsing cells with PBS, and trypsin treatment 
for detachment. The detached cells were collected in culture medium and centrifuged at 1000 
rpm for 4 min, supernatant removal and a repeat spinning step for 2 mins to remove all 
remaining supernatant. Cell pellets were then re-suspended in medium at a final 
concentration of 4 million cells per 15ul and explanted on CAM. The embryos were returned 
to the incubators (Forma Scientific, Model-3336), were they were kept at 37°C and 60% 
humidity for the entire duration of the experiment. On d14.5, tumor-carrying CAM was 
dissected and frozen for cutting into 4 zones (2mm x 15mm each) for DNA extraction (figure 
17c). 
 
 
3.15 DNA Extraction 
 
For each sample 300µl of Lysis buffer (100mM NaCl, 50mM Tris pH8.0, 10mM EDTA pH 
8.0, 0.1%SDS) was used followed by addition of 18µl of proteinase K (20mg/ml) 
(Macherey-Nagel, Ref-740506). Samples were incubated for 3hrs at 55°C. After incubation, 
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the samples were heated to 95°C for 20 min to inactivate proteinase K and immediately 
transferred onto ice, followed by the addition of 30 l of 3M sodium acetate and 750 l of 
ice cold ethanol (100%). This was followed by an overnight incubation of the samples at -
20°C.  On the next day, the samples were spun at full speed for 30 min at 4°C, and the pellet 
of precipitated nuclei acid was washed again with 300 l of ice-cold ethanol (70%). 
Following another full speed centrifugation step (20 min at 4°C) the supernatant was 
removed and the pellet re-suspended in 100 l of distilled water. 
 
 
3.16 ddPCR  
 
To find “traces” of human DNA as proxy for the presence of cancer cells within CAM tissue 
we used the droplet digital PCR (ddPCR) technique and primers suited to selectively amplify 
regions of the hypervariable D-Loop sequence of human (cancer cell measure) versus 
chicken (normalization product with constant expression across CAM zones) mitochondrial 
DNA (mtDNA) in the samples (figure 7). The ddPCR was performed as described in [216]. 
Briefly, genomic DNA was extracted from the MDA-MB231 explant itself (zone 0 in figure 
17b) as well as from zones 1, 2 and 3 (each representing a 2mm x 15mm wide strip of tissue: 
figure 17b) to determine the quantity of human D-loop amplicon, normalized to the chicken 
D-loop amplicon, as a function of distance from the initial explant. The approach reveals 
species specific amplification of the D-loop product with regard to positive controls 
(genomic DNA from a) humanMDA-MB231 cells, b) chicken liver) and the expected 
decreasing quantity of the human amplicon with regard to zones 0-3 (increasing distance 
form graft) (figure 17b). For the quantitative ddPCR we employed the same specific primers 
in conjunction with an internal fluor-probes labelled with FAM: (Fluorescein), and Yakima 
yellow i.e.: a) human specific ddPCR: Fwd primer: 5´CTAAATAGCCCACACGTTCC 3´, 
Rev primer: 5´ TAGGATGAGGCAGGAATCAA 3´, probe: 5´ FAM-
TCACGATGGATCACAGGTC-BHQ1 3´) and b) chicken specific PCR Fwd primer: 5´ 
TACTTCATGACCAGTCTCAGG 3´, Rev primer: 5´ AGTTCAGGAGTTATGCATGG 3´, 
probe: 5´ Yakima Yellow ACCGTACCTCTGGTTCCTC BHQ1 3´). The primer probe pairs 
were used in a single reaction together with 1ng/ul of zone 0-3 extracted DNA and 10ul of 
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2x supermix (ddPCR™ Supermix for Probes #186-3010: Bio-Rad), in a 20ul reaction. PCR 
was carried out at 95 °C × 10 min (1 cycle), 94 °C × 30 s and 60.5 °C × 30 s (40 cycles), 98 
°C × 10 min (1 cycle), and 12 °C hold.  
  
 
 
3.17 MRI Metastases detection. 
 
To detect metastases in liver, 4 million U87 and MCF7 cells were labeled with iron particles 
prior MRI imaging in order to increase the MRI contrast of the postulated metastasis in the 
subsequent measurement. For that purpose, cells treated with Ferucarbotran (Resovist: 
Bayer) at 100 g Fe/ml (BAYER Resovist®) were inoculated onto the CAM on d9. Again, 
explants were treated with AVA, and CHC alone and in combination. The experiment was 
stopped on d14.5 through i.v. injection of 100mM KCL solution. Next, embryos were 
transferred into 15 screw cap tubes and stored at 4°C for further MRI imaging. All 
measurements were performed in a Bruker 4.7 T BioSpec 47/40 (Bruker BioSpin MRI 
GmbH, Ettlingen, Germany) with a gradient strength of 375 mT/m and a slew rate of 3375 
T/m/s equipped with a linear polarized 1H mouse whole body transmit-receive RF coil. 
 
After a gradient-echo (GRE) localizer in 3 spatial directions, the imaging protocol included 
an axial T2-weighted Turbo Rapid Acquisition with Relaxation Enhancement (Turbo-
RARE) sequence with following parameters: echo time TE 11ms; effective echo time TE 33 
ms and repetition time TR 4440 ms; matrix 256 x 256; FoV 25 x 25 mm, rare factor 8, 
Figure 7: Human mitochondrial DNA 
with a D-loop region at upper right 
position. (figure adapted from 
Harrison's Principles of Internal 
Medicine, 17th edition [292]). 
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number of averages = 6, slice thickness = 1 mm, acquisition time 10 min 39 sec). For water 
diffusion assessment a diffusion-weighted spin-echo echo-planar imaging (EPI) was applied 
(effective TE = 29 ms, TR = 5000 ms, number of averages = 10, fat saturation; slice thickness 
= 1 mm, two b-values with 0 s/mm2 and 717 s/mm2, acquisition time 6 min 40 sec). All 
MRI experiments where performed in collaboration with Dr. Andreas Boss and Dr. Christian 
Eberhardt (Institut für Diagnostische und Interventionelle Radiologie Universitätsspital 
Zürich). We thank them for their immense support and guidance. 
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4. Results 
 
(Manuscript is submitted to carcinogenesis journal, which includes data, as marked in this 
section) 
 
4.1 Assessing CAM/tumor explant 
 
The chorio-allantoic membrane (CAM) model as pre-clinical and animal saving 
methodology for assessing both, development and malignancy of cancers, was performed 
with tumor cells explanted on the surface of the CAM in ex ovo assays. Nine different cell 
lines were examined as candidate explants and included human hepatoma (HEP3B), murine 
(B16F10) and human (501) melanoma, human glioblastoma (U87), human renal clear cell 
carcinoma with innate loss-of-function (LoF) mutation in the VHL tumor suppressor gene 
to generate constitutively active HIF signaling (i.e VHL LoF; cell line: RCC4) versus a 
VHL-reconstituted, HIF-inducible clone (cell line: RCC4/VHL) and three breast carcinoma 
cell lines of lesser (MCF7) and more virulent tumorigenic behavior(MDA-MB-468 and 
MDA-MB 231). 
CAM compatibility of all above cell lines was analyzed through scoring cell growth, solid 
mass formation (3D structure) and induction of angiogenesis of a given tumor cell explant 
on the CAM on day 14 (d14) of chick embryo development. 80% of chicken embryos 
bearing explants survived.  
From the nine cell lines tested only HEP3B, U87 and MCF7 (figure 8) formed vascularized 
solid masses (Table 3). Grafts of all other cell lines were either smaller, not vascularized or 
did not develop at all (dried cell mass). HEP3B, U87 and MCF7 tumors, however, yielded 
reproducible post-explant growth patterns. Subsequent microscopic observations showed 
that tumor grafts (i.e. HEP3B, U87) on the CAM remained dormant at first but started to 
develop a vascular network around the tumor periphery as a result of angiogenesis by day 
4 of inoculation. In addition, larger vessels running more distant to the graft where attracted 
by the tumor. Increased perfusion could be seen as direct evidence for the functionality of 
the tumor capillaries under higher Doppler magnification (figure 12e and 14a-c). 
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Neovascularization and tumor growth steadily progressed until d6 after cell explanation.  
 
 
As described in table 3 top scores of CAM suitability were found for HEP3B and U87 cells, 
which let us to select U87 cells as line of interest since it represent a highly proliferative 
glioblastoma neoplasm, which in vivo, however, rarely metastasizes [217], [218]. In 
contrast, malignant breast cancer (MDA-MB 231) is a well described entity with high risk 
of spreading to many different organs, particularly bone, brain, liver and lung [214], [215]. 
For these reason we selected the U87 line as our main CAM model for primary tumor 
characteristics. In parallel, MDA-MB 231 cell lines where used in examining metastatic 
behavior in CAM assays (Data from table 3 included in manuscript). 
 
 
Figure 8: Examples of vascularized 
solid masses formed by cells 
explanted on the chicken CAM. a) 
HEP3B, b) U87 and c) MCF7. 
Initially, cells were loaded at off-
center locations of the CAM that did 
not directly superimpose with the 
embryo on d9 of chick embryo 
development (see figure 6 in 
introduction). Images were made at 
day 6 after tumor cells explantation. 
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Table 3: Scoring chart detailing the growth patterns of different cell lines on CAM. 
Type 
 
Cell Lines 
 
Cell 
Growth 
Solid Mass 
Formation 
Angiogenesis Cell lines of 
Interest 
Renal carcinoma RCC4 - - - - 
Renal carcinoma RCC4/VHL - - - - 
Murine melanoma B16F10 + - + ++ 
Human hepatoma HEP3B + + + +++ 
Human melanoma 501 Mel + - - + 
Glioblastoma U87 + + + +++ 
Breast carcinoma MCF7 + + + +++ 
Breast carcinoma MDA-MB468 + - + ++ 
Breast carcinoma MDA-MB231 + - - + 
 
4.2 H&E staining: 
 
Hematoxylin and eosin (H&E) staining was used to evaluate histological details in U87 
tumor sections (figure 9). Tumor cells, recognized by their much larger cells and hyper-
chromatic nuclei, were detected in intimate contact with the membrane surface (figure 9, 
left) and while invading the chorioallantoic mesenchyme (figure 9, right). Development of 
tumor vascularization can be seen at CAM/tumor interphase (Figure 9 included in 
manuscript). 
 
Figure 9: H&E stained paraffin section of a U87 tumor 6 days after cell explantation. Left: 
overview of explant/CAM interface. Right: detailed view of tumor cells (large nuclei) 
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invading CAM mesenchyme. Hematoxylin and eosin (H&E) staining showed histological 
details in U87 tumor sections. Tumor cells can be recognized by their much larger cells and 
hyperchromatic nuclei, while invading the chorioallantoic mesenchyme (figure 9, right).  
 
4.3 Drug Toxicity Assay for U87 cell line 
 
To study the in vitro cytotoxic effects of different anti angiogenic drugs and the MCT1 
inhibitor (CHC) on U87 cells 80% confluent cell cultures were used. 24 hours after drug 
application (for concentrations see Materials & Methods), cell viability was assessed using 
Trypan blue dye exclusion assays. Figure 10 shows the percent of viable cells for increasing 
concentrations of a) AVA, b) Sunitnib, c) Raxozane and d) CHC. As compared to non-
treated controls (100% viable cells) 0.01, 0.05, 0.1, 0.5, 1, and 5mg/ml treatments of AVA 
hardly resulted in any toxicity. Even at maximal 5mg/ml AVA 93% (±2%) of cells retained 
viability. Similar results of marginal toxicity were seen with Sunitnib (0.01, 0.1, 1 and 10 
M concentrations; 94% (±0.75%) viability at 10 M) and Raxozane treatments (5, 10, 50, 
100, and 200 M concentrations; 96% (±0.92%) viability 200 M). In contrast, CHC 
application induced significant cell death in a dose-dependent manner. While 1mM CHC 
was hardly toxic on cells (viability of 96 ±2.06%) ~30%, 70% and 95% cell death were noted 
at 10, 15 and 25 mM, respectively (figure 10).  Data from figure 10b & 10c is not included 
in manuscript.  
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Figure 10: Viability of U87-MG glioblastoma cells (80% confluent cell cultures) in response to 
increasing concentrations of the indicated compounds a) AVA; b) Sunitnib; c) Raxozane; d) CHC. 
Cell death was induced by 0.1M NaCl solution (i.e. HS=high salt solution) and all treatments 
compared to non-treated controls. No significant cytotoxicity could be seen with AVA treatments 
whereas CHC imparted significant cell death in U87-MG glioma cells at concentrations of 5 mmol 
and above. Data are means ±SEM, n=3. Statistical differences among the mean coverage against 
controls were tested with one-way ANOVA, and significance was accepted at p<0.05. Asterisk 
indicates a statistically significant difference (* = p<0.05, ***=P<0.001). 
 
4.4 Testing drug toxicity on the CAM 
 
Regarding the in vivo toxic effects CHC, Raxozane and Sunitnib were applied onto the CAM 
and AVA i.v injected. On day 9 of chick embryo development (n=3 assays/compound) 
0.0154mg of AVA (10mg/kg), 0.00154mg of Sunitinib (1mg/kg), 0.0154mg Raxozane 
(10mg/kg) and 0.0924mg of CHC (60mg/kg) in PBS/DMSO were applied (see below for 
dose rationale). As control, an equal volume of PBS for AVA and DMSO for other drugs 
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was loaded onto other CAMs. Embryos were observed for the next 4 days. Microscopic 
observations revealed no major incidences of hemorrhage, hyperemia or coagulation at the 
application site of the CAM and all embryos survived till the end of experiment (day 14). 
As no fatalities were observed by any of these drug doses, we decided to use these 
concentrations in the subsequent experiments with tumor explants.   
To compare the above drug dilutions with in-vitro toxicity data (figure 10a, d), the mg/kg 
doses had been converted to molar concentrations considering 1kg to be equivalent to 1liter 
(1kg≈1liter). Thus 60mg/liter CHC corresponds to 0.3171mM CHC applied onto the CAM. 
Similarly, concentrations calculated for AVA, Sunitinib and Raxozane corresponded to 
0.01mg/ml, 2.5 M and 37.3 M respectively.  These concentrations were all well within the 
non-toxic range for cells, (figure 10a, d).  
 
 
4.5 Chicken embryo mortality 
 
Moreover the effect of different drug and tumor cells application methods (i.v. vs. topical) 
on chicken embryo mortality were assessed by treating the CAMs on day 9 (d9) of chicken 
embryo development and observing for any embryo deaths until day 14 (d14). Overall i.v. 
injections had a higher mortality rate as compared to topical applications. Topical application 
of drugs onto the CAM had a survival rate of 90% (27 survived out of 30) whereas i.v. 
infusion survived 53.34% embryos (16 survived out of 30) (figure 11a). While embryo death 
was rare under untreated conditions with 93.34% survival rate (28 survived out of 30) (figure 
11a) for tumor cell explant vs. i.v. infusion similar effect as for the drug application was 
seen. Chicken embryo survival rate was lower with i.v. cell infusion into CAM vessels 
(46.65%) as compared to topical tumor cell explantation (83.34%) onto the CAM (figure 
11b).  
 
This higher mortality rate with i.v. infusion is best explained by the delicate CAM 
vasculature and that placement of a needle into CAM vessels requires practice and skills. 
The major problems with i.v. infusion were a) sustained bleeding during and after i.v. 
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infusion, eventually leading to blood pressure drop as a cause for embryonic death and b) 
difficulty in introducing the needle into the vessel lumen due to small vessel diameter and 
low or no mechanical immobilization of the vessel at injecting site, as CAM membrane is a 
free floating structure on egg white. 
 
Next the effect of multiple tumor cell explants on chicken embryo survival was investigated 
as well by explanting, on day 9 (d9) of chicken embryo development, 4 million cells (15ul) 
onto the CAM and quantifying the embryo deaths until day 14 (d14). Chicken embryo 
survival rate was lower (65%), when two explants (4 million each) where done on single 
CAM (13 survived out of 20) as compared to single 4 million cell explant (83.34%) on a 
CAM (25 survived out of 30) (figure 11c). Data from figure 11 not included in manuscript.  
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Figure 11: Chicken embryo mortality after drug application or tumor cell explantation, a) 
Topical application of Drugs on CAM had higher survival rate of 90% as compared to i.v 
infusion with 53.34% surviving embryos. b) For tumor cell (explantation vs. i.v. infusion) a 
similar effect was seen. Chicken embryo survival rate was lower with 46.65%, after i.v. cell 
infusion into CAM vessels as compared to tumor cell explantation (83.34%) onto the CAM. 
c) Multiple tumor cell explants on the CAM reduced chicken embryo survival rate to 65% 
when two explants where done on single CAM as compared to a single explant (83.34%). 
For 9a, 9b &9c Mantel–Cox test gave a significant difference between the groups (* = p<0.05 
compared to normal embryo). 
 
4.6 Technique for monitoring tumor blood flow  
 
To measure the blood flow within the tumor and its periphery, a real-time blood perfusion 
imaging technique was utilized. This non-invasive approach measures blood flow in 
microcirculation without physical contact with the tissue. Thus, interfering influence on the 
measurement can be kept to a minimum. The result is a computer-generated color-coded 
image with red colors indicating maximal and blue tones least perfusion (figure 12b). Yet, 
initial CAM/Tumor explant assays yielded unsatisfactory results due to a considerable 
background interference (motion artifacts) observed in the image during flux measurements 
(figure 12a, b). These artifacts were mainly caused by overlay of the yolk sack blood 
perfusion in the vascular network of the embryo with the perfusion in the CAM, thus, 
creating erroneous color codes (e.g. figure 12b) (Figure 12 not included in manuscript). 
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Figure 12: Technique for optimizing laser Doppler perfusion imaging a) Image of a tumor 
on the native CAM, b) color-coded perfusion image of the CAM shown in a) with red colors 
indicating maximal, and blue tones least, amount of motion (cf. color scale shown in c)). d) 
Tumor image with a plastic strip beneath for blocking the background perfusion signal 
arising from the yolk sack, e) color-coded perfusion image of the CAM shown in d) with red 
colors indicating maximal, and blue tones least, and amount of motion (cf. color scale shown 
in c)). Note the effective blocking of the perfusion signal arising from the yolk sack by 
placing the plastic strip directly underneath the explant bearing site (figure 12d, e) and, thus, 
producing less noisy, reproducible and conclusive flow images. 
 
   This problem was successfully solved by blocking tumor flow signals from background 
interference by inserting a solid polystyrene plastic strip through a small cut into a poorly 
vascularized region of the CAM and placing it directly underneath the explant bearing site 
(figure 12d).  Now, blood flow measurements were less noisy, reproducible and conclusive. 
Figure 12e presents an exemplary color-coded image of blood flow measurements for the 
U87 explant shown in figure 12d. Arrows highlight blood vessels that were attracted by the 
tumor. Change in color intensity, indicating higher blood flow due to active angiogenesis, 
can be seen at the tumor periphery as a greenish “halo” around tumor (indicated by arrow 
head). In contrast, note the relative low perfusion in the core region of the tumor (cf. color 
coding scale for flux values, figure 12c). This approach was further used for flux 
measurements after drug treatment. 
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4.7 Drug treatment and growth kinetics of U87 Tumors 
 
After successfully establishing U87 explants as model tumors in CAM assays this setup was 
subsequently used to measure tumor growth kinetics under anti-angiogenic drug (AVA, 
10mg/kg) and MCT1 inhibitor (CHC, 60mg/kg) treatment, alone and in combination. Figure 
13a-d clearly demonstrates, on exemplary U87 grafts, the decreasing tumor size as function 
of drug treatment. Particularly the AVA+CHC combination therapy evidenced its additive 
effect in inhibiting mass accumulation of the primary growth (figure 13d).  
Image analysis allowed quantifying the tumor growth over time (see Material & Methods). 
By day 4 and 6 of the CAM assay, control tumor grafts (PBS treated) had increased their 
approximated volume by 1.1 and 2.6 fold respectively. On day 6 of the assay, the different 
treatments (figure 13e) indicated striking anti-tumor effects. While the angiogenesis-
inhibiting effect of AVA monotherapy was able to slow growth of the primary mass (i.e. 
relative tumor volume, d6 of assay: 269.24 (better 270) % ± 16.48% (control)  139± 
11.89% with AVA), CHC alone (122.04% ± 22.28%) and AVA plus CHC (50.65% ± 
41.13%) combinatorial treatment resulted, relative to control masses, in a marked retardation 
of tumor growth (shrinkage) Data from figure 13 is included in manuscript. 
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Figure 13: Tumor growth kinetics as function of treatment between day 2 and 6 of U87 cells 
after explanation onto the CAM (day 0 = explant day). Representative images of tumor 
explants subjected to: a) Control (PBS, 10µl topically applied around the explant); b) AVA 
(i.v. injected: 10mg/kg); c) CHC, (60mg/kg) topically applied around the explant; d) 
AVA+CHC (10mg/kg+60mg/kg). White arrows point to the respective primary mass. e) 
Quantification of tumor growth kinetics by image analysis (see Material & Methods for 
details). Starting with a tumor volume set to 100% at day 2 control, AVA, CHC and 
AVA+CHC treated tumors changed their size to 269.24 ± 16.48 %, 139.81 ± 11.89 %, 
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122.04 ± 22.28 % and 50.65 ± 41.13 %, respectively, within 4 days. Data are means ±SEM, 
n=6. Statistical differences among the mean coverages against controls were tested with two-
way ANOVA, and significance was accepted at p<0.05. Asterisk indicates a statistically 
significant difference (***=P<0.001). 
 
4.8 Angiogenesis and blood flow measurements in U87 tumors with AVA 
or CHC mono-therapy and combination of both  
 
As routine protocol for subsequent assessment of tumor formation and angiogenic 
response due to drug treatment AVA 10mg/kg and CHC 60mg/kg alone and in combination 
was used. Figure 14 shows color-coded image of the spatial distribution of micro vascular 
blood flow in and around the tumor periphery. As can be seen, for control (PBS treated) and, 
surprisingly, AVA-treated grafts a greenish angiogenesis “halo” around the tumor is clearly 
visible (figure 14b). In contrast, CHC application visibly reduced the halo (figure 14c). From 
the tumor subjected to combinatorial treatment, only cell loading site can be seen, as 
compared with vehicle and AVA, CHC treated tumors (figure 14d).  
Figure 14 illustrates the continuous reduction in blood flow when comparing control 
treatment (397.22 ± 31.96 flux units, 100%) with AVA (342.01 ± 40.18; 86%) or CHC 
(288.05 ± 43.43; 72.51%) monotherapies. Yet, blood flow dwindled to maximal extent in 
response to the AVA+CHC combinatorial treatment (198.61 ± 37.72; 48.99%), thus, 
highlighting the most potent anti-tumorigenic efficacy of this particular intervention. It is 
reassuring to note that flux at internal and tumor-remote CAM control sites was far less 
affected by these treatments, dropping only from 244.99 ± 25.81 units (100%, ctrl) to 204.48 
± 14.95 (83.46%) in the AVA+CHC group (figure 14f) (Data from figure 14 included in 
manuscript). 
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Figure 14: Laser Doppler blood perfusion imaging of U87 tumor explants. Panels a-e show 
representative blood flow recordings from tumors treated with (a-d) PBS (control), AVA, 
CHC and AVA+CHC (application mode and concentration used as in figure 13). e) Color 
scale for perfusion. i) Quantified blood flow (flux) measurements in U87 tumors in response 
to the indicated treatments. Note the significant reduction of peripheral tumor blood flow to 
almost CAM levels in response to AVA+CHC combinational treatment. Data are means 
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±SEM, n=6. Statistical differences among the mean coverage against control were tested 
with two-way ANOVA, and significance was accepted at p<0.05. Asterisk indicates a 
statistically significant difference (**=P<0.01). 
 
 
4.9 Pimonidazole staining 
 
To document the effects on tumor hypoxia by AVA-only (10mg/kg body weight), CHC-only 
(60mg/kg) and AVA+CHC treatments tumors were subjected to pimonidazole staining. 
Figure 15 shows exemplary sections in stereotypical orientation, i.e. on top the tumor surface 
exposed to air (tumor edge, hatched line), then tumor core (mid-section), followed by CAM 
interface (bottom). Pimonidazole signals were quantified using MCID software according to 
a) intensity (figure 15f), and b) pimo-positive area (figure 15g), set to 100% for respective 
control grafts. As expected, pimonidazole binding was absent in tumor regions close to the 
air-exposed surface while it mainly occurred in the core region of tumors and within the 
interface with the CAM. As can be seen in figure 15, AVA monotherapy augmented both 
intensity (figure 15 c, f) and area (figure 15 c, g) of pimonidazole staining in U87 tumors, 
which not only agrees well with the clinical observation of increasing therapy-resistance and 
tumor spread in AI-treated malignancies, but also provides evidence for an AI-therapy-
dependent increase in tumor hypoxia. In contrast, CHC-only and AVA+CHC combinatorial 
applications reduced pimonidazole intensities in primary U87 masses to 90% (CHC-only) 
and 60% (AVA+CHC) of control tumors (figure 15f) whereas the pimonidazole-positive 
hypoxic areas (ratio) were reduced slightly to 90% of control explants (figure 15g). These 
data, therefore, strongly support the efficacy of CHC-based protocols in targeting and 
eradicating hypoxic cells in solid malignant tumors (Data from figure 15 included in 
manuscript). 
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Figure 15: Assessment of local tumor hypoxia. a) Representative brightfield image to 
indicate different regions on the tumor section. b-e: Representative images of pimonidazole 
(Pimo) stained (red) cross sections of U87 tumors after (right top to bottom) control (PBS), 
AVA, CHC and AVA+CHC treatments (application mode and concentration used as in 
figure 13). Both the severity of tissue hypoxia, inidcated by the intensity of pimonidazole 
signals (Pimo signal/tissue background (f)) in the left-top graph and the extent of tissue 
hypoxia, defined as percent pimonidazole-positive areas (pimo-positive area/total tumor area 
(g)) in the left-bottom graph, were quantified as function of treatment (see Materials & 
Mehtods for details). While monotherapeutic AVA application elevated the intensity and 
area of tumor hypoxia, particulalry the intensity readout was drastically reduced upon CHC 
treatment and, even further significant reduction, with  AVA+CHC treatment. Data are 
means ±SEM, n=4. Statistical differences among the mean coverage against control were 
tested with one-way ANOVA, and significance was accepted at p<0.05. Asterisk indicates 
a statistically significant difference (* = p<0.05). 
 
 
4.10 Accessing the vascular morphology with i.v. injected Evans blue 
 
To confirm the data obtained with Pimonidazole staining Evan blue was injected i.v. to look 
for the effect of drug treatment (AVA-only, CHC-only and AVA+CHC applications) on U87 
tumor vasculature. Evans blue is a non-toxic dye widely used in the study of the morphology 
of the vasculature and its permeability. It binds to serum albumin forming a conjugate that 
can be identified by its red fluorescence in tissue sections using fluorescence microscopes. 
As expected, Evans blue was absent in tumor regions close to the air-exposed surface while 
dense stained vasculature could be seen at the interface with the CAM (figure 16). AVA 
monotherapy showed lower vascular density compared to controls in line with the clinical 
observation and the hypothesis that anti-angiogenic therapy could lead to tumor hypoxia. 
Combinatorial treatment showed the least vessel density at the interface thus strongly 
supporting the efficacy of CHC-based protocols in targeting and eradicating hypoxic cells 
in solid malignant tumors. Due to time and money constrains the experiments could not be 
repeated. But more detailed investigation is required in this regard to confirm the above 
findings from the staining (Data from figure 16 not included in manuscript).  
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Figure 16: Assessment of vascular morphology. Evan blue staining was done to look for the 
effect of drug treatment (AVA-only, CHC-only and AVA+CHC applications) on U87 tumor 
vasculature. As expected, Evans blue binding was absent in tumor regions close to the air-
exposed surface while dense stained vasculature could be seen at the interface with the CAM. 
AVA monotherapy (b) showed lesser dense vasculature compared to controls (a). While 
combinatorial treatment (d) showed minimal vessels at the interface thus strongly supporting 
the efficacy of CHC-based protocols in targeting and eradicating hypoxic cells in solid 
malignant tumors.  
 
 
4.11 In Vivo cell mobility assay with aggressive MDA-MB231 cell lines. 
 
To study tumor cell spreading, MDA-MB 231 cells, known to have a high risk of spreading, 
were used on the Ex-ovo Cam assay as a measure for metastasis and its response to the 
different therapy regimes investigated in the present study. First, CellTracker™ Green 
CMFDA dye labelled MDA-MB231 breast carcinoma cells where used to generate tumor 
explants that were then treated with AVA (i.v. injected: 10mg/kg) and (CHC, 60mg/kg) 
alone and in combination. Six days after tumor cell explantation representative images where 
made with a fluorescent microscope to track the cells on the CAM (figure 17a). 
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Unfortunately this method did not allow exact quantification of cell spreading. Therefore, 
genomic DNA was extracted from Tumor explanted CAM as well as nearby CAM tissue, 
divided into 4 zones (Zone 0, 1, 2, and 3) as detailed in materials and methods (figure 17b). 
PCR amplification showed the primers where species specific (figure 17 c). The presence of 
human DNA within the different zones of the CAM tissues was determined using ddPCR by 
amplifying human and chicken specific D-Loop sequences in the samples. The amount of 
human DNA was then normalizes to the amount of chicken DNA. Starting with zone 0 
(tumor on CAM) was set to 100% for detected signals with Control (±7.6%), AVA (±4.7%), 
CHC (±4.1%) and AVA+CHC (±5.0%) treatments. Significant change in cell spreading was 
observed in zone 1 of control (30.68±3.2%), AVA (56.35±15.49%), CHC (22.49±1.1%) and 
AVA+CHC (14.97±1.9%) treatments with AVA showing highest cell motility. A similar 
although non-significant effect was seen in zone 2 as well with a motility of 1.8±0.4%, 
6.0±0.1%, 1.5±0.7% and 0.5±0.4% for the respective treatments. Only negligible signals 
where detected in zone 3. These findings demonstrate the overall increase in spread 
(motility) of MDA-MB231 cells with AVA treatment as compared to controls and other 
treatments while reduction in motility was observed with CHC treatment and even further 
reduction with AVA+CHC treatment (figure 17d). Of note, these experiments again 
demonstrate the suitability of CAM/Tumor explant approach in study of cancer biology 
including cell motility (Data from figure 17 included in manuscript). 
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Figure 17: Spreading behavior of MDA-MB231 cells on the CAM in response to AVA and 
CHC (application mode and concentration used as in figure 13) treatments alone and in 
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combination. Six days after tumor explantation representative images where made from 
CAMs bearing tumors of CellTracker™ Green CMFDA dye labelled MDA-MB231 cells 
(figure 17a). For exact quantification of cell spreading genomic DNA was extracted from 
tumor explanted CAM as well as nearby CAM tissue, divided into 4 zones (Zone 0, 1, 2, and 
3) as detailed in materials and methods and sketched in figure 17b. PCR amplification 
revealed species specific amplification of the D-loop product with regard to positive control 
genomic DNA from a) humanMDA-MB231 cells [figure 17c, lane 2], b) chicken liver) 
[figure 17c, lane 3] and DNA extract from tumor explant from CAM [figure 17c, lane 4]. 
The content of human DNA within CAM tissues was determined using ddPCR by 
amplifying human and chicken specific D-Loop sequences in each sample. Starting with 
zone 0 (tumor explanted CAM) that was set to 100% for detected signals with control 
(±7.6%), AVA (±4.7%), CHC (±4.1%) and AVA+CHC (±5.0%) treatments. Differences in 
cell spreading were observed in zone 1 of control (30.68±3.2%), AVA (56.35±15.49%), 
CHC (22.49±1.1%) and AVA+CHC (14.97±1.9%) treatments with AVA showing highest 
motility. A similar effect was seen in zone 2 as well with a percentage of human DNA of 
1.8±0.4%, 6.0±0.1%, 1.5±0.7% and 0.5±0.4% for respective treatments, while negligible 
amounts of human DNA where detected in zone 3. These findings demonstrate the overall 
increase in spread of MDA-MB231 cells with AVA treatment as compared to controls and 
other treatments. In contrast, reduced spread was observed with CHC treatment and even 
more with AVA+CHC treatment (figure 17d) demonstrating the suitability of CAM/Tumor 
explant approach also for studying metastasis behavior of tumor cells. Data are means 
±SEM, n=3. Statistical differences among the mean coverage against control were tested 
with Wilcoxon rank-sum test (Significance was accepted at p<0.05=*). 
 
 
 
4.12 Metastases detection with MRI 
 
Magnetic resonance imaging in humans is one of the most common medical examinations 
to detect metastasis. As the CAM vessels convert finally to the embryonic liver we decided 
to use MRI of the chicken liver obtained from CAM assays with U87 cells explanted and 
subjected to drug treatment (AVA-only, CHC-only and AVA+CHC applications). Data 
analysis from diffusion-weighted EPI sequence and Turbo-RARE sequences could not 
detect metastases in the liver, despite the good image quality (figure 18). To corroborate the 
observed results, experiments where repeated by i.v. injection of U87 cells in chicken 
embryo, which as well could not provide the evidence of metastasis (images not shown) 
probably due to cell behavior. As U87 cell lines rarely metastasize [217], [218],  the 
experiment was repeated in a similar setup (explant + i.v: images not shown) but with the 
malignant breast cancer (MCF7) cell line. MCF7 is a well described entity with high risk of 
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spreading to other organs, particularly bone, brain, liver and lung [219]. But again no 
metastases were detectable (Data from figure 18 not included in the manuscript).  
 
Figure 18 Search for liver metastasis chicken embryos with U87 cell explants on the CAM. 
Representative Turbo-RARE MRI images showing the organs of 14.5 day old chicken 
embryos (Liver: arrow) that had been subjected to a) Control (PBS, 10µl topically applied 
around explant); b) AVA (=; i.v. injected: 10mg/kg); c) CHC, (60mg/kg) topically applied 
around explant and d) AVA+CHC (10mg/kg+60mg/kg) treatments. No evidence of 
metastasis was seen in MRI scans in none of the embryos. 
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5. Discussion 
 
Growth of malignant tumors requires continued supply with oxygen and nutrients, which is 
achieved through the angiogenesis. Thus, there was great hope that tumor treatment with 
angiogenesis inhibitors, could be an efficient anti-tumor strategy. However clinical studies 
showed that AIs often not only induced the expected growth retardation of the primary mass, 
but also cancer recurrence and metastasis [188], [189]. For this reason, renowned clinical 
oncologists voiced the growing need for reliable pre-clinical screens to better assess the 
efficacy and safety of future AI-applications. For example, the previous president of the 
Swiss Cancer League, Prof. T. Cerny, stressed the urgent need for additional investigation 
to recognize most effective anti-angiogenic treatment approaches at minimal adverse impact 
for the patient [193]. Such improved cancer therapies should simultaneously eradicate both 
aerobic and hypoxic tumor compartments of solid malignancies. Otherwise, surviving 
hypoxic cells might trigger the emergence of an increasingly virulent and therapy-resistant 
phenotype. By explanting tumor cell lines on the chorion-allantois-membrane (CAM) of 
living chicken embryos the objective of the present study was to evaluate both efficacy and 
safety of AI-applications, given either individually or in combination with antagonists of 
lactate uptake. That way it was aimed to shed some light on the mechanisms underlying the 
growth retardation of the primary mass and the heightened risk of tumor spreading in AI-
treated cancer models.  
The CAM assay characterizes a methodological alternative to the most commonly used 
tumor model, the mouse xenograft approach. During 2011 alone, around 402,600 mice and 
nearly 116,000 rats were involved in animal experimentation in Switzerland [220]. Despite 
the enormous use of rodent models in general, inoculation of tumor cell lines into mice is 
always an ethical problem due to the potential suffering of animals. In contrast, the CAM 
contains no nerves thus tumor growth cannot induce pain in the embryo [204]. Consequently, 
Swiss law does not consider the CAM assay an animal experiment up to embryonic day 14.5 
[203], [204]. All experiments of this study have always been performed within this time 
frame. Additional advantages of the CAM over rodent-xenograft assays include a) ease of 
accessibility of tumor explants, for example, by optical methods including as Laser Doppler 
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imaging to allow observation of the tumor growth and functional monitoring of tumor blood 
flow respectively; b) high throughput screening of tumors treated by different therapeutic 
protocols; c) natural immunodeficiency of early stage chick embryos (i.e. lack of a mature 
lymphoid system) which, therefore, cannot reject xenogenic tumor cells [221], and d) 
excellent tool to study kinetics and single step processes of tumor cell metastasis under quasi 
in vivo conditions [221]. Research by other groups assessed glioblastomas [222], melanomas 
[223], prostatic cancer cells [224] and osteosarcomas [213]  as CAM models.  
The present study tested eight different cancer cell lines as CAM models. Tumor grafts onto 
the CAM remained dormant at the beginning but after 4 days the development of capillary 
network was observed around the tumor periphery as a result of angiogenesis. Out of these 
eight cell lines only human hepatoma (Hep3B), glioblastoma (U87) and breast carcinoma 
(MCF7) formed vascularized solid tumors with active angiogenesis (figure 8), from which 
we opted to focus on U87 line for pre-clinical drug screens (Table 3). In contrast, B16F10, 
501 melanoma and MDA-MB-468 tumors were smaller, not well vascularized with little or 
no angiogenic effect to CAM. The remaining cell lines tested here, RCC4+/+ and RCC4-/-, 
didn’t show any growth on the CAM. The underlying reason for all the above observations 
and uneven growth patterns in different cell types remains speculative, but it may be due to 
difference in source of origin of graft cells or graft-host membrane interactions or trauma of 
the procedure. Similar results in line with our observations were shown by Kaufman et al. 
[225] and Hurst et al. [226], where some cell lines showed  tumor development and others 
not [227].  
H&E staining of U87 tumor sections, showed cancer cells, as recognized by their larger size 
and hyperchromatic nuclei, intimate contact with the CAM surface (figure 9, left) and while 
invading the chorioallantoic mesenchyma (figure 9, right). Moreover, increased perfusion 
around the forming mass and penetration of blood vessels into the tumor (figure 12e) was 
indicative of ongoing tumor-induced neovascularization, presumably through the secretion 
of angiogenic growth factors. Similarly, using glioblastoma spheroids, Magalhaes et al. 
[228] demonstrated successfully on ex ovo CAM assays the development of the tumor 
vasculature and invasion without the use of exogenous growth factors. Also Hagedorn et al. 
[222] showed that the model reliably simulates key features of human glioma growth in a 
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short time span. In line with our findings the CAM/tumor model appears to be suitable not 
only for the study of angiogenesis and tumor growth but also to analyze invasion and 
metastasis [229]. Limitations in CAM-based preclinical screenings do include i) non-
specific inflammatory reactions as a result of explant, as some publications suggest which 
can induce a minor secondary angiogenic response [230], [231]. ii) Short time window of 
the assay (6 days) making it ideal only for fast growing highly aggressive cancer models. iii) 
High mortality rate due to bleeding with i.v. infusion of test agents (figure 11a, b). iv) An 
inefficient model for metastases detection by MRI (according to our data, figure 18) due to 
short time window for cells to undergo metastasis and/or insufficient cell load. Despite these 
disadvantages, the CAM assay appears to be one of the preferred methods to study 
angiogenesis [227], [232], [233].  
Using cultured U87 cells, the in vitro toxicity of established AIs was initially evaluated, 
including the a) VEGF antibody AVA (Bevacizumab); b) VEGFR2 antagonist Sunitinib®, 
and c) the vessel-normalization agent Razoxane®. In addition, the toxic effects of an 
antagonist of lactate uptake, the MCT-1 inhibitor (CHC) was tested. 24 hour application of 
up to 5mg/ml AVA revealed hardly any detrimental effect on growing U87 cells (figure 
10a). Similarly, concentrations of up to 10M Sunitinib [234] and 200M Raxozane® did 
not confer marked cytotoxicity as compared to controls (Figure 10b, c). In contrast, CHC 
induced significant cell death in U87 cells, at and above concentrations of 5mM, indicating 
cytotoxicity with higher concentrations.  
Colen et al. [235] argued that the cytotoxic effect of high CHC concentrations might be due 
to the general disruption of both mitochondrial and glycolytic metabolism as a result of long-
term inhibition of lactate uptake [235]–[237]. Alternatively, CHC might also trigger a 
disruption of nicotinamide cofactor redox cycling between NAD+/NADH or 
NADP+/NADPH forms [235], [238].  
Previous in vitro studies showed that higher CHC concentrations (10mM) can adversely 
impact invasive and proliferative character of U87 cells [238]. In line with these findings in 
the present study a slight anti-proliferative effects of CHC at 0.31mM concentration was 
seen. Subsequently combination treatment of cultured U87 cells showed similar effect as of 
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CHC indicating that there is no additive or synergetic effect on cell proliferation under in-
vitro conditions and, thus, supporting the idea of tumor microenvironments as an ideal target 
for treatment. 
Glioblastomas are a highly vascularized malignant entity and therefore an attractive target 
for anti-angiogenic therapies. In our case AVA alone was found to considerably slow down 
the growth of the primary mass (figure 13), and attenuate blood flow (nutrient supply) to the 
tumor periphery by ~16% (figure 14), which appears to agree with the clinical situation 
where application of the antibody has been shown to delay disease progression [239], [240]. 
Despite this moderate starvation and retardation, however, AVA as a monotherapy yielded 
no improvement of overall survival in patients with glioblastoma [241]–[243]. Similar CAM 
experiments with bevacizumab supported our findings of strong antiangiogenic effect on the 
CAM [244], [245]. The lack of complete inhibition of tumor growth and perfusion by AVA 
can be explained by remaining VEGF-independent angiogenesis signaling and recent 
publications highlighting increased tissue hypoxia in glioblastomas post-AVA treatment 
[246], [247]. Accordingly we found that, relative to control grafts, AVA monotherapy 
augmented both intensity and extent of pimonidazole-positive hypoxia in U87 explants 
(figure 15 f, g). Thus, AVA-treated malignancies might indeed develop heightened therapy-
resistance and tumor spread as they become more hypoxic.  
In cancer cells, VEGF is constitutively overexpressed, independent of oxygen tension, but 
its steady state level can further be increased by hypoxia in HIF-dependent and –independent 
manner [67], [248], [249]. Once AI treatment targets a specific cascade (e.g. AVA targeting 
VEGF-A signaling), cancer cells are prone to evade the pharmacological stress by activating 
alternative factors or signaling events that will continue to promote tumor angiogenesis. 
These AI-triggered responses may include a) Recruitment of pro-angiogenic cells (vascular 
progenitor cells, pro-angiogenic monocytes from the bone marrow) to the tumor site [250]–
[252], b) up-regulation of substitute pro-angiogenic signaling mechanisms, e.g induction of 
VEGFC [253], [254] and VEGFD [255], [256] signaling via VEGFR2, and/or stimulation 
of FGF-mediated neovascularization [257]. Especially glioblastoma cells can respond with 
a highly versatile defense repertoire during anti-vascular endothelial growth factor therapy. 
Agda and colleagues [257] recently demonstrated the up-regulation of several angiogenesis- 
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(interleukins, FGFs, angiogenin) and invasion- (SPARC, TIMPs, MMP-2, MMP-9 and 
MMP-12) promoting molecules once glioblastomas cells were challenged by AVA in vitro 
[257], [258]. c) Increased and tight pericyte coverage, thus, protecting tumor blood vessels 
and d) enhanced capabilities for invasion without angiogenesis. Rubenstein et al. [259] for 
the first time demonstrated the invasive nature of orthotopic glioblastomas in mouse models 
under Anti-VEGF Antibody Treatment.  
Yet, despite the various scenarios to stimulate blood supply of nutrients, fast growing 
glioblastomas are notorious for developing severe local hypoxia and an associated increase 
in glycolytic flux, which may exceed that of the healthy brain areas by 3-fold or more [260], 
[261]. Consequently, one finds an increased ratio of lactate to pyruvate in these cancer cells 
[262]. Thus, upregulation of MCTs is believed to play an important role in intracellular 
homeostasis of malignant glioma and to support the tumors enormous virulence by enabling 
the use of lactate as oxidative fuel [191], [263], [264]. A number of reports demonstrated 
MCT1 to function as effective importer of lactate in tumor cells with active aerobic 
glycolysis [265]–[269]. Since lactate was shown to promote VEGF production by fibroblasts 
and macrophages [270]–[272], it might serve as key mediator in the organization, integrity 
and functionality of the vascular network around neoplastic masses. Accordingly our own 
data and other related publications [191], [273] suggest that blocking lactate uptake through 
MCT1 inhibition by CHC could be beneficial in treating tumor hypoxia and angiogenesis. 
Relative to AVA monotherapy, CHC application alone was far more effective in halting 
tumor growth (figure 13). It also reduced blood flow and nutrient supply to the tumor 
periphery by ~37% (figure 14). Most importantly, and in agreement with expectation, 
application of CHC attenuated intensity and extent of pimonidazole-positive hypoxia in U87 
explants, which illustrates the selective cell kill within hypoxic/glycolytic compartments of 
the tumors (figure 15). These effects of CHC were clearly potentiated by the combinatorial 
application of AVA+CHC. This dual anti-angiogenic/anti-MCT1 strategy resulted in real 
shrinkage of tumor growth (figure 13), a nearly 2-fold reduction in overall blood supply to 
the tumor (see figure 14) and dwindling pimonidazole-positive hypoxia intensities down to 
40% of control explants (figure 15f). Hypoxic areas in primary U87 masses were reduced to 
~90% of control tumors. This weakened pimonidazole staining in glioblastoma grafts treated 
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by AVA+CHC combination therapy is indicative for the eradication of hypoxic cells and the 
effective block of therapeutic resistance. Representative vessel staining with Evans blue as 
well, showed dwindled vessel at CAM/tumor interphase of combinatorial treatments as 
compared to monotherapies and controls supporting the hypothesis. 
Due to previous failed attempts to detect metastases/mobility in U87 and MCF7 tumors with 
MRI (figure 18), we switched to completely new cell line and new detection technique 
(developed in our lab). The major drawback of a CAM/glioblastoma explant setup is the fact 
that glioblastoma, in vivo, hardly ever metastasize [217], [218]. To also be able to assess the 
efficacy of mono- and combinatorial AVA and CHC treatments on cell metastasis/mobility, 
we switched our cell system to metastasis-prone MDA-MB 231 breast carcinoma cells [214], 
[215], [274]. MDA-MB 231 cell migration around the tumor was assessed under AVA-only, 
CHC-only and AVA+CHC applications (figure 17) with AVA treatments showing increased 
cell migrations as compared to monotherapies and control treatments supporting our 
previous findings, but as this assay is not a complete metastasis assay (due to lack of 
intravasation and extravasation) a thorough investigation is required in this regard before 
commenting on the metastatic behavior of MDA-MB 231 tumors with AVA-only, CHC-
only and AVA+CHC treatments. The reliability of CAM/migration assay for studying the 
cell behavior (migration), is also reported by a number of other publications [275]–[278] as 
well. 
The major findings of this study are: i) The observed growth of the tumor explant, its active 
angiogenesis in conjunction with regional pimonidazole-indicated tissue hypoxia and its 
invasion of host tissue all demonstrate the suitability of the CAM/tumor explant approach as 
pre-clinical tool for the development and malignant progression of primary tumors (see 
Table 3 and figure 8). ii) Monotherapy with angiogenic inhibitors (AIs) such as AVA 
resulted in the increased, not diminished, intensity and extension of pimonidazole-positive 
tumor hypoxia, a finding in line with the selection towards more hypoxia-tolerant and 
virulent secondary growth (see figure 15). iii) Anti-angiogenic therapy, when combined with 
MCT1 inhibitors (i.e. AVA + CHC), did not only inhibit most effectively both growth (see 
figure 13) and nutrient supply (see figure 14) toward the primary mass by targeting primarily 
the oxygenated/aerobe compartment of the tumor. This combinatorial treatment also resulted 
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in a significant diminishment of patches with severe tissue hypoxia within the residual tumor 
(see figure 15). Particularly the latter observation suggests AI/CHC treatments to be suitable 
to overcome the compensatory (anti-angiogenic) drug resistance of surviving clones that are 
adapted to withstand severe deprivation of O2 and other essential nutrients. 
Combinatorial therapeutic practices have become standard procedure for anti-cancer 
interventions in the clinic [279], [280]. For example, AVA [280] in combination with 
paclitaxel or temozolomide has been shown to exert potentiated antitumor effects on human 
breast cancer, glioma xenografts [281]–[284]. Using CHC as a pretreatment modality was 
found to effectively sensitize U87 tumors to radiotherapy [235].   
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6. Conclusion 
 
To date, however, pre-clinical data on anti-angiogenic tumor therapy do not translate very 
productively into the clinic, often associated with tumor aggressiveness and metastatic. But 
our intervention protocol of combining anti-angiogenic drugs (i.e Avastin) with agents that 
selectively target hypoxic microenvironments (i.e MCT1 inhibitors) within the tumor, have 
shown first hand evidence that, it might be able to shrink primary masses and minimize the 
risk of malignant progression and tumor spread at the same time, thus overcoming the 
compensatory angiogenic responses responsible for drug resistance and metastasis. Of 
course, these strategies need further analyses of suitable cell models and drug combinations 
in CAM and murine models and an appropriate approach for translating the results into the 
clinic. Also, we demonstrated the animal saving applicability of CAM/explant methodology 
as a cheap, easy-to-implement pre-clinical drug screen. In conjunction with a reduced 
number of xenograft analyses in rodents, a two-tiered approach, 1) high-throughput CAM 
screening of drugs and 2) an alternative to rodent models. That way we hope to address the 
urgent need for additional pre-clinical tools to identify most effective anti-angiogenic 
treatment strategies at minimal negative impact for the patient.  
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7. Future Perspectives 
 
Anti-angiogenic drugs (i.e. AVA) are already approved for clinical use in therapy of solid 
cancers. CHC (MCT-1 inhibitor) so far to the best of our knowledge is not yet in clinical use 
however other MCT1 inhibitors like AZD3965 are currently undergoing phase 1 clinical 
trials [285]. Coupled with anti-angiogenic drugs, the new-found roles of lactate metabolism 
in solid tumors could be a high- priority target for cancer therapeutics. Our findings with 
CAM assay has opened a new window in cancer treatment and we hope this findings will 
first lead to test our concept in animal models and second result in clinical trials. But to 
optimize the efficacy of this combinatorial protocol a better understanding is needed 
specifically in understanding the lactate shuttling and VEGF expression in malignancies of 
different tumor types and development stages along with the identification of biological 
markers that are associated with response and/or resistance to this combinatorial protocol. 
Treatments primarily aimed to target one cell compartment also affect several cell types in 
a tumor, such as tumor cells, endothelial cells and immune cells information on activity or 
output of precarious signaling pathway that are related to this cell types is also necessary, in 
order to develop a rational way of targeting. On the long run we expect that our novel 
therapeutic approach will aid in development of series of clinically potent and selective 
MCT-1 inhibitors and advancement in best drug combinations with safer and more efficient 
anti-cancer therapies. Thus, help to save and prolong the life of many patients.  
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Project B (Side project) 
 
(Role of Interleukin 6 (IL-6) in Ewing's sarcoma spread) 
 
8 Introduction 
 
8.1 Interleukin (IL-6) in Ewing's sarcoma spread 
 
Ewing's sarcoma is a rare disease associated with small round-cell tumor characteristically 
found in the bones, and sometimes soft tissues[286], [287]. It is most commonly seen in 
children and adolescents, comprising 16% of the total primary bone sarcomas[288]. Majority 
of the cases of Ewing sarcoma (85%) are due to Chromosomal translocation (between 
chromosome 22 and 11), fusing EWS gene from chromosome 22 to FL1 gene from 
chromosome 11[288]. In children Ewing Sarcomas is often associated with development of 
fever that is persistent.  Cytokines, like IL6, IL8 etc are known fever mediators and at the same 
time, interleukins like IL-6 are also known to promote cancer progression to a more virulent, 
invasive stage, working through numerous signaling cascades[289]. It is observed that 
patients with Ewing’s sarcoma, have significant elevated levels of serum IL-6, in correlation 
with a poor overall survival[290]. And as Ewing sarcomas are characterized with a strong 
potential to metastasize, the lungs are the most common site (50%), followed by bone (25%) 
and bone marrow (20%)[291]. In a small study using Cam assay we tried to answer the 
question. Does the fever mediator IL-6 boost tumor spread in Ewing’s sarcoma? 
 
9 Material and methods 
 
9.1 CAM assay to evaluate role of IL-6 in motility Ewing Sarcoma cells  
 
The A4573 Ewing sarcoma cell line, engineered to stably overexpress green fluorescent 
protein (GFP), was a generous gift from the group of Prof. Kontny (as above). For the in 
vivo motility assay 2.5x106 A4573/GFP cells were initially inoculated on the CAM on d9 of 
development (as described in section 3.4.1). On the following day, three explants, each 
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growing on a separate embryo, were treated with a) 10 l PBS (control), b) 10ul IL-6 
(25ng/ul) and c) 10 l IL-6 (50 ng/l)). IL-6 was purchased from R&D system (catalog 
number: 206-IL) and dissolved in PBS. On day 14 CAM images were made with fluorescent 
microscope to look for cell migration. A4573/GFP cells were detected under the fluorescent 
microscope (excitation: 488nm; emission: 507nm) and quantified as a function of migration 
distance from the perimeter of the explant. For that purpose three images per tumor were 
taken, each superimposed by a 15x12 square grid that allowed to subdivide the entire image 
into five equal-size zones (each with 3x12 square area) out of five, three zones where 
analysed: Considering zone 3 (tumor edge), zone 2 (adjacent to zone 3) and zone 1 (adjacent 
to zone 2) (see figure 19e). Next, cell coverage in each square was estimated with values 
ranging from 0 (no cells present) to 5 (square 100% filled with cells). Mean coverage values 
were computed from all three images per zone and tumor modality (control, 250ng IL-6, 
500ng IL-6).  
 
10 Results 
 
10.1 Effect of IL6 on cell migration. 
 
Ewing Sarcomas in children are often associated with development of fever. Cytokines, 
inlcuding IL6, IL8 etc. are known fever mediators. At the same time, interleukins (i.e. IL-6) 
can promote cancer progression to a more virulent, invasive phenotype. Thus, the question 
dealt with this experiment was: Does the fever mediator IL-6 boost tumor spread? Ewing 
Sarcoma-CAM tumor explants, treated with and without IL6, are ex vivo models in this 
context to look at the role of IL6 for an intensified cell migration on CAM. For this 
experiment GFP positive Ewing Sarcoma cells (A4573) explants where treated with a) PBS 
(control), b) 10ul IL-6 (25ng/ul) and c) 10ul IL-6 (50ng/ul)). On day 14 of chick embryo 
development, images were made around the tumor periphery with fluorescent microscope to 
look for cell migration (figure 19 a-c). Considering zone 3 (tumor edge), zone 2 (adjacent to 
zone 3) and zone 1 (adjacent to zone 2) (see figure 19e), data were analyzed as described in 
materials and methods (section 9.1). 500ng IL6 treatments clearly showed higher migration 
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rates as compared to controls and 250ng IL6 treatment (figure 19d), thus, confirming the 
previous findings for role of IL6 in inducing metastasis spread.  
 
 
Figure 19: Effect of IL-6 on spreading of GFP positive Ewing Sarcoma cells (A4573) 
explants. Tumors where treated with a) PBS (control), b) 10ul IL-6 (25ng/ul) and c) 10ul IL-
6 (50ng/ul)). Considering zone 3 (tumor edge), zone 2 (adjacent to zone 3) and zone 1 
(adjacent to zone 2) (see figure 19e), data was analyzed as described in materials and 
methods (see section 9.1). 500ng IL6 treatments clearly showed higher migration rates as 
compared to controls and 250ng IL6 treatment. Data are means ±SEM, n=3. Statistical 
differences among the mean coverages against control were tested with Kruskal–Wallis one-
way analysis of variance, which stated the effect of IL6 was not significant. (Significance 
was accepted at p<0.05, ns = not significant) 
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11. Comment 
 
Ewing sarcoma is known to show aggressive behavior, disseminating to vital organs (e.g 
lungs) Our data from Ewing sarcoma tumor showed dose dependent increase in cell 
migration with IL-6 treatment (figure 19) in line with the previous findings for role of IL6 
in inducing metastasis spread [289]. Clinical data suggest patients with Ewing’s sarcoma, 
have significantly high levels of serum IL-6, corelated with poor overall survival [290]. In 
case of this assay still a thorough investigation is required before commenting on the 
migration/metastatic behavior of Ewing sarcoma cells on CAM. nonetheless as a first hand 
evidence, the observed growth of the tumor explant, in conjunction with its cell migration 
under IL6 treatment all demonstrate the suitability of the CAM/explant approach as pre-
clinical tool to portray the development and malignant progression of primary tumors. The 
reliability of CAM/migration assay for studying the cell behavior (migration), is well 
reported by a number of other publications [275]–[278] as well. 
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13.1 Abstract 
 
Hypoxia inducible factors 1 and 2 (HIF-1 and HIF-2) control hypoxia induced gene 
expression by activating, in different subsets of cells, common as well as unique  HIF-1 or 
HIF-2 dependent sets of genes. . In general, it is assumed that the oxygen-labile HIF-1α or 
HIF-2α subunit dimerizes with ARNT (also known as HIF-1β) to form the transcriptionally 
active HIF complex, which also recruits gene specific coactivators. We have used 
fluorescence resonance energy transfer (FRET) to measure differences in the assembly of 
HIF-1 vs.  HIF-2 complexes. The FRET method also allowed us to study any potential 
homodimerization between HIF-1α and HIF-2α subunits. Whereas HIF-1α did not form 
homodimers, HIF-2α/HIF-2α and HIF-1/HIF-2α dimers were found and their existence 
confirmed by co-precipitation. Electromobility shift assays, however, revealed the lack of 
DNA binding to symmetrical or asymmetrical HIF binding sites by these newly described 
dimers. In addition, deletion constructs lacking the DNA binding domain still revealed HIF-
2α/HIF-2α and HIF-1/HIF-2α dimer formation despite the inability to bind DNA. To define 
a potential function of HIF-2α/HIF-2α and HIF-1/HIF-2α dimers target gene expression for 
HIF-1 or HIF-2 dependent genes was studied. We were able to show competition for HIF-
1α/ARNT complex formation by HIF-1α/HIF-2α dimers reducing the expression of a HIF-
1 target by forced accumulation of HIF-2α. Our data indicate a potential non-canonical 
tuning of the formation and activity of HIF alpha:beta heterodimers by HIF alpha-subunit 
homodimers in hypoxia induced gene expression. 
Note: Above is an abstract of a poster presented at Keystone conference by Prof. Dr. med. 
Joachim Fandrey. 
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Signaling and Regulation
Interaction of HIF and USF Signaling Pathways in Human
Genes Flanked by Hypoxia-Response Elements and E-box
Palindromes
Junmin Hu1, Daniel P. Stiehl2, Claudia Setzer1, Daniela Wichmann1, Dheeraj A. Shinde1, Hubert Rehrauer3,
Pavel Hradecky5, Max Gassmann1,4, and Thomas A. Gorr1,6
Abstract
Rampant activity of the hypoxia-inducible factor (HIF)-1 in cancer is frequently associated with the malignant
progression into a harder-to-treat, increasingly aggressive phenotype. Clearly, anti-HIF strategies in cancer cells are
of considerable clinical interest. One way to ﬁne-tune, or inhibit, HIF's transcriptional outﬂow independently of
hydroxylase activities could be through competing transcription factors. A CACGTG-binding activity in human
hepatoma cells was previously found to restrict HIF's access to hypoxia response cis-elements (HRE) in aDaphnia
globin gene promoter construct (phb2). TheCACGTG factor, and its impact on hypoxia-responsive human genes,
was analyzed in this study by genome-wide computational scans as well as gene-speciﬁc quantitative PCR, reporter
and DNA-binding assays in hepatoma (Hep3B), cervical carcinoma (HeLa), and breast carcinoma (MCF7) cells.
Among six basic helix-loop-helix transcription factors known to target CACGTG palindromes, we identiﬁed
upstream stimulatory factor (USF)-1/2 as predominant phb2CACGTG constituents inHep3B,HeLa, andMCF7
cells. Human genes with adjacent or overlappingHRE and CACGTGmotifs included with lactate dehydrogenase A
(LDHA) and Bcl-2/E1B 19 kDa interacting protein 3 (BNIP3) hypoxia-induced HIF-1 targets. Parallel recruitment
of HIF-1a and USF1/2a to the respective promoter chromatin was veriﬁed for all cell lines investigated. Mutual
complementing (LDHA) or moderating (BNIP3) cross-talk was seen upon overexpression or silencing of HIF-1a
and USF1/2a. Distinct (LDHA) or overlapping (BNIP3) promoter-binding sites for HIF-1 and USFs were
subsequently characterized. We propose that, depending on abundance or activity of its protein constituents,
O2-independent USF signaling can function to ﬁne-tune or interfere with HIF-mediated transcription in cancer
cells. Mol Cancer Res; 9(11); 1520–36. 2011 AACR.
Introduction
Relaying minutes-to-hours of inadequate oxygenation
(hypoxia) onto the level of DNA via the hypoxia-inducible
transcription factors 1 and 2 (HIF-1 and HIF-2) is a highly
conserved signaling event across the animal kingdom (1–3).
When exposed to low oxygen partial pressures (pO2), the
mammalian HIF-1/-2 complexes function as heterodimer of
HIF-1a or HIF-2a and HIF-1b subunits (4). Whereas
HIF-1b, also known as aryl hydrocarbon receptor nuclear
translocator (ARNT), is constitutively present, the activity
and abundance ofHIF-a subunits are regulated as a function
of pO2. In the presence of oxygen, homologs of prolyl
hydroxylase domain 1-3 (PHD1-3) dioxygenases catalyze
the Fe (II)-dependent hydroxylation of 2 proline residues
contained within the oxygen-dependent degradation
(ODD) domain and the N-terminal transactivation domain
(NAD; rear proline only) of HIF-1a and HIF-2a (5–7).
Once prolyl hydroxylated, HIF-a subunits are captured by
the von Hippel-Lindau tumor suppressor protein and rap-
idly degraded via the ubiquitin–proteasome pathway (6, 8).
A second, O2-requiring posttranslational modiﬁcation of
HIF-1a/-2a targets a single asparagine residue within the
subunits' C-terminal transactivation domain (CAD). It is
catalyzed by an asparaginyl hydroxylase called factor inhibit-
ing HIF-1 (FIH-1) to prohibit HIF-a:coactivator interac-
tion and suppress transactivation of genes under high oxygen
(9, 10). During hypoxia, both PHD and FIH-1 activities are
progressively inhibited, leading to a-subunit accumulation,
a:b-subunit dimerization in the nucleus and binding of the
heterodimer to hypoxia response elements (HRE) within
target genes. Being members of canonical CANNTG E-box
Authors' Afﬁliations: 1Institute of Veterinary Physiology; 2Institute of
Physiology; 3Functional Genomics Center Zurich; 4Zurich Center for Inte-
grativeHumanPhysiology, University of Zurich, Zurich, Switzerland; 5Altra-
Bio, Lyon, France; and 6Center for Pediatrics and Adolescent Medicine,
University Medical Center Freiburg, Freiburg, Germany
Note: Supplementary data for this article are available at Molecular Cancer
Research Online (http://mcr.aacrjournals.org/).
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ogy, Vetsuisse Faculty, University of Zurich,Winterthurerstrasse 260, 8057
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E-mail: tgorr@access.uzh.ch
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motifs, HREs consist of a consensus 50-VNVBRCGTG-30
(V ¼ not T; N ¼ any; B ¼ not A; R ¼ A or G; ref. 11). To
date, several hundred potential (12) and more than 70
validated (11) hypoxia-responsive and HRE-ﬂanked gene
targets of HIF-1 have been identiﬁed. Through this tran-
scriptional outﬂow, HIF-1 is able to reprogram cellular
metabolism, growth, apoptosis, and O2 supply in response
to declining pO2 (11).
Nonredundant roles of these hydroxylase systems in the
regulation of HIF-1a/-2a activities were only recently
unraveled when it became clear that the Michaelis constant
(Km) of all 3 PHDs and FIH-1 predicted a distinctly lower
oxygen afﬁnity for the former (13). Consequently, PHD1-3
hydroxylases start to experience, relative to FIH-1, inacti-
vation at higher pO2 during progressing hypoxia (14).
Differential hydroxylase activities will eventually translate
into a differential regulation of HIF-1 targets. By combining
transcriptional proﬁling data (15) with a numerical model of
the regulatory dynamics of the FIH-1 and PHD oxygen
sensors along a virtual oxygen gradient (16), Pouyssegur and
colleagues were able to allocate HIF-1 targets into 2 cate-
gories: (i) FIH-1–inhibited genes, that is, those induced by
progressive hypoxia once the NAD and, subsequently, CAD
of HIF-1a/-2a are both released from inhibition (e.g.,CA9,
PHD3, and LDHA), and (ii) non–FIH-1–inhibited genes,
that is, those requiring solely HIF-a NAD activity upon
sufﬁcient PHD inhibition while being refractory to any
CAD activation (e.g., PGK1 and GAPDH; refs. 15, 17).
This categorization predicts expression of FIH-1–inhibited
genes to be altered during severe hypoxia, whereas moderate
degrees of O2 deprivation already affect non–FIH-1–inhib-
ited genes.
Yet, as another and hydroxylase-independent layer of
control, HIF's transcriptional outﬂow is also prone to be
inﬂuenced by competing transcription factors. When we
previously used reporter constructs of the tripartite globin-2
gene (hb2) promoter (phb2) of the planktonic crustacean
Daphnia magna in heterologous transfections of human
cancer cells, we noticed a constitutive CACGTG-binding
factor which was able to interfere with the HIF-1–driven
induction of the phb2 luciferase reporter (18). Now, we
identify this phb2 CACGTG factor across several cancer cell
lines as a complex of O2 independently acting upstream
stimulatory factors 1 and 2 (USF1 andUSF2). To assess both
the extent and mode (positive/negative) of the impact of
USF signaling on HIF's transcriptional outﬂow, we imple-
mented a genome-wide computational scan to identify
candidate human genes that contain adjacent or overlapping
HRE and CACGTG palindrome motifs in their up- or
downstream sequences. Our results suggest the occurrence
of both positive (promoter of lactate dehydrogenase A
(LDHA): USFs complement HIF control) and variably
negative [promoter of Bcl-2/E1B 19 kDa interacting protein
3 (BNIP3): USF interactions range from moderating to
competing with HIF-1] cross-talk modes when HIF-1/USF
constituents were overexpressed or silenced. This work,
therefore, provides a proof-of-principle for the oxygen-
independent USF pathway to inﬂuence, and, upon strong
activation or overexpression, even inhibit HIF/HRE-
mediated gene expression in human cancer cells.
Materials and Methods
Cells, RNA, and quantitative PCR
Human hepatoma (Hep3B; ATCC HB-8064), cervical
carcinoma (HeLa; ATCC CCL-2), and breast carcinoma
cells (MCF7; ATCC HTB-22) were purchased as short
tandem repeat–authenticated lines from the American Tis-
sue Culture Collection (ATCC) and maintained in high
glucose (4.5 g/L) Dulbecco's modiﬁed Eagle's medium as
described earlier (18). Normoxic (N) cultures: 37C, room
air in water–saturated atmosphere with 5%CO2 (i.e., a pO2
¼ 141.6 mmHg, [O2]¼ 18.6%O2). Hypoxic (H) cultures
in HERA Cell240 incubator (Heraeus) or a polymer glove
box (Coy)—16-hour exposures: 37C, in water-saturated
1% or 3% or 10% O2/5% CO2/balance N2 atmosphere.
Isolation of total RNA, reverse transcriptions, and SYBR-
Green quantitative real-time PCR (qRT-PCR) was carried
out as previously reported (19, 20). All primers used for
qPCR are listed in Supplementary Table S1.
Antibodies
Mouse monoclonal anti–ATF-1 antibody (25C10G, sc-
270) and rabbit polyclonal anti-USF1 (C-20, sc-229) were
purchased from Santa Cruz Biotechnology, Inc. Rabbit
polyclonal anti-USF1M, anti-USF2F, anti-USF2G, anti-
USF2Z, and anti-USF2aO antibodies were kindly provided
byDr. B. Viollet (21). Additional antibody gifts included: (i)
rabbit anti-human DEC1 (CW27; ref. 22); (ii) rabbit anti-
human MYC (23); (iii) rabbit anti-mouse ARNT (anti-
mARNT R-1 IgG; ref. 24); (iv) rabbit anti-human ARNT
(anti-hARNTC34; ref. 25); (v) rabbit anti-humanUSF full-
length antibody (USF FL; ref. 26).
Sequence scan for HREmotif and CACGTG palindrome
We used the repeat-masked human genome sequence as
provided by the UCSC Genome Bioinformatics Website
(Version hg19, GRCh37) at http://hgdownload.cse.ucsc.
edu/goldenPath/hg19/bigZips/chromFaMasked.tar.gz.
Gene deﬁnitions and transcription start sites were from
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/data-
base/refGene.txt.gz (downloaded April 09, 2010). The
search for motifs, implemented as R-script, was conducted
among the 1,000 base ﬂanking region up- and downstream
(¼  1,000 bp) of annotated transcripts. Genes containing
both HRE and CACGTG palindrome motifs within the
1,000 bp ﬂanks were considered as HRE/palindrome
gene only if the motif–motif distance was 100 bp or less.
On the basis of these criteria, we used theGeneGoMetaCore
system to identify pathways where HRE/palindrome genes
are overrepresented (see Table 1).
Luciferase reporter
With genomic DNA, we ampliﬁed the promoter region
around the HRE and E-box palindrome motifs via nested
PCR (for primers, see Supplementary Table S1). Of note,
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the 30-end of any given amplicon is always extended into the
ﬁrst coding exon of the respective gene. In detail, we
ampliﬁed and cloned the following promoter regions
(start/end always relative to translation start ATG codon):
(i) human 4EBP1 gene, 518/þ403; (ii) human MC1R
gene, 880/þ9; (iii) human LDHA gene, 2,617/þ530;
(iv) human TYR gene, 400/þ108. Following TOPO
cloning of the PCR products into the pCRII-TOPO vector
(Invitrogen), the liberated insert was ligated into pGL3-basic
luciferase vector (Promega AG) to generate the luciferase
reporter constructs. We also obtained the BNIP3/pGL3-
basic (753/þ3; ref. 27) and the PHD2/pGL3-basic
(607/þ3; ref. 28) luciferase reporter vector as kind gifts.
HIF-1a (i.e., pcDNA3.1-hHIF-1-PK tag) as well as USF
(pCR3-USF1, pCR3-USF2a, and pCR3-USF2b) expres-
sion plasmids were generously supplied by Prof. P. Maxwell
(29) and Dr. B. Viollet (30), respectively.
Electrophoretic mobility shift assay and pull-down assay
Isolation of nuclear protein extracts of Hep3B, HeLa and
MCF7 cells, and analysis of in vitro protein–DNA interac-
tion by electrophoretic mobility shift assay (EMSA; ref. 18)
and pull-down assays (31), was done as previously reported.
All oligonucleotide sequences used as probes for either assay
are shown in Supplementary Table S1. For EMSA gel
supershifts (ss), 1.0 to 1.5 mL of rabbit anti-USF1M, rabbit
anti-USF2G, or mouse anti-HIF-1a (mgc3) was added into
the reaction (30 minutes, room temperature). Negative
supershift controls included 1.5 mL preimmune serum from
the same rabbit to be immunized against USF1M or
USF2G, as well as 1.0 mL rabbit anti-human immunoglob-
ulin (IgG; code: 309-005-003 Jackson Immuno Research).
About pull-down assays, wild-type andmutated phb2146
palindrome or 107 HRE oligonucleotides, and wild-type
and mutated BNIP3 251/246 HRE oligonucleotides,
biotinylated at the 50-end and PAGE puriﬁed, were annealed
into double-stranded DNA and immobilized on streptavi-
din-coated magnetic beads (Dynal Biotech) as described
(31).
Western blot and coimmunoprecipitation
Proteins were resolved in 10% SDS polyacrylamide gels,
transferred onto nitrocellulose membranes (Whatman), and
the membranes incubated at 4C overnight with the fol-
lowing primary antibodies diluted in 5%milk Tris-buffered
saline and Tween 20: (i) anti-HIF1a (mgc3; 1:500) or (ii)
anti-USF1M or anti-USF2G (1:750). The signal was
detected with horseradish peroxidase–conjugated goat
anti-mouse or anti-rabbit (1:5,000) and luminol substrate.
For coimmunoprecipitation experiments, 150 mg nuclear
protein was incubated with 20 mL mouse anti-HIF-1a or
0.75 mg anti-mARNT or 2.5 mL USF antiserum and
subsequently rotated at 4C overnight. The next day, 40
mL of protein G beads were added into the mix and
incubated at 4C for another 2.5 hours. The extract/anti-
body/bead mix was collected by centrifugation, the pellet
boiled at 95C in 1 SDS sample buffer for 10minutes, and
the supernatant analyzed by Western blot.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were con-
ducted in human Hep3B, HeLa, and MCF7 cells after a 4-
hour exposure to normoxic (air) or hypoxic (1% O2) atmo-
spheres as described (32). In brief, genomic DNA was cross-
linked with bound proteins (10minutes, room temperature)
with 1% formaldehyde in 1 PBS and sonicated in a
Bioruptor UCD-200 (Diagenode SA) or a Soniﬁer cell
disruptor B15 (Branson) into 500- to 1,000-bp fragments.
For immunoprecipitation of the DNA:protein mix, 4.5 mL
rabbit polyclonal anti–HIF-1a IgG (ab2185; Abcam) or
10 mL rabbit polyclonal anti-USF1M or anti-USF2G were
added into the chromatin solution. Preimmune rabbit
antiserum (10 mL) and 2.5 mL rabbit anti-human IgG were
used as negative controls. The puriﬁed DNA was ampliﬁed
by PCR using the ChIP primer pairs shown in Supplemen-
tary Table S1.
Transient luciferase reporter transfection
Half-conﬂuent Hep3B, HeLa, and MCF7 cells were
transfected overnight by the help of the calcium phosphate
method with different luciferase reporter constructs and
normalization plasmids expressing b-galactosidase. For
cotransfections, 15 to 500 ng HIF-1a plasmid and/or 15
to 100 ng USF1, USF2a, or USF2b plasmid were added. In
each transfection, pUC18 plasmidwas used as ﬁller DNA for
a total of 2 to 3 mg DNA. The following day, each batch of
transfected cells was split into 2 for parallel 16 hours
normoxia and hypoxia exposure. After 16-hour normoxia/
hypoxia exposure, cells were lysed and luciferase activity was
measured with a commercially available Luciferase Assay
System (Promega AG) and a SIRIUS Luminometer (Bert-
hold Technologies). Luciferase activity was normalized by
b-galactosidase activity (b-Galactosidase Enzyme Assay kit;
Promega AG) and expressed as "relative luciferase activity" in
percent (% RLA) of the total activity of all normoxic and
hypoxic reactions of a given assay.
Transient knockdown of HIF-1a, USF1, or USF2a
For transient silencing, the speciﬁc siRNA HIF-1a and
siRNA USF1 oligonucleotides were selected based on pre-
vious publications (33–35). All siRNA sequences (see Sup-
plementary Table S1) were synthesized by Dharmacon
Research Inc. SiCONTROL nontargeting siRNA pool #2
was used as scrambled (scr) siRNA control (Dharmacon).
Half-conﬂuent Hep3B cells were transfected with a total of
200 nmol/L of siRNAs using Oligofectamine reagent (Invi-
trogen). In the combined USF1 þ USF2a siRNA transfec-
tion targeting both USFs, 100 nmol/L of each siRNA were
added to the cells.
Statistics
With STATA 10.0 software (Stata 10.0; StataCorp), we
compared control versus experimental mean transcript
expression levels (Fig. 3) and RLAs for each reporter assay
(Fig. 6) within the same oxygen category (either normoxic or
hypoxic results; Figs. 3 and 6) or for the hypoxic/normoxic
fold inductions (Fig. 3, Table 3). In accordance with prior
Hu et al.
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testing for normality of data populations and for
equal variances between samples, statistical signiﬁcance
(i.e., P < 0.05) was calculated by (i) one-way ANOVA/post
hoc Sidakmodeling (normality/variance equality bothmain-
tained) or Welch-approximated t tests in case of unequal
sample variances (e.g., Fig. 6B and C; symbols used: ; þ)
and (ii) nonparametric Kruskal–Wallis tests plus Wilcoxon
rank-sum tests for pairwise sample comparisons when both
assumptions were violated (e.g., Figs. 3, 6A and D; symbols
used: #; ¶).
Results
CACGTG palindromic E-boxes often serve as binding
sites for several non-HIF basic helix-loop-helix (bHLH)
transcription factors, including ARNT (36, 37), MYC
(38, 39), USFs (21), STRA13/DEC1 (22), ATF-1, and
CREB-1 (40). To identify the factor(s) responsible for the
HIF-interfering constitutive activity at the146 CACGTG
element within the promoter of the hb2 gene (phb2) of
Daphnia magna (18) andmap the factor(s) occurrence across
different cancer cells, we conducted an EMSA survey using
normoxic nuclear extracts from human hepatoma (Hep3B),
cervical carcinoma (HeLa), and breast carcinoma cells
(MCF7). Because HeLa and MCF7 EMSA screens yielded
compatible results, Fig. 1A presents Hep3B data only (Fig.
1A). The protein components within the constitutive com-
plex (cc) of the 146 phb2 binding activity were identiﬁed
using speciﬁc antibodies directed against USFs, DEC1,
MYC, ARNT, and ATF-1. Of these 5 factors screened by
supershifts, onlyUSF1 andUSF2were recognized asmain in
vitro binding factors of the146 phb2 palindrome (Fig. 1A;
lanes 3, 5, 7, 9, and 11) while all other factors either failed
(MYC and ATF-1) binding this motif or interacted (DEC1)
weakly with it (Fig. 1A, lane 15;5%10% of total pool).
The preponderance of USFs as protein components in the
HIF-interfering complex of Daphnia's hb2 promoter
prompted us to subsequently focus on this transcription
factor family. Increasing the volume of anti-USF1M (left)
and anti-USF2G (right) antiserum in the binding reaction
nuclear extracts from normoxic and hypoxicHep3B reduced
the intensity of the CACGTG complex in a dose-dependent
manner (Supplementary Fig. S1A). Binding of USF proteins
to the 146 phb2 E-box was clearly oxygen independent
(Supplementary Fig. S1A).
We reevaluated our EMSA results through independent
pull-down assays of Hep3B, HeLa, and MCF7 nuclear
proteins with biotinylated phb2 oligonucleotides bound to
streptavidin-coated magnetic beads. In a representative assay
with HeLa normoxic and hypoxic nuclear extracts (Fig. 1B
and C), wild-type biotinylated oligonucleotides (w-bio),
containing the 146 CACGTG phb2 palindrome, were
able to pull down 43 kDa USF1 (Fig. 1B), 44 kDa USF2a,
and 38 kDa USF2b proteins in an oxygen-independent
manner (Fig. 1C). In support of a speciﬁc interaction,
competition assays (50 comp. lanes) or beads coated with
146mutant (m-bio) E-boxmotifs (50-CAATGT-30) great-
ly reduced or abolished the USF pull-down. Similar results
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were obtained with extracts from Hep3B and MCF7 cells
(not shown). Further pull-down and coimmunoprecipita-
tion analyses veriﬁed that (i)USF1/2 (CACGTGpreference)
and HIF-1 complexes (TACGTG preference) display high-
afﬁnity binding to distinct elements within phb2 and (ii) the
USF–HIF interference within phb2 is DNA context depen-
dent, because we, and others (41), could not detect any direct
physical interaction between USFs and HIF subunits (see
Supplementary Fig. S1B–E).
To move beyond the Daphnia hb2 promoter as a model
for occurring cross-talk amongE-box complexes, we adopted
Daphnia phb2 coordinates to conduct a genome-wide screen
and enrichment analysis for human genes that harbor, within
1,000 bases from their transcriptional frame (in up- and
downstream direction), both a 50-VNVBRCGTG-30 HRE
consensus motif (11) and a 50-CACGTG-30 palindrome
with a motif–motif distance of 100 bp or less. According to
these criteria, our survey found multiple examples of known
HIF targets among the list of HRE/palindrome genes
including VEGF factor C (VEGFC), LDHA, phosphogluco-
mutase 2, enolase 1, transferrin (TF), eukaryotic translation
initiation factor 4E binding protein 1 (4EBP1), Bcl-2/E1B
19 kDa interacting protein 3-like (BNIP3L), and Bcl-2–
associated X protein (BAX; an Excel ﬁle with the detected
human HRE/palindrome candidate genes is available upon
request). When we looked at the top-scoring GeneGo path-
ways, whose signaling components showed a highly signif-
icant enrichment of HRE/palindrome genes (see Table 1),
we noticed several signal transductions where USFs seem
to impinge on hypoxia signals in a highly localized manner
(e.g., insulin-regulated/cap-dependent mRNA translation,
HIF-mediated transcription, and cytoskeletal or cell-cycle
control functions). Interestingly, particular focal points of
HRE/palindrome gene clusters included the eIF4F check-
point of the cap-dependent translation control, cell surface
receptors for insulin and growth factors as well as actin
USFs
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Figure 1. EMSA supershifts and pull-down analysis to identify the phb2-binding CACGTG complex in Hep3B cells. A, to identify factor(s) able to bind to the
146 CACGTGmotif in phb2, we used the following antibodies in EMSA supershift reactions with Hep3B normoxic nuclear extracts as indicated in the ﬁgure
underneath each lane. (), no antibody; PI, preimmune serum; ns, nonspeciﬁc; cc, constitutive CACGTG complex; ss, supershifted CACGTG complex. From
lanes 4 to 13, EMSA reactions were supplemented by corresponding PI and immune serum from the same rabbit used to generate anti-USF–directed
antibodies (e.g., lanes 4 þ 5: PI-1M and anti-USF1M). Results reproduced in n ¼ 3 independent assays. B and C, pull-down analysis with beads (w-bio)
coated with 146 phb2 E-box–carrying oligonucleotides (50-CACGTG-30) and HeLa normoxic (N) and hypoxic (H) nuclear extracts. Binding speciﬁcity was
assessed either through beads coated with 146 mutant (m-bio) E-box motifs (50-CAATGT-30) or with binding reactions containing 50-fold molar
excess of free wild-type oligonucleotide as competitor (50 comp.). Immunoblot of bound factors with a-USF1M (B), a-USF2G antibody (C, left), a-USF2aO
antibody (C, right). Staining of ns proteins indicated as loading control. Results reproduced in n ¼ 3 to 4 independent assays.
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remodeling genes (see Table 1; Gene symbols). These
pathway aggregations of possibly coregulated genes inspired
this study to try and provide solid proof-of-principle for a
USF-based modulation of, or interference with, the HIF
transcriptional outﬂow for at least some of the known targets
listed above. If successful, future work will need to com-
prehensively assess USF–HIF cross-talk in cancer cells in a
physiologic context (see Discussion).
For initial insights on HIF/USF convergence at DNA
level, we (i) established those genes with a strong human–
mouse–rat (hmr) conservation of the HRE/palindrome
motifs within the aligned promoter regions (Table 2; Sup-
plementary Fig. S2) and (ii) examined themRNA expression
of 5 such hmr-conserved HRE/palindrome candidates by
quantitative real-time PCR (qRT-PCR) in conjunction with
transient, siRNA-based knockdowns of HIF-1a, USF1, and
USF2a in Hep3B (see Fig. 2 for knockdown efﬁcacy assess-
ment by Western blot). Transfection with scrambled RNA
did not affect steady-state abundance of HIF-1a, USF1, and
USF2a proteins [scrambled: compare with nontransfected
(non-TF) cells]. In contrast, exposing Hep3B cells to
siRNAs speciﬁcally directed against HIF-1a (siHIF-1a),
USF1 (siUSF1), USF2a (siUSF2a), or the combination of
both USFs (siUSF1/2a) resulted in a drastically diminished
expression of the respective factor(s). In cells subjected to a
USF1 knockdown (siUSF1), effects on the expression of
USF2a ranged from unaltered to a slight elevation. Con-
versely, silencing of USF2a (siUSF2a) was accompanied by a
strong reduction of USF1 protein level (Fig. 2, USF1 signal
in siUSF2a). Similar to these ﬁndings, both USFs were
concomitantly lost in USF2 knockout mouse models, sug-
gestingUSF2 to be generally required asUSF1 transactivator
(42).
Following transient knockdown of HIF-1 and USFs in
normoxic and hypoxicHep3B cells, changes inmRNA levels
of the HRE/palindrome candidates LDHA, BNIP3,
BNIP3L, 4EBP1, and VEGFC were assessed by qRT-PCR
(Fig. 3). Transcripts of BNIP3, BNIP3L, LDHA, and
VEGFC were all upregulated by 1% O2/16-hour exposure
in Hep3B treated with scrambled RNA. The 4- to 5-fold
hypoxic induction of the BNIP3 and BNIP3LmRNA levels
was entirely (BNIP3) or almost entirely (BNIP3L) driven by
HIF-1a (see siHIF-1a data). Silencing USF1 and USF2a
expression, however, resulted in moderately (siUSF1) or
signiﬁcantly (siUSF2a) increased fold hypoxic inductions of
BNIP3 and BNIP3L genes. The stronger effect on the
hypoxic induction of BNIP3 and BNIP3L genes by the
siUSF2a treatment could result from its effective double
knockdown of USF1 and USF2a proteins (Fig. 2). Elevated
gene activity of LDHA in hypoxic Hep3B was weakly
attenuated following siHIF-1a treatment but not impacted
by either USF knockdown. Expression of 4EBP1, mildly
suppressed in hypoxic hepatoma cells (scr data), was con-
stitutively reduced upon the knockdown ofUSF factors. The
approximate 2-fold hypoxic induction of VEGFC mRNA
(scr data) was lost upon USF siRNA treatment due to a
strong increase of transcript level in normoxic Hep3B cells.
With regard to the vividly O2-responsive BNIP3 and
BNIP3L genes, we also noted that the potentiation of the
induction in USF-silenced cells subjected to 1% O2 pre-
dominantly derived from a reduced normoxic, rather than
strengthened hypoxic, gene activation (Fig. 3). This obser-
vation highlighted the importance of USF1/2a in maintain-
ing the basal transcription of either gene in oxygenated cells.
Because HIF-1 is known to regulate BNIP3 activity with an
unusually broad O2 response proﬁle (15, 17), the factor
could likely encounter USFs at the BNIP3 promoter even in
subnormoxic cells. In additional qRT-PCR analyses, we
therefore assessed if, during episodes of moderate (3%
O2) or very mild degrees of O2 scarcity (10% O2), HIF-1
Table 2. E-box palindromes and HRE sites in promoters of human genes
Gene Sequence 50–30 References
183 178 91 86 (67)
TYR gaaaagtcagtCATGTGcttttca—gccaagaCATGTGataat—aggaaga (atg)
413 408 (28)
PHD2 gccgtggtgTACGTGcagagcgcgcagagcgagt—gccgccgccgcc (atg)
179 174 120 115
4EBP1 ggggatccCACGTGgaagc–caaatcccaggGGCGTGgggcgg–gagacc (atg)
24652460 23672362 23532348 (62, 68)
LDHA cagcgCACGTGgagcg–actcaCACGTGggttcccgCACGTCcgccggc–aat (atg)
742 737 461 456 (67)
MC1R acgttgaCAGCTGagttgctg–ccccggCATGTGgccgccct–ggacaggact (atg)
251 246 (61)
BNIP3 cgcgcacgcgccgCACGTGccacacgcacccca—gccctctggcgcc (atg)
NOTE:HIF-1andUSFcoregulatedcandidategenes:4EBP1,LDHA,MC1R, andBNIP3; control genes:TYRandPHD2. Translationstart
site ATG as þ1 (in brackets). 50-ﬂanking region upstream of ATG is given for human TYR, PHD2, 4EBP1, LDHA, MC1R, and BNIP3
genes. HRE and E-box palindromes are capitalized. Human-mouse-rat (hmr) conservedHREs: boldþ underlined; variable HREs: bold
only; hmr conserved E-boxes: italicizedþ underlined; variable E-box: italics only. For conservation: see alignments in Supplementary
Fig. S2.
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continues to control BNIP3. We also asked if, relative to
harsher hypoxia (1%O2), USFs will compete more potently
withHIF-1 for theBNIP3 regulatory binding sites at 3% and
10%O2 (see Discussion for further reasoning). Steady-state
levels of BNIP3 mRNA indeed revealed for scr-transfected
Hep3B cells robust inductions of 3.3- and 1.6-fold in cells
subjected to 16 hours of 3% and 10% O2, respectively
(Table 3). Together with the proﬁling at 1% O2 (4.8-fold
transcript induction), the exquisite sensitivity of the BNIP3
gene toward a wide range of changes in oxygen concentra-
tions became fully evident. Moreover, as silencing of HIF-
1a expression abrogated the inductions at 1%, 3%, and 10%
O2 all equally efﬁcient down to transcript parity (i.e., H/N
ratios ¼ 1.0 for siHIF-1a treatment; see Fig. 3, Table 3),
responses ofBNIP3 from1% to 10%O2 seem to rest entirely
on functional HIF-1. Upon silencing of USF1, but surpris-
ingly not USF2a, we observed the BNIP3 induction to be
potentiated almost signiﬁcantly at 3% O2 [3.3-fold (scr)!
4.6-fold (siUSF1); P ¼ 0.070] and to a signiﬁcant extent
at 10% O2 [1.6-fold (scr) ! 2.2-fold (siUSF1); P ¼
0.019; Table 3). This USF1 loss-of-function mediated
enhancement resulted from the combination of reduced
normoxic [1.0 (scr) ! 0.7 (siUSF1)] and, toward
milder hypoxia, progressively increasing hypoxic levels of
BNIP3 transcripts [with 100% mRNA level (scr)! 84%–
95%–105% mRNA level at 1% O2–3% O2–10% O2
(siUSF1)].
Although we were encouraged by these early data suggest-
ing a competitive cross-talk to occur between basally active
HIF-1 and USF factors in cells facing a subnormoxic milieu,
the remainder of the study focused on providing proof-of-
principle evidence for USF-mediated positive or negative
functional interactions withHIF-1 at 1%O2. At this level of
deoxygenation, HIF-1 activity peaks in many cell lines,
hence, its transcriptional control of the bulk of downstream
targets is expected to operate with optimal efﬁcacy. Align-
ments of the homologous regions of BNIP3 promoters had
revealed a remarkable hmr conservation around the HRE
motif (Supplementary Fig. S2). For this reason, we went on
to compare the promoter responses of BNIP3, where the
HRE and CACGTG motifs are contained within a single
cis-element, with those ofMC1R, 4EBP1, and LDHA genes,
which all possess distinct HRE and palindrome sites of
variable hmr conservation (Table 2; Supplementary Fig.
S2). Parallel ChIP experiments conﬁrmed the recruitment
of HIF-1a- and constitutive USF1- and USF2a-containing
complexes to both LDHA (Fig. 4A) and BNIP3 (Fig. 4B)
promoter sequences in intact Hep3B (Fig. 4, left), MCF7
(Fig. 4, right), and HeLa cells (not shown). This coordinate
binding of HIF-1 and USFs was seen both at low oxygen (at
LDHAþ BNIP3 promoter) and in oxygenated nuclei as well
(see HIF-1a at BNIP3 promoter; Fig. 4). The latter ﬁnding
added weight to the notion of HIF-1 controlling BNIP3
transcription even under subnormoxic/normoxic conditions
(see previous paragraph).
To further study the convergence of HIF and USF path-
ways at DNA level, the promoter regions in question were
ampliﬁed from genomic DNA, cloned, sequence conﬁrmed,
and inserted into pGL3 basic luciferase reporter plasmids.
The set of luciferase promoter reporters thus obtained
included both donated (i.e., BNIP3 and PHD2) and self-
generated constructs (TYR, 4EBP1, LDHA, and MC1R),
siRNA:
Oxygen:
post-siRNA TF (h):
HIF-1α
ns. protein for
equal loading
ns. protein for
equal loading
USF1
USF2a
48 72 48 72 48 72 48 72 48 72 48 72 48 72 48 72 48 72 48 72 72 72
N H N H N H N H N H N H
scr siHIF-1α siUSF1 siUSF2a siUSF1/2a non-TF
Figure 2. Western blot analysis for assessment of transient siRNA knockdown efﬁcacy of HIF-1a, USF1, and USF2a in Hep3B cells. Transfections with
scrambled siRNA (scr) and nontransfected (non-TF) cells were used as negative controls. Cells were harvested at 2 post-siRNA transfection time points: 48
and72hours. Hypoxia (H, 1%O2) exposure started at timepoint 42 hours post-siRNA transfection for 6 and30hours, respectively. Normoxia (N): air exposure.
As shown in the ﬁgure, protein level expression of HIF-1a and each USF in transiently transfected Hep3B cells was robustly silenced from 48 hours (¼ 42þ 6
hours hypoxia) up to 72 hours (¼ 42 þ 30 hours hypoxia) post-siRNA transfection. ns, nonspeciﬁc.
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and covered USF-speciﬁc targets (i.e., TYR; ref. 43) or HIF-
1–speciﬁc targets (i.e., PHD2; ref. 44) plus 4 HRE/palin-
drome candidates (4EBP1, LDHA, MC1R, and
BNIP3; Table 2; Supplementary Fig. S2). We initially
examined the hypoxia (1% O2/16 hours) responsiveness of
these candidate promoters. Respective reporter transfections
of Hep3B, MCF7, and HeLa cells included negative control
reactions (i.e., "bVec" ¼ empty pGL3 basic luciferase
vector; Fig. 5) to monitor basal and hypoxia nonresponsive
luciferase activity. In contrast, thePHD2 luciferase construct
was induced approximately 3- to 8-fold in hypoxic Hep3B,
HeLa, and MCF7 cells (Fig. 5). Luciferase assays with the 4
candidates, 4EBP1, LDHA, MC1R, and BNIP3, revealed
only for LDHA (2-fold) and BNIP3 (4- to 7-fold) a robust
upregulation by hypoxic conditions in Hep3B, MCF7, and
HeLa cells.
Next, we investigated the possible coregulation of BNIP3
and LDHA reporter by HIF and USF cascades in cotransfec-
tions with HIF-1a and USF1, USF2a, or USF2b expression
plasmids (Fig. 6). In pilot studies (not shown), we had
carefully titrated for each cell line the amount of HIF-1a
plasmid (i.e., 15–100 ng) needed for an optimal hypoxic
induction of either reporter and of any USF plasmid (i.e., 15
ng) needed for an optimal speciﬁc activation of either
reporter construct (Fig. 6). The activity of theTYR promoter
reporter rose constitutively 4- to 7-fold upon USF1-, and up
to 20-fold upon USF2a, cotransfection. Overexpression of
HIF-1a did not impact the TYR reporter (Fig. 6A). On the
contrary, PHD2 reporter activity was signiﬁcantly increased
in normoxic and hypoxic Hep3B upon HIF-1a overexpres-
sion. The impact of overexpressed USFs on the PHD2
reporter was either negligible (USF1) or attributed to non-
speciﬁc stimulation by the overexpressed factor (USF2a)
exerted on the vector backbone. Therefore, both control
reporters responded speciﬁcally to the overexpression of their
respective transcriptional driver(s) (Fig. 6A).
The LDHA promoter was induced by endogenous hyp-
oxia signals almost 2-fold in Hep3B (Fig. 6B), and addi-
tionally stimulated upon cotransfection with USF1, and
particularly, USF2a and USF2b plasmids. Of note, over-
expressed USFs augmented LDHA luciferase activity pre-
dominantly under normoxia, thereby reducing the original
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Figure 3. qRT-PCR for (top left to
bottom right) BNIP3, BNIP3L,
LDHA, 4EBP1, and VEGFC mRNA
levels in Hep3B transfected with
siRNAs. Hep3B cells were
transfected with HIF-1a, USF1, or
USF2a siRNA at a ﬁnal
concentration of 200 nmol/L.
Scrambled siRNA (scr) was used as
negative control. RNA was isolated
fromHep3Bat 66 hours post-siRNA
transfection, that is, at a time point
where the silencing effect of HIF-1a
and USFs was still in effect (see Fig.
2). Hypoxia exposure started at time
point 50 hours post-siRNA
transfection for 16 hours. mRNA
levels of above named genes were
quantiﬁed by qRT-PCR and
normalized by L28 expression. All
data are presented as the means 
SD of 4 independent experiments.
Normoxia (N), air; Hypoxia (H), 1%
O2 16 hours. Mean H/N-fold
inductions of each transcript are
indicated above the respective pair
of columns. Mean expression of
individual transcripts were
compared (i) within same O2
category (NorH) and (ii) for H/N-fold
changes of siRNA-treated
experimental groups (siHIF-1a,
siUSF1, and siUSF2a) relative to scr
controls. For signiﬁcant scr/si
comparisons, the used symbol
denotes pairwise nonparametric
Wilcoxon rank-sum tests (#). See
Materials and Methods for more
details.
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hypoxic induction to an almost constitutive expression in
Hep3B (Fig. 6B) and MCF7 cells (not shown). The switch-
ing from HIF- to USF-driven transactivation modes, and
vice versa, was further observed for the endogenous LDHA
promoter, particularly in Hep3B (Fig. 4A, left) and HeLa
cells (not shown). Here, hypoxia clearly promoted HIF-1
binding and, in parallel, attenuated the occupancy of
USF1 and USF2a. Thus, HIF-1 and USF complexes
recruited to the LDHA promoter cap the activity of one
another to yield a pO2-dependent complementation mode
of gene control.
On the basis of these data, transactivation of the LDHA
gene by HIF-1 and USFs proceeds from distinct motifs
(below) and peaks at varying pO2 (USFs! aerobic LDHA
expression; HIF-1 ! hypoxic LDHA expression). In con-
trast, both pathways must converge onto a single stretch of
DNA within the BNIP3 promoter (Supplementary Fig. S2,
and below). The relevant reporter was nearly 3-fold hypoxia
induced by endogenous HIF-1–mediated (Fig. 3) signaling
in Hep3B (Fig. 6C) and HeLa cells (Fig. 6D). Cotransfec-
tion with USF1 and USF2a, or with USF2b, enhanced
BNIP3 promoter activity in both cell lines particularly under
normoxia and consequently weakened the reporters' hypoxic
induction. Overexpression of HIF-1a ampliﬁed the hypoxic
BNIP3 activity robustly in Hep3B (6.6-fold; Fig. 6C) and
moderately in HeLa cells (3.2-fold, Fig. 6D). However, this
potentiated hypoxia response of BNIP3 by ectopic HIF-1a
was signiﬁcantly impaired through the simultaneous
cotransfection with USF1 or USF2a, but not USF2b, in
Hep3B and HeLa cells (Fig. 6C and D, see # arrows).
Increasing the amount of USF1/2a plasmids further
(15 ! 100 ng) converted the hypoxic transactivation of
the reporter into an increasingly constitutive response,
especially in Hep3B cells (Fig. 6C). These data suggest that
Table 3. BNIP3 mRNA fold inductions in mildly deoxygenated Hep3B transfected with siRNAs
O2 scr siHIF-1a siUSF1 siUSF2a
3% 3.325  0.754 1.078  0.148 4.583  0.472 4.222  0.907
P (siX vs scr) — P ¼ 0.0072 P ¼ 0.0704 ns
10% 1.622  0.177 1.055  0.038 2.145  0.159 1.560  0.313
P (siX vs scr) — P ¼ 0.0056 P ¼ 0.0189 ns
NOTE:Hep3B transfectionswith scrambled (scr) control RNAorHIF-1a, USF1 orUSF2a siRNA followed the identical protocol used for
thequantitative expression analyses in Fig. 3. Bnip3mRNA levelswerequantiﬁedbyqRT-PCRandnormalizedbyL28expression. Fold
inductions ofBnip3 transcript levels in mildly deoxygenated (H: 3% or 10%O2; 16 hours) versus normoxic (N: air; 16 hours) Hep3B are
given as means ( SD) of 3 independent experiments. P values for H/N-fold changes between siRNA-treated experimental groups
(i.e., siX¼ siHIF-1a or siUSF1 or siUSF2a) and the scr control group of the same O2 category (i.e., comparison done only within 3% or
10% O2 category) are indicated.
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HIF-1a and USF1 or USF2a compete dose dependently
with each other over the control of the BNIP3 site.
The functionality of the computed HIF-1 and USF1/2
sites in the LDHA and BNIP3 promoter was assessed by
EMSA screens with Hep3B, HeLa, and MCF7 normoxic
and hypoxic nuclear extracts. Representative results are
shown for LDHA (MCF7 nuclear extracts, Fig. 7A) and
BNIP3 (Hep3B nuclear extracts, Fig. 7B). The wild-type
CACGTG-motif in region I (Supplementary Fig. S2) of the
LDHA promoter was weakly bound by a hypoxia-regulated
complex containingHIF-1a [see supershift (ss)—lane 4; Fig.
7A] and avidly bound by the cc factors USF1 andUSF2a (see
ss in lanes 6, 7, 9, and 10; Fig. 7A, reg.I wt). Another
radiolabeled oligonucleotide, spanning the wild-type region
II and III (Supplementary Fig. S2: reg. II/III ww) was tightly
bound both by HIF-1a and USF1/2 (Fig. 7A, bottom;
detection of HIF-1a ss: lane 4; USF2G ss: 9 þ 10). When
using a reg. II/III double site oligonucleotide carrying a
mutation in region II and an unaltered wild-type sequence in
region III (reg. II/III mw), only the hypoxia-inducible
complex, supershifted by anti–HIF-1a, was detected in
conjunction with a complete loss of the constitutive binding
activity by USFs (Fig. 7A: reg. II/III mw). The reverse
sequence alteration in region III but not II (reg. II/III wm)
left the oligonucleotide attachment by the constitutive USF
complex undisturbed, but erased any interaction with HIF-
1. Thus, the LDHA region II acts as exclusive, high-afﬁnity
site for USFs, whereas LDHA region III attracts HIF-1 to
this promoter in deoxygenated nuclei.
In contrast to this segregated binding of HIF-1 and USFs
in the LDHA promoter, either complex interacted with the
259/236 DNA of the BNIP3 promoter containing the
HRE at 251/246 (Supplementary Fig. S2; Fig. 7B).
Speciﬁc supershifts were able to positively identify HIF-1a
(ss: lane 4) as constituent of a hypoxic binding activity (lane
2), and USF1 (ss: lanes 6þ 7) and USF2 (ss: lanes 9þ 10) as
participants of a constitutive complex (lanes 1þ 2; Fig. 7B).
We further elaborated whether the HIF–USF interplay at
the 251/246 core element of BNIP3 is governed by
differential afﬁnities of the respective factors. To that end, we
conducted additional pull-down analyses using magnetic
beads coated with w-bio BNIP3 HRE probes (Supplemen-
tary Table S1) and assessed binding speciﬁcity and avidity in
reactions containing 10 or 50 excess of wt competitor
(comp.) oligonucleotides or beads coated with mutant
(m-bio) probes (Supplementary Fig. S3). Excess probe
(10 and 50) diminished the initial binding activity (set
to 100% in each case) to a mean (n ¼ 3–4 independent
assays) residual activity of: (i) approximately 8.8% (10)
and approximately 5.4% (50) for hypoxic HIF-1; (ii)
approximately 1.3% and approximately 0.4% for normoxic
or hypoxic USF1; and (iii) approximately 2.6% and approx-
imately 1.4% for normoxic or hypoxic USF2a, respectively.
The fact that 10/50 excess probe sufﬁciently eliminated
almost all of the USF–bead interaction showed the, relative
to hypoxic HIF-1, much weaker in vitro afﬁnity by which
USF1 and USF2a constitutively bind to the BNIP3 HRE
(Supplementary Fig. S3).
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Figure 5. Endogenous response of PHD2, 4EBP1, LDHA, MC1R, and
BNIP3 luciferase reporter. Hep3B (A), MCF7 (B), and HeLa (C) cells were
transfected with 2.0 mg of 4EBP1, LDHA, andMC1R or 1.5 mg of PHD2 or
BNIP3 luciferase reporter plasmid in a total of 3.0 mg plasmid. After 16-
hour hypoxic (1% O2: H, black bars) or normoxic (air; N, white bars)
exposure, RLA was determined and normalized with b-galactosidase
activity (% RLA, as mean  SD). Plasmid-free transfections (null) and
transfections with the empty pGL3 basic vector (bVec) were used as
negative controls. Mean H/N-fold inductions of each reporter are
indicated above the respective pair of columns.
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Discussion
One way to ﬁne-tune, or inhibit, HIF's transcriptional
outﬂow independently of hydroxylase activities could be
through competing transcription factors.We reported earlier
(18) that binding of aHep3B factor toCACGTGmotifs was
able to counteract the HIF-driven induction of the phb2
reporter from HREs at adjacent positions. Evidently, pal-
indrome factors can engage in positive or negative cross-talk
with nearby HIF/HRE complexes (45–47). En route toward
a more physiologic understanding of hypoxic signaling, we
thought to analyze gene control mechanisms not just as a
function of the stability/activity of HIF-1 per se. Rather, the
dynamic interplay between transcriptional complexes that
governs the hierarchy by which HIF-1 and related factors
gain access to DNA and regulate expression was considered.
This study, thus, aimed to identify the phb2 CACGTG-
binding entity in human cancer cells and investigate the
factors interplay with HIF-1 in the control of selected
examples of cotargeted genes.
Both, EMSA supershifts and oligonucleotide pull-down
assays consistently identiﬁed USF1 and USF2a/2b as
the main phb2 CACGTG complex in nuclear extracts
from Hep3B and HeLa (Fig. 1) or MCF7 cell lines. Our
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pull-down assays also documented the preferential in vitro
docking of HIF-1 to the asymmetric 107 phb2 HRE and
of USFs to the symmetrical 146 phb2 palindrome motif
(Supplementary Fig. S1B and C, 50 comp. lanes). Thus,
the single base substitution within the hexameric core of
either motif (i.e., 107 HRE: 50-TACGTG-30; 146
palindrome: 50-CACGTG-30), and presumably additional
changes in neighboring nucleotides, are key in conferring the
vastly differing afﬁnities of HIF and USF transcription
factors to these motifs. This observation ﬁts well with the
general perception that CACGTG-palindromes tend to
attract non-HIF bHLH factors (25, 36, 37, 47), and,
consequentially, are notably underrepresented amongst
functional HIF elements (48–50). Our coimmunoprecipi-
tations further demonstrated the interactive precipitation of
HIF-1a by ARNT proteins and vice versa but failed to reveal
any physical contact between USF2a and either subunit of
HIF-1 [HIF-1a and ARNT; see Fig. S1D, S1E and ref. 41].
Thus, the constitutive USF1/2a are the main factors that
indirectly interfere with the HIF/HRE-driven induction of
hb2 globin gene by binding to the phb2 CACGTG palin-
drome in human cancer cells (18, 31).
Upstream stimulatory factors belong to the bHLH-leu-
cine zipper family of transcription factors (21, 51, 52). They
can mutually inﬂuence each other's expression, both in
positive [USF2 transactivates USF1 gene (42); USF2a
knockdown yields diminished USF1 levels; Fig. 2)] and
negative ways [USF1 represses USF2 gene; USF1/ mice
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Figure 7. EMSA supershifts with
LDHA and BNIP3 E-box
oligonucleotides. Gel supershift
using LDHA HRE and E-box
palindrome oligonucleotides
together with MCF7 nuclear
extracts (A) and BNIP3 HRE
oligonucleotides together with
Hep3B nuclear extracts (B). All
oligonucleotides used in this EMSA
are listed in Supplementary Table
S1. For HIF-1a or USFs gel
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hypoxia; cc, constitutive complex,
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show elevated USF2 levels (42)]. USFs have been implicated
in conferring the UV-induced tanning response in melano-
cytes and in acting as antiproliferative agents in cells trans-
formed by overexpressed MYC or activated RAS signaling
(53). Following a marked depletion of intracellular calcium
during the differentiation of erythroid progenitor and ery-
throleukemia cells, endogenousUSFs start to accumulate and
transactivate several adult marker genes (e.g., b globin) that
ultimately drive the cells into maturity (54). Beyond MYC,
other palindrome complexes can also tailor, or interfere with,
HIF's transcriptional read-out. To date, 3 human genes have
been examined as HIF/USF coregulated targets, that is, the
genes encoding plasminogen activator inhibitor-1 (PAI-1;
refs. 55–57), the catalytic subunit telomerase reverse tran-
scriptase (TERT) of the telomerase complex (58–60), and
the glycolytic enzyme L-type pyruvate kinase (L-PK; ref. 41).
Guided by phb2 coordinates of Daphnia, we conducted a
genome-wide computational survey forHIF/USF-corespon-
sive human genes that were ﬂanked by closely adjacent or
overlapping CACGTG palindrome and HRE motifs.
Among those, we found LDHA and BNIP3 to be expressed
and hypoxia induced at transcript level in human Hep3B
cells (Fig. 3). This induction was entirely dependent
(BNIP3) or aided (LDHA), by HIF-1a in Hep3B cells. The
O2-responsive control of BNIP3 via HIF-1a ranged, in
Hep3Bs' at least, from harsh (1% O2) to moderate (3%
O2) tomild (10%O2) degrees of deoxygenation. Because the
promoter of either gene recruited both HIF-1 and USFs in
hypoxic Hep3B and MCF7 cells in vivo (Fig. 4), control of
LDHA and BNIP3 expression was considered suitable to
examine HIF/USF cross-talk at DNA level in greater detail.
Previous studies had already validated human LDHA and
BNIP3 genes as hypoxia-inducible HIF-1 targets in HeLa
and MCF7 cells, respectively (48, 61).
Luciferase reporter of the LDHA (2-fold) and BNIP3
(3.5- to 7-fold) promoter yielded a robust upregulation by
hypoxic (1%O2/16 hours) conditions across Hep3B, HeLa,
and MCF7 cells (Fig. 5). In cotransfection assays in Hep3B
cells, overexpressed USFs were found to upregulate the
LDHA reporter particularly in normoxic conditions (Fig.
6B). The role of USFs in transactivating LDHA in oxygen-
ated cells implies the factors as candidate drivers of aerobic
glycolysis in cancer cells (Warburg effect). A previous study
had already described rat LDHA as MYC target and further
noticed the weak upregulation of the gene by USFs under
normoxia via binding of both E-box sites, regions I and II,
within the rat LDHA promoter (62). The human LDHA
promoter was, during low pO2, predominantly bound by
HIF-1, which, in Hep3B and HeLa but not MCF7 cells,
evidently served to displace LDHA-attached USFs (Fig. 4A).
Subsequent EMSA gel supershift assays revealed region I of
the 50 ﬂank of the LDHA gene as weak HIF-1 and strong
USF1/2a site. The region II palindrome and region III
asymmetric E-box of LDHA, however, functioned as
USF1/2 (reg. II) and HIF-1 (reg. III) binding sites, respec-
tively (Fig. 7A). To rationalize these data, we surmise that, in
Hep3B and HeLa cells at least, the sites in regions I to III do
not seem to be segregated. Upon changes in pO2, they rather
act as adaptable platform for the dominant transcription
factor entity. Thus, in hypoxic Hep3B and HeLa cells, HIF-
1 might variably expand its LDHA occupancy from its
holdout at region III onto regions I and II as well and, by
doing so, displaces bound USFs from these regions in intact
cells. At the same time, the presence of distinct, nonover-
lapping sites in the LDHA promoter forms the very foun-
dation for the complementing control of this gene by HIF-1
and USF pathways (Figs. 6and 7A). This complementation
allows the HIF-driven expression of LDHA during hypoxia
to eventually switch to a USF (and MYC)-mediated control
under high pO2 which, in turn, ensures production of this
glycolytic enzyme in response to a broader O2 spectrum and
additional microenvironmental stimuli of solidmalignancies
(i.e., acidic milieu).
Cotransfection of Hep3B and HeLa cells with HIF-1,
USF1, and USF2a revealed the dose-dependent interference
with the HIF-1–mediated BNIP3 induction at 1% O2 by
USFs (see arrows, Fig. 6C and D). Conversely, the transient
loss ofUSF1þUSF2a functions (siUSF2a treatment, Fig. 2)
or of USF1 activity alone (siUSF1 treatment), resulted in
Hep3B cells in a signiﬁcantly augmented induction of
BNIP3 (and BNIP3L) genes at harsh (1% O2) and mild
(10% O2) degrees of deoxygenation, respectively (Fig.
3, Table 3). These data support the notion of an increasing
competition of HIF's BNIP3 control by endogenous USF1
in mildly O2-deprived cells (see also below). The HRE at
position251/246 in the promoter of the human BNIP3
gene was ﬁrst identiﬁed by Kothari and colleagues to
function as a direct functional binding site for HIF-1 under
hypoxia (61). Our EMSA screen with a single site oligonu-
cleotide (259/236; Supplementary Table S1) character-
ized this HRE-containing sequence as being cotargeted by
HIF-1 and USFs in hypoxic (1% O2/16 hours) cells (Fig.
7B). Additional pull-down assays revealed hypoxic (1% O2/
16 hours) HIF-1 complexes to dock, in vitro, much more
tightly to the BNIP3HRE than do USF1 and USF2a factors
(Supplementary Fig. S3). Because pull-downs use, EMSA-
like, nuclear extracts with free,DNA-dissociateda-subunits,
they cannot provide insights on the binding of normoxic
HIF-1 to the cis-element in question. Nonetheless, we
extrapolate amarkedly inferior afﬁnity ofUSFs to theBNIP3
HREwhen compared with hypoxic HIF-1 complexes under
in vivo conditions as well.
Although USF expression manipulations affected BNIP3
gene/reporter activity particularly in normoxia [i.e., note
BNIP3 inductions at 1% O2 in (i) Fig. 3, USF1/2a knock-
down: 4.8fold (scr)! 6.6- to 7.6-fold knockdown; (ii) Fig.
6C and D; USF1/2a overexpression: 2.8-fold (endogenous)
! 1.5- to 1.8-fold (overexpression)], several additional
observations implied the USF/HIF convergence onto
BNIP3 to follow far more intricate rules than a LDHA-like
segregation between normoxic/USF and hypoxic/HIF occu-
pations would suggest. First, ChIP analysis of all 3 cell lines
(Hep3B,MCF7, andHeLa) showedmeasurable amounts of
HIF-1 during normoxia, and of USF1/2 complexes during
normoxia and hypoxia, attached to the BNIP3 promoter
chromatin (Fig. 4 and data not shown). Second, the USF1/2
HIF–USF Interaction
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dimers, tethered to the same 251/246 core sequence as
the hypoxia-inducible factor during low pO2 (Fig. 7B),
showed virtually no signs of displacement by incoming
HIF-1 (Fig. 4). Such a persisting attachment of USF factors
during hypoxic periods of HIF-1 occupancy could be
achieved by the presence of secondary docking sites within
the BNIP3 promoter. Indeed, we noted hmr conserved
CACGCR motifs dubbed E1 and E2, separated by 3-
nucleotide spacers on either side of the251/246 BNIP3
HRE (i.e., 50-CACGCGccgCACGTGccaCACGCA-30;
E1/E2 ¼ capital; spacers ¼ small; HRE ¼ capital/bold;
see Table 2; Supplementary Fig. S2). Subsequent EMSA
experiments with triple site E1-HRE-E2 oligonucleotide
probes in www (all 3 sites intact) and mwm (HRE intact,
E1 þ E2 mutated) conﬁguration revealed for hypoxic
extracts (HIF-1 docked to HRE) a 1.3- to 2.3-fold stronger
binding of USF complexes to www than mwm sequences
(not shown). Thus, intact E1/E2 motifs (and several other
CACGCN promoter sites) can temporarily provide alterna-
tive USFs sites at the BNIP3 gene. When HIF-1 approaches
the BNIP3 HRE during low pO2 in vivo, USFs may be able
to sidestep displacement by sliding onto E1 and E2.
The fact that we detected HIF-1a tethered to the BNIP3
promoter in normoxia only in vivo (ChIP), but not by in
vitro (EMSA, pull-down) measures, may highlight the pro-
tective effect of chromatin and/or the required HIF-1
heterodimer under conditions where free a-subunits are all
but depleted due to ongoing hydroxylation and degradation.
Because none of the usual proinﬂammatory agents (e.g.,
cytokines, growth factors, and reactive oxygen species),
known to spark a strong nonhypoxic HIF-1a accumulation
and induced expression of HIF-1 targets, were added to our
cultures the select interaction of HIF-1 with the BNIP3
promoter in oxic cells seems to occur independently of
changes in cytokine/growth factor/ROS concentrations.
About the question whether DNA-bound HIF-1 in oxic
cells maintains transcriptional functionality, we found that,
in Hep3B cells subjected to 16-hour periods of 3% and 10%
O2, HIF-1a still manages to drive the induction of BNIP3
(Table 3). Overall, however, our knowledge is meager at best
when it comes to events emanating from HIF signaling in
mildly deoxygenated or completely aerobic cells. A noted
exception is a study by Welford and colleagues which
documented HIF-1 to be strictly necessary in delaying the
onset of cellular senescence in aerobic murine embryonic
ﬁbroblasts, in part via the transcriptional control of the
proinﬂammatory macrophage migration inhibitory factor
(63).
Taken together, the distinct sites of the LDHA promoter
allow switching betweenUSF/normoxic andHIF-1/hypoxic
states, in favor of a complementing expression proﬁle with a
broadened O2 sensitivity. In contrast, the single BNIP3
sequence around the251/246CACGTGmotif seems to
be the platform for a pO2-dependent, conditional compe-
tition between USF1/2a and HIF-1 [i.e., (i) normoxic/sub-
normoxic state: USF$ HIF-1; (ii) hypoxic (1% O2) state:
HIF-1 only; with$¼ competition]. If so, this conditional
competition would argue for different DNA afﬁnities and/or
transactivation competences of normoxic and hypoxic HIF-
1 complexes, respectively. Inadequate a:b subunit interac-
tions, however, are unlikely be involved in debilitating
afﬁnity or transcriptional capacity of normoxic HIFs (rela-
tive to species at 1% O2). Recent ﬂuorescence resonance
energy transfer measurements revealed, at least for proteol-
ysis-saturating levels of overexpressed HIF-2a and ARNT,
identical a:b distances in normoxic and hypoxic HIF-2
heterodimers (64). Although the assembly of HIF in oxy-
genated and severely hypoxic nuclei appears to match one
another, the a-subunits in such high pO2, HRE-tethered
dimers should show hydroxylation at ODD-prolyl and/or
CAD-asparaginyl residues.
The recent categorization of HIF-1 targets into PHD-
(driven by HIF-1a NAD activity) and PHD/FIH-depen-
dent cohorts (driven by HIF-1aNADþ CAD activity) has
yielded some surprising new insights about theO2 proﬁles of
LDHA and BNIP3 genes (15–17). Here, BNIP3 expression
was characterized by extremely low FIH-1 sensitivity scores,
indicating full responsiveness of the gene by marginal drops
of pO2 and transcriptional gene induction (rather than
inhibition) by active FIH-1. In line with this concept, we
ﬁnd BNIP3 to be induced via HIF-1a in hepatoma cells at
1%, 3%, and 10% O2 (Fig. 3, Table 3). Although possible
functions of BNIP3, in addition to the factors proapoptotic/
proautophagic dichotomy (65, 66), need to be clariﬁed for
mildly versus profoundly hypoxic cancer cells, the binding of
HIF-1 to the BNIP3 promoter under a wide range of pO2,
and to the LDHA sites selectively during hypoxia, agrees
with such nonredundant impacts of PHDs and FIH-1 on the
activity of these HIF targets. In USF-1–silenced Hep3B,
BNIP3 mRNA expression levels were, relative to controls
transfected with scrambled RNA, reduced in normoxia and
steadily increasing in cells experiencing ever milder degrees
of hypoxia. This mix of effects yielded, as result of the USF1
knockdown, a progressive potentiation of the BNIP3 induc-
tion from harsh (1% O2) to moderately (3% O2) to mildly
(10% O2) deoxygenated Hep3Bs (Fig. 3, Table 3). We
therefore surmise that endogenous USFs primarily cap the
activity of the HIF-1/HRE complex at BNIP3 during
normoxia-mild hypoxia; that is, interfere with HIF-1 com-
plexes whose a-subunits remain either fully (i.e., at ODD/
NADþ CAD) or partially (i.e., at CAD) hydroxylated. The
HIF-1/HRE complex under strictly hypoxic (1% O2) con-
ditions, that is, with complete dehydroxylation of a-sub-
units at NAD and CAD regions, is, however, due to HIF's
superior DNA afﬁnity dominant over endogenous USFs.
Now, upstream stimulatory factors will only through over-
expression still be able to shift the binding equilibrium to the
BNIP3 HRE in their favor and guard the site against HIF-1.
Thus, USF1 and USF2a are best viewed as pO2-dependent
conditional, not compulsory, HIF-interfering factors. Their
delimiting impact on hypoxic signaling likely occurs most
effectively toward HIF's temporal or O2 limits (i.e., during
anoxia or reoxygenation), or in response to a strong phys-
iologic activation of the USF pathway [i.e., (i) UV-induced
USF1 phosphorylation in cells of melanocytic origin (53);
(ii) Ca2þ depletion–based protection from proteolysis in
Hu et al.
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differentiating erythroid progenitor/erythroleukemia cells
(54)]. Future work should tap into genome-wide implica-
tions of coactivated cross-talk between endogenous USFs
and HIF-1 in appropriate models.
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